Last updated: 2022-08-20
Checks: 6 1
Knit directory: genie_ras_hallmarks/
This reproducible R Markdown analysis was created with workflowr (version 1.7.0). The Checks tab describes the reproducibility checks that were applied when the results were created. The Past versions tab lists the development history.
The R Markdown is untracked by Git. To know which version of the R Markdown file created these results, you'll want to first commit it to the Git repo. If you're still working on the analysis, you can ignore this warning. When you're finished, you can run wflow_publish to commit the R Markdown file and build the HTML.
Great job! The global environment was empty. Objects defined in the global environment can affect the analysis in your R Markdown file in unknown ways. For reproduciblity it's best to always run the code in an empty environment.
The command set.seed(20220803) was run prior to running the code in the R Markdown file. Setting a seed ensures that any results that rely on randomness, e.g. subsampling or permutations, are reproducible.
Great job! Recording the operating system, R version, and package versions is critical for reproducibility.
Nice! There were no cached chunks for this analysis, so you can be confident that you successfully produced the results during this run.
Great job! Using relative paths to the files within your workflowr project makes it easier to run your code on other machines.
Great! You are using Git for version control. Tracking code development and connecting the code version to the results is critical for reproducibility.
The results in this page were generated with repository version 12e3255. See the Past versions tab to see a history of the changes made to the R Markdown and HTML files.
Note that you need to be careful to ensure that all relevant files for the analysis have been committed to Git prior to generating the results (you can use wflow_publish or wflow_git_commit). workflowr only checks the R Markdown file, but you know if there are other scripts or data files that it depends on. Below is the status of the Git repository when the results were generated:
Ignored files:
Ignored: .DS_Store
Untracked files:
Untracked: analysis/table_s7.Rmd
Note that any generated files, e.g. HTML, png, CSS, etc., are not included in this status report because it is ok for generated content to have uncommitted changes.
There are no past versions. Publish this analysis with wflow_publish() to start tracking its development.
| HUGO symbol | Codon | Cancer type | Group | variants (n) | patients (n) | Mean | Median | 2.5% | 97.5% |
|---|---|---|---|---|---|---|---|---|---|
| KRAS | G12A | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | appendiceal cancer | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | colorectal cancer | <40yrs | 7 | 565 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12A | colorectal cancer | 40-50yrs | 28 | 1280 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | 50-65yrs | 70 | 2815 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | >65yrs | 40 | 2055 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12A | cancer of unknown primary | <40yrs | 0 | 167 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | 40-50yrs | 1 | 211 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | 50-65yrs | 5 | 810 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | >65yrs | 8 | 797 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | non-small cell lung cancer | <40yrs | 0 | 161 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | 40-50yrs | 3 | 585 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | 50-65yrs | 67 | 3677 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | >65yrs | 156 | 5698 | 0.03 | 0.03 | 0.02 | 0.03 |
| KRAS | G12A | non-small cell lung cancer | Age:NA | 0 | 10 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12A | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | 50-65yrs | 2 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | >65yrs | 4 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | 50-65yrs | 4 | 1000 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | >65yrs | 9 | 1205 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | <40yrs | 1 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | >65yrs | 3 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | >65yrs | 1 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | uterine cancer | <40yrs | 0 | 57 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | uterine cancer | 40-50yrs | 1 | 162 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | uterine cancer | 50-65yrs | 17 | 1046 | 0.02 | 0.01 | 0.01 | 0.02 |
| KRAS | G12A | uterine cancer | >65yrs | 13 | 988 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12A | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | <40yrs | 1 | 87 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ovarian cancer | <40yrs | 3 | 141 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | ovarian cancer | 40-50yrs | 1 | 253 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | 50-65yrs | 6 | 1092 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | >65yrs | 4 | 849 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | 40-50yrs | 1 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | esophagogastric cancer | >65yrs | 5 | 725 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cervical cancer | 50-65yrs | 1 | 144 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | 40-50yrs | 1 | 110 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | hepatobiliary cancer | 50-65yrs | 5 | 525 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | hepatobiliary cancer | >65yrs | 1 | 601 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | <40yrs | 5 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | anal cancer | 40-50yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | anal cancer | 50-65yrs | 1 | 88 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | anal cancer | >65yrs | 0 | 45 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | 40-50yrs | 1 | 55 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12A | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | <40yrs | 1 | 25 | 0.01 | 0.00 | 0.00 | 0.08 |
| KRAS | G12A | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | bladder cancer | >65yrs | 2 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 142 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | small bowel cancer | 40-50yrs | 0 | 29 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12A | small bowel cancer | 50-65yrs | 3 | 96 | 0.02 | 0.02 | 0.01 | 0.06 |
| KRAS | G12A | small bowel cancer | >65yrs | 1 | 78 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12A | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | 40-50yrs | 1 | 61 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | >65yrs | 1 | 67 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | vaginal cancer | 50-65yrs | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G12A | vaginal cancer | >65yrs | 1 | 30 | 0.02 | 0.02 | 0.00 | 0.09 |
| KRAS | G12A | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ampullary cancer | 40-50yrs | 1 | 12 | 0.05 | 0.02 | 0.00 | 0.22 |
| KRAS | G12A | ampullary cancer | 50-65yrs | 0 | 40 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | ampullary cancer | >65yrs | 0 | 50 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | small cell lung cancer | >65yrs | 1 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | germ cell tumor | <40yrs | 4 | 650 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | 40-50yrs | 2 | 131 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | 50-65yrs | 1 | 92 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | >65yrs | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | nerve sheath tumor | 40-50yrs | 1 | 27 | 0.02 | 0.01 | 0.00 | 0.09 |
| KRAS | G12A | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | nerve sheath tumor | >65yrs | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12C | appendiceal cancer | <40yrs | 1 | 28 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | G12C | appendiceal cancer | 40-50yrs | 1 | 62 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12C | appendiceal cancer | 50-65yrs | 2 | 161 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12C | appendiceal cancer | >65yrs | 5 | 90 | 0.04 | 0.03 | 0.01 | 0.08 |
| KRAS | G12C | colorectal cancer | <40yrs | 16 | 565 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | colorectal cancer | 40-50yrs | 34 | 1280 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | colorectal cancer | 50-65yrs | 102 | 2815 | 0.03 | 0.03 | 0.03 | 0.04 |
| KRAS | G12C | colorectal cancer | >65yrs | 58 | 2055 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | cancer of unknown primary | <40yrs | 0 | 167 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12C | cancer of unknown primary | 40-50yrs | 3 | 211 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12C | cancer of unknown primary | 50-65yrs | 28 | 810 | 0.03 | 0.03 | 0.02 | 0.05 |
| KRAS | G12C | cancer of unknown primary | >65yrs | 30 | 797 | 0.04 | 0.04 | 0.02 | 0.05 |
| KRAS | G12C | non-small cell lung cancer | <40yrs | 1 | 161 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12C | non-small cell lung cancer | 40-50yrs | 41 | 585 | 0.07 | 0.07 | 0.05 | 0.09 |
| KRAS | G12C | non-small cell lung cancer | 50-65yrs | 439 | 3677 | 0.12 | 0.12 | 0.11 | 0.13 |
| KRAS | G12C | non-small cell lung cancer | >65yrs | 731 | 5698 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12C | non-small cell lung cancer | Age:NA | 1 | 10 | 0.09 | 0.08 | 0.01 | 0.27 |
| KRAS | G12C | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | 50-65yrs | 3 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | >65yrs | 5 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | soft tissue sarcoma | <40yrs | 2 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | 50-65yrs | 1 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | >65yrs | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | pancreatic cancer | <40yrs | 0 | 87 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | 40-50yrs | 1 | 200 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | 50-65yrs | 6 | 1000 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | pancreatic cancer | >65yrs | 15 | 1205 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | >65yrs | 2 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | 40-50yrs | 1 | 216 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | head and neck cancer | 50-65yrs | 1 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | uterine cancer | <40yrs | 0 | 57 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | uterine cancer | 40-50yrs | 0 | 162 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | uterine cancer | 50-65yrs | 13 | 1046 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | uterine cancer | >65yrs | 13 | 988 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ovarian cancer | <40yrs | 4 | 141 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12C | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | 50-65yrs | 3 | 1092 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | >65yrs | 3 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | <40yrs | 1 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | 50-65yrs | 2 | 752 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | >65yrs | 2 | 725 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | 50-65yrs | 1 | 374 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | >65yrs | 1 | 370 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | 50-65yrs | 1 | 144 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | <40yrs | 0 | 138 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | 50-65yrs | 5 | 525 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | hepatobiliary cancer | >65yrs | 5 | 601 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | >65yrs | 1 | 440 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | neuroendocrine tumors | <40yrs | 0 | 22 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | neuroendocrine tumors | 40-50yrs | 1 | 55 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12C | neuroendocrine tumors | 50-65yrs | 1 | 161 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | <40yrs | 0 | 25 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bladder cancer | 50-65yrs | 3 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bladder cancer | >65yrs | 5 | 962 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | small bowel cancer | 40-50yrs | 0 | 29 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | G12C | small bowel cancer | 50-65yrs | 7 | 96 | 0.06 | 0.06 | 0.02 | 0.12 |
| KRAS | G12C | small bowel cancer | >65yrs | 1 | 78 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12C | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | vaginal cancer | 50-65yrs | 1 | 34 | 0.02 | 0.02 | 0.00 | 0.08 |
| KRAS | G12C | vaginal cancer | >65yrs | 0 | 30 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G12C | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ampullary cancer | 40-50yrs | 0 | 12 | 0.04 | 0.03 | 0.00 | 0.10 |
| KRAS | G12C | ampullary cancer | 50-65yrs | 3 | 40 | 0.05 | 0.04 | 0.01 | 0.13 |
| KRAS | G12C | ampullary cancer | >65yrs | 1 | 50 | 0.03 | 0.03 | 0.00 | 0.08 |
| KRAS | G12C | small cell lung cancer | 40-50yrs | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12C | small cell lung cancer | 50-65yrs | 1 | 144 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | small cell lung cancer | >65yrs | 2 | 224 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | 40-50yrs | 3 | 131 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12C | germ cell tumor | 50-65yrs | 1 | 92 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12C | germ cell tumor | >65yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.06 |
| KRAS | G12C | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | lung cancer | >65yrs | 2 | 18 | 0.12 | 0.10 | 0.02 | 0.29 |
| KRAS | G12C | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12D | appendiceal cancer | <40yrs | 12 | 28 | 0.31 | 0.29 | 0.22 | 0.47 |
| KRAS | G12D | appendiceal cancer | 40-50yrs | 18 | 62 | 0.28 | 0.28 | 0.21 | 0.36 |
| KRAS | G12D | appendiceal cancer | 50-65yrs | 40 | 161 | 0.26 | 0.26 | 0.21 | 0.32 |
| KRAS | G12D | appendiceal cancer | >65yrs | 22 | 90 | 0.26 | 0.26 | 0.20 | 0.33 |
| KRAS | G12D | colorectal cancer | <40yrs | 86 | 565 | 0.14 | 0.14 | 0.12 | 0.16 |
| KRAS | G12D | colorectal cancer | 40-50yrs | 180 | 1280 | 0.14 | 0.14 | 0.12 | 0.15 |
| KRAS | G12D | colorectal cancer | 50-65yrs | 365 | 2815 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12D | colorectal cancer | >65yrs | 253 | 2055 | 0.13 | 0.13 | 0.11 | 0.14 |
| KRAS | G12D | cancer of unknown primary | <40yrs | 5 | 167 | 0.05 | 0.05 | 0.02 | 0.07 |
| KRAS | G12D | cancer of unknown primary | 40-50yrs | 8 | 211 | 0.05 | 0.05 | 0.03 | 0.07 |
| KRAS | G12D | cancer of unknown primary | 50-65yrs | 43 | 810 | 0.05 | 0.05 | 0.04 | 0.07 |
| KRAS | G12D | cancer of unknown primary | >65yrs | 51 | 797 | 0.06 | 0.06 | 0.04 | 0.08 |
| KRAS | G12D | non-small cell lung cancer | <40yrs | 6 | 161 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | 40-50yrs | 19 | 585 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | 50-65yrs | 154 | 3677 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | >65yrs | 253 | 5698 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | Age:NA | 0 | 10 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | 40-50yrs | 1 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | 50-65yrs | 4 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | >65yrs | 5 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | Age:NA | 1 | 10 | 0.02 | 0.00 | 0.00 | 0.14 |
| KRAS | G12D | soft tissue sarcoma | <40yrs | 3 | 672 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | 40-50yrs | 1 | 367 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | 50-65yrs | 3 | 951 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | >65yrs | 4 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | pancreatic cancer | <40yrs | 16 | 87 | 0.26 | 0.26 | 0.15 | 0.33 |
| KRAS | G12D | pancreatic cancer | 40-50yrs | 56 | 200 | 0.29 | 0.29 | 0.23 | 0.34 |
| KRAS | G12D | pancreatic cancer | 50-65yrs | 327 | 1000 | 0.32 | 0.32 | 0.30 | 0.35 |
| KRAS | G12D | pancreatic cancer | >65yrs | 383 | 1205 | 0.32 | 0.32 | 0.29 | 0.34 |
| KRAS | G12D | leukemia | <40yrs | 3 | 204 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | leukemia | 40-50yrs | 0 | 128 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | leukemia | 50-65yrs | 7 | 515 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | leukemia | >65yrs | 11 | 720 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | 50-65yrs | 5 | 1016 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | >65yrs | 9 | 1259 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | <40yrs | 1 | 140 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | 50-65yrs | 3 | 799 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | uterine cancer | <40yrs | 1 | 57 | 0.04 | 0.04 | 0.01 | 0.07 |
| KRAS | G12D | uterine cancer | 40-50yrs | 14 | 162 | 0.06 | 0.06 | 0.04 | 0.11 |
| KRAS | G12D | uterine cancer | 50-65yrs | 50 | 1046 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12D | uterine cancer | >65yrs | 37 | 988 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | non-melanoma skin cancers | 50-65yrs | 1 | 149 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 2 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | >65yrs | 2 | 664 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ovarian cancer | <40yrs | 12 | 141 | 0.06 | 0.06 | 0.03 | 0.11 |
| KRAS | G12D | ovarian cancer | 40-50yrs | 10 | 253 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | ovarian cancer | 50-65yrs | 40 | 1092 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | ovarian cancer | >65yrs | 20 | 849 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12D | esophagogastric cancer | <40yrs | 2 | 122 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | 40-50yrs | 4 | 200 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | 50-65yrs | 12 | 752 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12D | esophagogastric cancer | >65yrs | 15 | 725 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | 50-65yrs | 3 | 374 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | cervical cancer | <40yrs | 1 | 85 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12D | cervical cancer | 40-50yrs | 2 | 99 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12D | cervical cancer | 50-65yrs | 5 | 144 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | cervical cancer | >65yrs | 2 | 36 | 0.03 | 0.03 | 0.01 | 0.08 |
| KRAS | G12D | hepatobiliary cancer | <40yrs | 6 | 138 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | hepatobiliary cancer | 40-50yrs | 4 | 110 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | hepatobiliary cancer | 50-65yrs | 16 | 525 | 0.04 | 0.04 | 0.02 | 0.05 |
| KRAS | G12D | hepatobiliary cancer | >65yrs | 29 | 601 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | kidney cancer | 40-50yrs | 2 | 159 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | kidney cancer | 50-65yrs | 1 | 628 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | kidney cancer | >65yrs | 2 | 440 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | <40yrs | 2 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | 40-50yrs | 4 | 687 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | >65yrs | 2 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | >65yrs | 2 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | anal cancer | 40-50yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | anal cancer | 50-65yrs | 1 | 88 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | anal cancer | >65yrs | 0 | 45 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | neuroendocrine tumors | <40yrs | 0 | 22 | 0.03 | 0.03 | 0.00 | 0.08 |
| KRAS | G12D | neuroendocrine tumors | 40-50yrs | 6 | 55 | 0.07 | 0.06 | 0.02 | 0.16 |
| KRAS | G12D | neuroendocrine tumors | 50-65yrs | 5 | 161 | 0.04 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | neuroendocrine tumors | >65yrs | 3 | 121 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | bladder cancer | <40yrs | 0 | 25 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12D | bladder cancer | 40-50yrs | 0 | 78 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12D | bladder cancer | 50-65yrs | 12 | 511 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | bladder cancer | >65yrs | 20 | 962 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | <40yrs | 5 | 142 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.03 | 0.03 | 0.00 | 0.07 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 1 | 48 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | >65yrs | 2 | 42 | 0.04 | 0.03 | 0.01 | 0.08 |
| KRAS | G12D | small bowel cancer | 40-50yrs | 2 | 29 | 0.11 | 0.11 | 0.05 | 0.18 |
| KRAS | G12D | small bowel cancer | 50-65yrs | 12 | 96 | 0.12 | 0.12 | 0.07 | 0.18 |
| KRAS | G12D | small bowel cancer | >65yrs | 10 | 78 | 0.12 | 0.12 | 0.07 | 0.18 |
| KRAS | G12D | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | bone cancer | <40yrs | 1 | 342 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | >65yrs | 1 | 67 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | vaginal cancer | 50-65yrs | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G12D | vaginal cancer | >65yrs | 1 | 30 | 0.02 | 0.02 | 0.00 | 0.09 |
| KRAS | G12D | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ampullary cancer | 40-50yrs | 0 | 12 | 0.12 | 0.08 | 0.00 | 0.33 |
| KRAS | G12D | ampullary cancer | 50-65yrs | 11 | 40 | 0.27 | 0.27 | 0.16 | 0.40 |
| KRAS | G12D | ampullary cancer | >65yrs | 17 | 50 | 0.32 | 0.31 | 0.20 | 0.46 |
| KRAS | G12D | small cell lung cancer | 40-50yrs | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | small cell lung cancer | 50-65yrs | 1 | 144 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | small cell lung cancer | >65yrs | 3 | 224 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | germ cell tumor | <40yrs | 7 | 650 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | 40-50yrs | 2 | 131 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | germ cell tumor | 50-65yrs | 0 | 92 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | >65yrs | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12D | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | 50-65yrs | 2 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12F | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | 50-65yrs | 1 | 2815 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | >65yrs | 0 | 2055 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | 50-65yrs | 1 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | >65yrs | 2 | 797 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | 50-65yrs | 10 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | >65yrs | 22 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | 50-65yrs | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | >65yrs | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | <40yrs | 1 | 141 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | >65yrs | 0 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12R | appendiceal cancer | <40yrs | 0 | 28 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | appendiceal cancer | 40-50yrs | 1 | 62 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | appendiceal cancer | 50-65yrs | 2 | 161 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | appendiceal cancer | >65yrs | 0 | 90 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | 40-50yrs | 7 | 1280 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | 50-65yrs | 13 | 2815 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | >65yrs | 14 | 2055 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | <40yrs | 0 | 167 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | 40-50yrs | 2 | 211 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | cancer of unknown primary | 50-65yrs | 9 | 810 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | cancer of unknown primary | >65yrs | 6 | 797 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | 40-50yrs | 3 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | 50-65yrs | 11 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-small cell lung cancer | >65yrs | 22 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | breast cancer | <40yrs | 1 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | 50-65yrs | 2 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | <40yrs | 1 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | 50-65yrs | 1 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | pancreatic cancer | <40yrs | 4 | 87 | 0.08 | 0.08 | 0.03 | 0.12 |
| KRAS | G12R | pancreatic cancer | 40-50yrs | 16 | 200 | 0.09 | 0.09 | 0.06 | 0.12 |
| KRAS | G12R | pancreatic cancer | 50-65yrs | 102 | 1000 | 0.10 | 0.10 | 0.08 | 0.12 |
| KRAS | G12R | pancreatic cancer | >65yrs | 154 | 1205 | 0.12 | 0.12 | 0.10 | 0.14 |
| KRAS | G12R | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | >65yrs | 1 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | >65yrs | 2 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | 50-65yrs | 1 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | >65yrs | 1 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | >65yrs | 2 | 664 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ovarian cancer | <40yrs | 1 | 141 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | 40-50yrs | 3 | 253 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | ovarian cancer | 50-65yrs | 3 | 1092 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | >65yrs | 3 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | esophagogastric cancer | 40-50yrs | 1 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thyroid cancer | 50-65yrs | 1 | 374 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cervical cancer | >65yrs | 1 | 36 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | G12R | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | 50-65yrs | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | >65yrs | 2 | 601 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | prostate cancer | 50-65yrs | 2 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | neuroendocrine tumors | 50-65yrs | 2 | 161 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | 50-65yrs | 2 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | >65yrs | 1 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small bowel cancer | 40-50yrs | 0 | 29 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | small bowel cancer | 50-65yrs | 1 | 96 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | small bowel cancer | >65yrs | 2 | 78 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ampullary cancer | 40-50yrs | 0 | 12 | 0.02 | 0.01 | 0.00 | 0.08 |
| KRAS | G12R | ampullary cancer | 50-65yrs | 0 | 40 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12R | ampullary cancer | >65yrs | 3 | 50 | 0.05 | 0.04 | 0.01 | 0.12 |
| KRAS | G12R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | germ cell tumor | <40yrs | 3 | 650 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | 40-50yrs | 3 | 131 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | germ cell tumor | 50-65yrs | 1 | 92 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | germ cell tumor | >65yrs | 1 | 12 | 0.03 | 0.01 | 0.00 | 0.13 |
| KRAS | G12R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12S | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | appendiceal cancer | >65yrs | 1 | 90 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | colorectal cancer | <40yrs | 15 | 565 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12S | colorectal cancer | 40-50yrs | 23 | 1280 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12S | colorectal cancer | 50-65yrs | 51 | 2815 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12S | colorectal cancer | >65yrs | 37 | 2055 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12S | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | 50-65yrs | 1 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cancer of unknown primary | >65yrs | 4 | 797 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | 40-50yrs | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | 50-65yrs | 21 | 3677 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | >65yrs | 30 | 5698 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | 40-50yrs | 1 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | 50-65yrs | 4 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | 50-65yrs | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | >65yrs | 1 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | 50-65yrs | 2 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | uterine cancer | >65yrs | 4 | 988 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | >65yrs | 1 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | <40yrs | 1 | 141 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | 40-50yrs | 1 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | esophagogastric cancer | >65yrs | 3 | 725 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cervical cancer | <40yrs | 0 | 85 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | cervical cancer | 40-50yrs | 1 | 99 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | cervical cancer | 50-65yrs | 2 | 144 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12S | cervical cancer | >65yrs | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | hepatobiliary cancer | >65yrs | 2 | 601 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | 50-65yrs | 1 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bladder cancer | 50-65yrs | 1 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bladder cancer | >65yrs | 1 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small bowel cancer | 40-50yrs | 0 | 29 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | small bowel cancer | 50-65yrs | 3 | 96 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12S | small bowel cancer | >65yrs | 0 | 78 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ampullary cancer | 40-50yrs | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G12S | ampullary cancer | 50-65yrs | 1 | 40 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | G12S | ampullary cancer | >65yrs | 0 | 50 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | germ cell tumor | <40yrs | 2 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | germ cell tumor | 40-50yrs | 2 | 131 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12S | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | germ cell tumor | >65yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12S | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | >65yrs | 2 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 27 | 0.04 | 0.03 | 0.00 | 0.14 |
| KRAS | G12S | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12V | appendiceal cancer | <40yrs | 6 | 28 | 0.14 | 0.13 | 0.08 | 0.24 |
| KRAS | G12V | appendiceal cancer | 40-50yrs | 5 | 62 | 0.11 | 0.11 | 0.06 | 0.16 |
| KRAS | G12V | appendiceal cancer | 50-65yrs | 20 | 161 | 0.12 | 0.12 | 0.08 | 0.17 |
| KRAS | G12V | appendiceal cancer | >65yrs | 10 | 90 | 0.12 | 0.12 | 0.08 | 0.17 |
| KRAS | G12V | colorectal cancer | <40yrs | 32 | 565 | 0.07 | 0.07 | 0.05 | 0.09 |
| KRAS | G12V | colorectal cancer | 40-50yrs | 118 | 1280 | 0.09 | 0.09 | 0.08 | 0.11 |
| KRAS | G12V | colorectal cancer | 50-65yrs | 279 | 2815 | 0.10 | 0.10 | 0.09 | 0.11 |
| KRAS | G12V | colorectal cancer | >65yrs | 191 | 2055 | 0.09 | 0.09 | 0.08 | 0.10 |
| KRAS | G12V | cancer of unknown primary | <40yrs | 0 | 167 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G12V | cancer of unknown primary | 40-50yrs | 12 | 211 | 0.06 | 0.05 | 0.03 | 0.09 |
| KRAS | G12V | cancer of unknown primary | 50-65yrs | 48 | 810 | 0.06 | 0.06 | 0.04 | 0.08 |
| KRAS | G12V | cancer of unknown primary | >65yrs | 47 | 797 | 0.06 | 0.06 | 0.04 | 0.08 |
| KRAS | G12V | non-small cell lung cancer | <40yrs | 3 | 161 | 0.04 | 0.04 | 0.01 | 0.06 |
| KRAS | G12V | non-small cell lung cancer | 40-50yrs | 20 | 585 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12V | non-small cell lung cancer | 50-65yrs | 202 | 3677 | 0.05 | 0.05 | 0.05 | 0.06 |
| KRAS | G12V | non-small cell lung cancer | >65yrs | 323 | 5698 | 0.06 | 0.06 | 0.05 | 0.06 |
| KRAS | G12V | non-small cell lung cancer | Age:NA | 0 | 10 | 0.04 | 0.05 | 0.01 | 0.09 |
| KRAS | G12V | breast cancer | <40yrs | 2 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | 40-50yrs | 4 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | 50-65yrs | 15 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | >65yrs | 9 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | soft tissue sarcoma | <40yrs | 2 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | 50-65yrs | 1 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | pancreatic cancer | <40yrs | 2 | 87 | 0.04 | 0.04 | 0.01 | 0.10 |
| KRAS | G12V | pancreatic cancer | 40-50yrs | 31 | 200 | 0.16 | 0.15 | 0.11 | 0.21 |
| KRAS | G12V | pancreatic cancer | 50-65yrs | 229 | 1000 | 0.23 | 0.23 | 0.20 | 0.25 |
| KRAS | G12V | pancreatic cancer | >65yrs | 320 | 1205 | 0.26 | 0.26 | 0.24 | 0.29 |
| KRAS | G12V | leukemia | <40yrs | 3 | 204 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | leukemia | 40-50yrs | 0 | 128 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | leukemia | 50-65yrs | 7 | 515 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | leukemia | >65yrs | 6 | 720 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | >65yrs | 2 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | uterine cancer | <40yrs | 0 | 57 | 0.04 | 0.04 | 0.00 | 0.06 |
| KRAS | G12V | uterine cancer | 40-50yrs | 11 | 162 | 0.06 | 0.06 | 0.04 | 0.10 |
| KRAS | G12V | uterine cancer | 50-65yrs | 63 | 1046 | 0.06 | 0.06 | 0.04 | 0.07 |
| KRAS | G12V | uterine cancer | >65yrs | 38 | 988 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12V | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-melanoma skin cancers | >65yrs | 1 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | >65yrs | 1 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ovarian cancer | <40yrs | 11 | 141 | 0.06 | 0.06 | 0.03 | 0.11 |
| KRAS | G12V | ovarian cancer | 40-50yrs | 15 | 253 | 0.05 | 0.05 | 0.03 | 0.08 |
| KRAS | G12V | ovarian cancer | 50-65yrs | 31 | 1092 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | ovarian cancer | >65yrs | 26 | 849 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | esophagogastric cancer | <40yrs | 1 | 122 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | esophagogastric cancer | 50-65yrs | 8 | 752 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | >65yrs | 6 | 725 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | <40yrs | 1 | 150 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | 40-50yrs | 0 | 122 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | 50-65yrs | 3 | 374 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | >65yrs | 2 | 370 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | cervical cancer | <40yrs | 2 | 85 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12V | cervical cancer | 40-50yrs | 2 | 99 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12V | cervical cancer | 50-65yrs | 6 | 144 | 0.03 | 0.03 | 0.02 | 0.06 |
| KRAS | G12V | cervical cancer | >65yrs | 1 | 36 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12V | hepatobiliary cancer | <40yrs | 0 | 138 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | 40-50yrs | 5 | 110 | 0.03 | 0.03 | 0.02 | 0.07 |
| KRAS | G12V | hepatobiliary cancer | 50-65yrs | 16 | 525 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | >65yrs | 17 | 601 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | 50-65yrs | 2 | 628 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | >65yrs | 2 | 440 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | mature t and nk neoplasms | 40-50yrs | 1 | 21 | 0.02 | 0.01 | 0.00 | 0.12 |
| KRAS | G12V | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | cns cancer | <40yrs | 2 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | 40-50yrs | 3 | 687 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | cns cancer | 50-65yrs | 3 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | 50-65yrs | 1 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | neuroendocrine tumors | <40yrs | 0 | 22 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | neuroendocrine tumors | 40-50yrs | 3 | 55 | 0.03 | 0.02 | 0.01 | 0.08 |
| KRAS | G12V | neuroendocrine tumors | 50-65yrs | 2 | 161 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12V | neuroendocrine tumors | >65yrs | 1 | 121 | 0.02 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | bladder cancer | <40yrs | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | bladder cancer | 40-50yrs | 0 | 78 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | bladder cancer | 50-65yrs | 7 | 511 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | bladder cancer | >65yrs | 12 | 962 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 142 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | small bowel cancer | 40-50yrs | 3 | 29 | 0.12 | 0.12 | 0.06 | 0.19 |
| KRAS | G12V | small bowel cancer | 50-65yrs | 12 | 96 | 0.12 | 0.12 | 0.08 | 0.18 |
| KRAS | G12V | small bowel cancer | >65yrs | 10 | 78 | 0.12 | 0.12 | 0.08 | 0.18 |
| KRAS | G12V | sex cord stromal tumor | <40yrs | 1 | 29 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | G12V | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | sex cord stromal tumor | 50-65yrs | 1 | 37 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | sex cord stromal tumor | >65yrs | 0 | 27 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ampullary cancer | 40-50yrs | 2 | 12 | 0.13 | 0.12 | 0.05 | 0.27 |
| KRAS | G12V | ampullary cancer | 50-65yrs | 6 | 40 | 0.13 | 0.12 | 0.06 | 0.22 |
| KRAS | G12V | ampullary cancer | >65yrs | 4 | 50 | 0.11 | 0.11 | 0.05 | 0.18 |
| KRAS | G12V | small cell lung cancer | 40-50yrs | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | small cell lung cancer | 50-65yrs | 2 | 144 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | small cell lung cancer | >65yrs | 1 | 224 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | germ cell tumor | <40yrs | 10 | 650 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12V | germ cell tumor | 40-50yrs | 6 | 131 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | G12V | germ cell tumor | 50-65yrs | 2 | 92 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12V | germ cell tumor | >65yrs | 0 | 12 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12V | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | b cell lymphoma | 40-50yrs | 1 | 105 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | b cell lymphoma | >65yrs | 2 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | peritoneal cancer | >65yrs | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | G13C | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | colorectal cancer | <40yrs | 1 | 565 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | 40-50yrs | 1 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | colorectal cancer | 50-65yrs | 15 | 2815 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | >65yrs | 7 | 2055 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | 50-65yrs | 4 | 810 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | >65yrs | 4 | 797 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | <40yrs | 2 | 161 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | 40-50yrs | 3 | 585 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | 50-65yrs | 42 | 3677 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | >65yrs | 62 | 5698 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Age:NA | 0 | 10 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13C | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | 50-65yrs | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | 50-65yrs | 1 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | >65yrs | 4 | 988 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | >65yrs | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | anal cancer | 40-50yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | anal cancer | 50-65yrs | 1 | 88 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13C | anal cancer | >65yrs | 0 | 45 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | >65yrs | 0 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | vaginal cancer | 50-65yrs | 1 | 34 | 0.02 | 0.02 | 0.00 | 0.08 |
| KRAS | G13C | vaginal cancer | >65yrs | 0 | 30 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G13C | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | appendiceal cancer | <40yrs | 0 | 28 | 0.04 | 0.04 | 0.00 | 0.07 |
| KRAS | G13D | appendiceal cancer | 40-50yrs | 4 | 62 | 0.05 | 0.04 | 0.02 | 0.10 |
| KRAS | G13D | appendiceal cancer | 50-65yrs | 4 | 161 | 0.04 | 0.03 | 0.01 | 0.06 |
| KRAS | G13D | appendiceal cancer | >65yrs | 6 | 90 | 0.05 | 0.05 | 0.02 | 0.10 |
| KRAS | G13D | colorectal cancer | <40yrs | 46 | 565 | 0.08 | 0.08 | 0.06 | 0.09 |
| KRAS | G13D | colorectal cancer | 40-50yrs | 93 | 1280 | 0.07 | 0.07 | 0.06 | 0.08 |
| KRAS | G13D | colorectal cancer | 50-65yrs | 197 | 2815 | 0.07 | 0.07 | 0.06 | 0.08 |
| KRAS | G13D | colorectal cancer | >65yrs | 162 | 2055 | 0.08 | 0.08 | 0.07 | 0.09 |
| KRAS | G13D | cancer of unknown primary | <40yrs | 3 | 167 | 0.02 | 0.01 | 0.01 | 0.03 |
| KRAS | G13D | cancer of unknown primary | 40-50yrs | 7 | 211 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G13D | cancer of unknown primary | 50-65yrs | 9 | 810 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | cancer of unknown primary | >65yrs | 7 | 797 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | non-small cell lung cancer | <40yrs | 0 | 161 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | 40-50yrs | 5 | 585 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | 50-65yrs | 37 | 3677 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | >65yrs | 45 | 5698 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Age:NA | 0 | 10 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | 50-65yrs | 5 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | pancreatic cancer | <40yrs | 0 | 87 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | 40-50yrs | 1 | 200 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | 50-65yrs | 5 | 1000 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | >65yrs | 8 | 1205 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | leukemia | <40yrs | 10 | 204 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | leukemia | 40-50yrs | 3 | 128 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G13D | leukemia | 50-65yrs | 7 | 515 | 0.02 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | leukemia | >65yrs | 5 | 720 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | >65yrs | 6 | 1259 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | 50-65yrs | 2 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | uterine cancer | <40yrs | 1 | 57 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | uterine cancer | 40-50yrs | 4 | 162 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | uterine cancer | 50-65yrs | 20 | 1046 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | uterine cancer | >65yrs | 21 | 988 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | <40yrs | 2 | 87 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | >65yrs | 4 | 664 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | <40yrs | 1 | 141 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | 40-50yrs | 3 | 253 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | ovarian cancer | 50-65yrs | 3 | 1092 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | >65yrs | 3 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | esophagogastric cancer | <40yrs | 1 | 122 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | 40-50yrs | 2 | 200 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | 50-65yrs | 7 | 752 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | esophagogastric cancer | >65yrs | 12 | 725 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cervical cancer | <40yrs | 0 | 85 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | cervical cancer | 40-50yrs | 3 | 99 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G13D | cervical cancer | 50-65yrs | 1 | 144 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | cervical cancer | >65yrs | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | hepatobiliary cancer | <40yrs | 0 | 138 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | hepatobiliary cancer | 40-50yrs | 2 | 110 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | 50-65yrs | 4 | 525 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | hepatobiliary cancer | >65yrs | 3 | 601 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | anal cancer | 40-50yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | anal cancer | 50-65yrs | 0 | 88 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | anal cancer | >65yrs | 1 | 45 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G13D | neuroendocrine tumors | <40yrs | 2 | 22 | 0.03 | 0.02 | 0.01 | 0.13 |
| KRAS | G13D | neuroendocrine tumors | 40-50yrs | 1 | 55 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G13D | neuroendocrine tumors | 50-65yrs | 2 | 161 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G13D | neuroendocrine tumors | >65yrs | 1 | 121 | 0.02 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | bladder cancer | 40-50yrs | 1 | 78 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | bladder cancer | >65yrs | 3 | 962 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | <40yrs | 8 | 142 | 0.05 | 0.05 | 0.02 | 0.10 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.00 | 0.00 | 0.06 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | small bowel cancer | 40-50yrs | 6 | 29 | 0.15 | 0.14 | 0.05 | 0.32 |
| KRAS | G13D | small bowel cancer | 50-65yrs | 4 | 96 | 0.05 | 0.05 | 0.02 | 0.10 |
| KRAS | G13D | small bowel cancer | >65yrs | 3 | 78 | 0.05 | 0.05 | 0.01 | 0.10 |
| KRAS | G13D | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ampullary cancer | 40-50yrs | 0 | 12 | 0.04 | 0.04 | 0.00 | 0.11 |
| KRAS | G13D | ampullary cancer | 50-65yrs | 3 | 40 | 0.06 | 0.05 | 0.02 | 0.13 |
| KRAS | G13D | ampullary cancer | >65yrs | 2 | 50 | 0.05 | 0.04 | 0.01 | 0.10 |
| KRAS | G13D | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | b cell lymphoma | <40yrs | 0 | 87 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | 40-50yrs | 1 | 105 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | 50-65yrs | 1 | 357 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | b cell lymphoma | >65yrs | 5 | 413 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | 40-50yrs | 1 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | 50-65yrs | 1 | 2815 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | >65yrs | 0 | 2055 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | 50-65yrs | 1 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | >65yrs | 0 | 797 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | 50-65yrs | 3 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | >65yrs | 3 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | 50-65yrs | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | >65yrs | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | >65yrs | 0 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | 50-65yrs | 0 | 2815 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | >65yrs | 2 | 2055 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | >65yrs | 0 | 797 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | 40-50yrs | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | 50-65yrs | 3 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | 50-65yrs | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | >65yrs | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | >65yrs | 0 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | 40-50yrs | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61H | appendiceal cancer | <40yrs | 1 | 28 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | Q61H | appendiceal cancer | 40-50yrs | 0 | 62 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | appendiceal cancer | 50-65yrs | 2 | 161 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | appendiceal cancer | >65yrs | 0 | 90 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | colorectal cancer | <40yrs | 2 | 565 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | colorectal cancer | 40-50yrs | 15 | 1280 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | colorectal cancer | 50-65yrs | 30 | 2815 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | Q61H | colorectal cancer | >65yrs | 17 | 2055 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | 50-65yrs | 5 | 810 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | >65yrs | 10 | 797 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | <40yrs | 0 | 161 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | 40-50yrs | 8 | 585 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | 50-65yrs | 52 | 3677 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | >65yrs | 71 | 5698 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Age:NA | 0 | 10 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | 50-65yrs | 1 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | pancreatic cancer | <40yrs | 0 | 87 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | Q61H | pancreatic cancer | 40-50yrs | 8 | 200 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | Q61H | pancreatic cancer | 50-65yrs | 25 | 1000 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | Q61H | pancreatic cancer | >65yrs | 53 | 1205 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | Q61H | leukemia | <40yrs | 1 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | 40-50yrs | 1 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | >65yrs | 1 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | >65yrs | 2 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | 50-65yrs | 3 | 1046 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | >65yrs | 3 | 988 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ovarian cancer | <40yrs | 2 | 141 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | 50-65yrs | 5 | 1092 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | >65yrs | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | >65yrs | 1 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | hepatobiliary cancer | <40yrs | 0 | 138 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | 40-50yrs | 1 | 110 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | 50-65yrs | 5 | 525 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | >65yrs | 8 | 601 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | kidney cancer | 50-65yrs | 1 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mature t and nk neoplasms | <40yrs | 1 | 28 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | Q61H | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | mature t and nk neoplasms | >65yrs | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | 40-50yrs | 1 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | >65yrs | 1 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | 50-65yrs | 1 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | neuroendocrine tumors | 40-50yrs | 1 | 55 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61H | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | 50-65yrs | 3 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | >65yrs | 0 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | <40yrs | 3 | 142 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | small bowel cancer | 40-50yrs | 2 | 29 | 0.04 | 0.03 | 0.01 | 0.11 |
| KRAS | Q61H | small bowel cancer | 50-65yrs | 3 | 96 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | Q61H | small bowel cancer | >65yrs | 1 | 78 | 0.03 | 0.02 | 0.00 | 0.06 |
| KRAS | Q61H | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | <40yrs | 1 | 342 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ampullary cancer | 40-50yrs | 0 | 12 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | Q61H | ampullary cancer | 50-65yrs | 0 | 40 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61H | ampullary cancer | >65yrs | 2 | 50 | 0.03 | 0.02 | 0.00 | 0.08 |
| KRAS | Q61H | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | b cell lymphoma | <40yrs | 0 | 87 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | b cell lymphoma | 40-50yrs | 2 | 105 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | b cell lymphoma | 50-65yrs | 2 | 357 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | b cell lymphoma | >65yrs | 6 | 413 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61K | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | 40-50yrs | 1 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | 50-65yrs | 3 | 2815 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | >65yrs | 8 | 2055 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | >65yrs | 1 | 797 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | 50-65yrs | 1 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | >65yrs | 1 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | 50-65yrs | 2 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | >65yrs | 1 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | 50-65yrs | 1 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | 50-65yrs | 1 | 374 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | <40yrs | 2 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | anal cancer | 40-50yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | anal cancer | 50-65yrs | 1 | 88 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61K | anal cancer | >65yrs | 0 | 45 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | neuroendocrine tumors | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | >65yrs | 0 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | Q61L | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | appendiceal cancer | >65yrs | 1 | 90 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | colorectal cancer | <40yrs | 2 | 565 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | 40-50yrs | 2 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | colorectal cancer | 50-65yrs | 13 | 2815 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | >65yrs | 7 | 2055 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | 50-65yrs | 1 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | >65yrs | 2 | 797 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | 50-65yrs | 11 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | >65yrs | 26 | 5698 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | 50-65yrs | 3 | 1000 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | >65yrs | 3 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | >65yrs | 1 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | 50-65yrs | 2 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | 50-65yrs | 2 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | >65yrs | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | >65yrs | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hepatobiliary cancer | 50-65yrs | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | >65yrs | 1 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | >65yrs | 1 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | >65yrs | 1 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | penile cancer | 50-65yrs | 0 | 11 | 0.03 | 0.01 | 0.00 | 0.15 |
| KRAS | Q61L | penile cancer | >65yrs | 1 | 11 | 0.07 | 0.05 | 0.00 | 0.25 |
| KRAS | Q61L | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | 40-50yrs | 1 | 105 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | appendiceal cancer | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | colorectal cancer | 40-50yrs | 5 | 1280 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | 50-65yrs | 8 | 2815 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | colorectal cancer | >65yrs | 7 | 2055 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | 50-65yrs | 3 | 810 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | cancer of unknown primary | >65yrs | 0 | 797 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | 50-65yrs | 3 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | >65yrs | 4 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | <40yrs | 0 | 841 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | pancreatic cancer | <40yrs | 0 | 87 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61R | pancreatic cancer | 40-50yrs | 2 | 200 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61R | pancreatic cancer | 50-65yrs | 9 | 1000 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61R | pancreatic cancer | >65yrs | 27 | 1205 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | Q61R | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | >65yrs | 1 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | >65yrs | 2 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | >65yrs | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | 40-50yrs | 2 | 253 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thyroid cancer | <40yrs | 2 | 150 | 0.02 | 0.01 | 0.01 | 0.03 |
| KRAS | Q61R | thyroid cancer | 40-50yrs | 2 | 122 | 0.02 | 0.01 | 0.01 | 0.03 |
| KRAS | Q61R | thyroid cancer | 50-65yrs | 6 | 374 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | Q61R | thyroid cancer | >65yrs | 5 | 370 | 0.02 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | <40yrs | 0 | 138 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hepatobiliary cancer | 50-65yrs | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | >65yrs | 1 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | 40-50yrs | 1 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | >65yrs | 1 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | 50-65yrs | 1 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | >65yrs | 1 | 962 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | sex cord stromal tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ampullary cancer | 40-50yrs | 0 | 12 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | Q61R | ampullary cancer | 50-65yrs | 2 | 40 | 0.04 | 0.03 | 0.00 | 0.11 |
| KRAS | Q61R | ampullary cancer | >65yrs | 0 | 50 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | 40-50yrs | 1 | 105 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | b cell lymphoma | 50-65yrs | 2 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | 50-65yrs | 1 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12C | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | 50-65yrs | 2 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | non-melanoma skin cancers | 50-65yrs | 1 | 149 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bladder cancer | 50-65yrs | 2 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | small cell lung cancer | >65yrs | 1 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | 50-65yrs | 1 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | >65yrs | 2 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | >65yrs | 1 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | 50-65yrs | 2 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | 40-50yrs | 1 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | >65yrs | 5 | 1259 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | 50-65yrs | 2 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | uterine cancer | 40-50yrs | 1 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | >65yrs | 1 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-melanoma skin cancers | <40yrs | 1 | 27 | 0.02 | 0.01 | 0.00 | 0.10 |
| HRAS | G12D | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | >65yrs | 1 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | 50-65yrs | 1 | 374 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bladder cancer | <40yrs | 1 | 25 | 0.01 | 0.01 | 0.00 | 0.07 |
| HRAS | G12D | bladder cancer | 40-50yrs | 2 | 78 | 0.01 | 0.01 | 0.00 | 0.05 |
| HRAS | G12D | bladder cancer | 50-65yrs | 1 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bladder cancer | >65yrs | 5 | 961 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12S | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | >65yrs | 1 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | 40-50yrs | 1 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | <40yrs | 1 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | 50-65yrs | 1 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | head and neck cancer | <40yrs | 1 | 140 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | 40-50yrs | 2 | 216 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | G12S | head and neck cancer | 50-65yrs | 3 | 799 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | >65yrs | 5 | 582 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12S | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | 50-65yrs | 1 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | >65yrs | 1 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | non-melanoma skin cancers | 40-50yrs | 1 | 20 | 0.02 | 0.01 | 0.00 | 0.10 |
| HRAS | G12S | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | non-melanoma skin cancers | >65yrs | 1 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | 50-65yrs | 1 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | >65yrs | 1 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bladder cancer | <40yrs | 1 | 25 | 0.02 | 0.01 | 0.00 | 0.10 |
| HRAS | G12S | bladder cancer | 40-50yrs | 1 | 78 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | thymic tumor | <40yrs | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | thymic tumor | 40-50yrs | 0 | 28 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | thymic tumor | >65yrs | 1 | 39 | 0.01 | 0.01 | 0.00 | 0.06 |
| HRAS | G12S | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12S | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12V | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | >65yrs | 1 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | 50-65yrs | 1 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | soft tissue sarcoma | <40yrs | 2 | 667 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | cervical cancer | 50-65yrs | 1 | 144 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13C | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | >65yrs | 1 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | 50-65yrs | 1 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13D | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | 50-65yrs | 3 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | >65yrs | 3 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | 50-65yrs | 1 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | 50-65yrs | 1 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | 50-65yrs | 2 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | thymic tumor | <40yrs | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | thymic tumor | 40-50yrs | 0 | 28 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | thymic tumor | 50-65yrs | 1 | 71 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | G13D | thymic tumor | >65yrs | 0 | 39 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13D | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13D | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | >65yrs | 3 | 795 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | 50-65yrs | 1 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | >65yrs | 3 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | 50-65yrs | 5 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | 50-65yrs | 1 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | 50-65yrs | 2 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | 40-50yrs | 2 | 216 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | 50-65yrs | 5 | 799 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | >65yrs | 3 | 582 | 0.01 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | >65yrs | 1 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | <40yrs | 2 | 667 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | 50-65yrs | 2 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thyroid cancer | <40yrs | 1 | 150 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | 50-65yrs | 1 | 374 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | bladder cancer | 50-65yrs | 2 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | bladder cancer | >65yrs | 6 | 961 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | <40yrs | 1 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | 50-65yrs | 1 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | >65yrs | 6 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | >65yrs | 1 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | >65yrs | 3 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | head and neck cancer | <40yrs | 1 | 140 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | head and neck cancer | 50-65yrs | 1 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | 50-65yrs | 1 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | non-melanoma skin cancers | 50-65yrs | 1 | 149 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | non-melanoma skin cancers | >65yrs | 1 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | 50-65yrs | 2 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | small cell lung cancer | >65yrs | 1 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61H | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | >65yrs | 2 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | 50-65yrs | 1 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | <40yrs | 1 | 166 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | cancer of unknown primary | 40-50yrs | 1 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | >65yrs | 1 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | >65yrs | 2 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | 50-65yrs | 1 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | 40-50yrs | 1 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | 50-65yrs | 4 | 1016 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | >65yrs | 3 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | head and neck cancer | <40yrs | 1 | 140 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | 50-65yrs | 3 | 799 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | 50-65yrs | 1 | 149 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | >65yrs | 1 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | <40yrs | 1 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thyroid cancer | <40yrs | 3 | 150 | 0.01 | 0.01 | 0.01 | 0.03 |
| HRAS | Q61K | thyroid cancer | 40-50yrs | 1 | 122 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61K | thyroid cancer | 50-65yrs | 5 | 374 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61K | thyroid cancer | >65yrs | 3 | 370 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61K | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | 40-50yrs | 1 | 110 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | prostate cancer | 50-65yrs | 4 | 960 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | prostate cancer | >65yrs | 2 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | >65yrs | 5 | 961 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | Q61L | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | <40yrs | 1 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | >65yrs | 0 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | 50-65yrs | 0 | 71 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | >65yrs | 0 | 39 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | <40yrs | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | 50-65yrs | 0 | 809 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | >65yrs | 0 | 795 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | 50-65yrs | 1 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | >65yrs | 2 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | 40-50yrs | 2 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | >65yrs | 2 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | <40yrs | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | 40-50yrs | 0 | 127 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | >65yrs | 0 | 719 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | <40yrs | 1 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | 50-65yrs | 3 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | >65yrs | 1 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | 40-50yrs | 1 | 216 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | 50-65yrs | 6 | 799 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | >65yrs | 2 | 582 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | uterine cancer | <40yrs | 0 | 56 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | 50-65yrs | 0 | 1043 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | >65yrs | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | non-melanoma skin cancers | 50-65yrs | 1 | 149 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | <40yrs | 0 | 667 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | 40-50yrs | 0 | 363 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | 50-65yrs | 0 | 936 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | >65yrs | 1 | 766 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | thyroid cancer | <40yrs | 4 | 150 | 0.03 | 0.03 | 0.02 | 0.05 |
| HRAS | Q61R | thyroid cancer | 40-50yrs | 2 | 122 | 0.03 | 0.03 | 0.01 | 0.04 |
| HRAS | Q61R | thyroid cancer | 50-65yrs | 9 | 374 | 0.03 | 0.03 | 0.02 | 0.04 |
| HRAS | Q61R | thyroid cancer | >65yrs | 15 | 370 | 0.03 | 0.03 | 0.02 | 0.05 |
| HRAS | Q61R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | 50-65yrs | 0 | 1438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | 50-65yrs | 4 | 960 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | >65yrs | 2 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | neuroendocrine tumors | <40yrs | 1 | 22 | 0.02 | 0.01 | 0.00 | 0.12 |
| HRAS | Q61R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | bladder cancer | <40yrs | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | Q61R | bladder cancer | 40-50yrs | 2 | 78 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | Q61R | bladder cancer | 50-65yrs | 3 | 511 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | >65yrs | 11 | 961 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | bone cancer | <40yrs | 0 | 335 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | 40-50yrs | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | 50-65yrs | 0 | 93 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | >65yrs | 0 | 63 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | thymic tumor | <40yrs | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | thymic tumor | 40-50yrs | 0 | 28 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | thymic tumor | 50-65yrs | 0 | 71 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | thymic tumor | >65yrs | 1 | 39 | 0.01 | 0.01 | 0.00 | 0.05 |
| HRAS | Q61R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | >65yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | <40yrs | 0 | 649 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | 40-50yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | 50-65yrs | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | 50-65yrs | 0 | 356 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12A | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | 50-65yrs | 1 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | >65yrs | 4 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | >65yrs | 2 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | leukemia | <40yrs | 1 | 204 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | 40-50yrs | 2 | 128 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G12A | leukemia | 50-65yrs | 1 | 515 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12A | leukemia | >65yrs | 10 | 720 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | G12A | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | melanoma | 40-50yrs | 2 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | melanoma | >65yrs | 3 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 3 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | >65yrs | 1 | 664 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | 40-50yrs | 1 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | <40yrs | 2 | 142 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12C | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | appendiceal cancer | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | colorectal cancer | <40yrs | 1 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | 40-50yrs | 3 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | 50-65yrs | 3 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | >65yrs | 9 | 2052 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | <40yrs | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | 50-65yrs | 1 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | 50-65yrs | 1 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | >65yrs | 2 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | leukemia | <40yrs | 3 | 204 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G12C | leukemia | 40-50yrs | 1 | 128 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | >65yrs | 4 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | 40-50yrs | 1 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | 50-65yrs | 3 | 1016 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | >65yrs | 8 | 1259 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | 40-50yrs | 1 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | 50-65yrs | 3 | 1046 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | >65yrs | 1 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | >65yrs | 1 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | >65yrs | 2 | 601 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | 40-50yrs | 1 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 142 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | colorectal cancer | <40yrs | 5 | 565 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | colorectal cancer | 40-50yrs | 13 | 1280 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | G12D | colorectal cancer | 50-65yrs | 16 | 2814 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | colorectal cancer | >65yrs | 19 | 2052 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | G12D | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | 50-65yrs | 1 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | >65yrs | 2 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | 50-65yrs | 4 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | >65yrs | 4 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | <40yrs | 1 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | leukemia | <40yrs | 8 | 204 | 0.04 | 0.04 | 0.03 | 0.06 |
| NRAS | G12D | leukemia | 40-50yrs | 8 | 128 | 0.05 | 0.05 | 0.03 | 0.07 |
| NRAS | G12D | leukemia | 50-65yrs | 24 | 515 | 0.05 | 0.04 | 0.03 | 0.06 |
| NRAS | G12D | leukemia | >65yrs | 31 | 720 | 0.04 | 0.04 | 0.03 | 0.06 |
| NRAS | G12D | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | 40-50yrs | 1 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | 50-65yrs | 6 | 1016 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | >65yrs | 10 | 1259 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | head and neck cancer | 50-65yrs | 3 | 799 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | 50-65yrs | 7 | 1046 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | >65yrs | 1 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | >65yrs | 1 | 317 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | <40yrs | 3 | 87 | 0.02 | 0.02 | 0.01 | 0.04 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.02 | 0.02 | 0.00 | 0.03 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 5 | 373 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | >65yrs | 12 | 664 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G12D | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | 40-50yrs | 1 | 253 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | ovarian cancer | 50-65yrs | 1 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | hepatobiliary cancer | >65yrs | 4 | 601 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | <40yrs | 2 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | neuroendocrine tumors | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | 50-65yrs | 1 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | <40yrs | 10 | 142 | 0.07 | 0.06 | 0.03 | 0.11 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | 40-50yrs | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 27 | 0.04 | 0.03 | 0.00 | 0.14 |
| NRAS | G12D | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | >65yrs | 0 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | >65yrs | 2 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | >65yrs | 2 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | 50-65yrs | 1 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | >65yrs | 5 | 664 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12S | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | >65yrs | 1 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | >65yrs | 1 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | 50-65yrs | 1 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | >65yrs | 1 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | 50-65yrs | 1 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | leukemia | <40yrs | 1 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | 40-50yrs | 1 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | 50-65yrs | 3 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | >65yrs | 1 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | melanoma | 40-50yrs | 1 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | melanoma | >65yrs | 4 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | 50-65yrs | 1 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | >65yrs | 1 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | >65yrs | 7 | 664 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12S | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | 50-65yrs | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | >65yrs | 1 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | <40yrs | 4 | 142 | 0.02 | 0.02 | 0.01 | 0.05 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G12S | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | germ cell tumor | 40-50yrs | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12S | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 27 | 0.04 | 0.03 | 0.00 | 0.14 |
| NRAS | G12S | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | peritoneal cancer | >65yrs | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G12V | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | <40yrs | 1 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | 40-50yrs | 1 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | 50-65yrs | 1 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | >65yrs | 4 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | 50-65yrs | 2 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | >65yrs | 1 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | 50-65yrs | 1 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | >65yrs | 2 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | leukemia | 40-50yrs | 1 | 128 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | leukemia | 50-65yrs | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | leukemia | >65yrs | 6 | 720 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12V | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | 50-65yrs | 2 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | >65yrs | 1 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | uterine cancer | 40-50yrs | 1 | 162 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | >65yrs | 2 | 664 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | 50-65yrs | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | germ cell tumor | <40yrs | 2 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-hodgkin lymphoma | >65yrs | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13C | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | 40-50yrs | 1 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | 50-65yrs | 1 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | >65yrs | 1 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | <40yrs | 1 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | 50-65yrs | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | >65yrs | 0 | 720 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | 40-50yrs | 1 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | melanoma | 50-65yrs | 0 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | >65yrs | 3 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | >65yrs | 5 | 664 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13C | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13D | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | <40yrs | 1 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | 40-50yrs | 2 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | 50-65yrs | 3 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | >65yrs | 6 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | >65yrs | 0 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | 50-65yrs | 1 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | <40yrs | 2 | 672 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | leukemia | <40yrs | 6 | 204 | 0.02 | 0.02 | 0.01 | 0.04 |
| NRAS | G13D | leukemia | 40-50yrs | 2 | 128 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | 50-65yrs | 10 | 515 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | >65yrs | 14 | 720 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | melanoma | 50-65yrs | 4 | 1016 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | melanoma | >65yrs | 4 | 1259 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | <40yrs | 1 | 57 | 0.01 | 0.01 | 0.00 | 0.06 |
| NRAS | G13D | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | <40yrs | 3 | 87 | 0.02 | 0.01 | 0.00 | 0.06 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 3 | 373 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | >65yrs | 3 | 664 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13D | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | neuroendocrine tumors | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | <40yrs | 5 | 142 | 0.03 | 0.03 | 0.01 | 0.06 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.02 | 0.02 | 0.00 | 0.06 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 1 | 48 | 0.02 | 0.02 | 0.00 | 0.06 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.02 | 0.02 | 0.00 | 0.05 |
| NRAS | G13D | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13D | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13D | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | appendiceal cancer | 50-65yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | 40-50yrs | 1 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | 50-65yrs | 13 | 2814 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | >65yrs | 5 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cancer of unknown primary | <40yrs | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | 40-50yrs | 1 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | 50-65yrs | 2 | 810 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | >65yrs | 1 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | >65yrs | 2 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | leukemia | <40yrs | 1 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | 50-65yrs | 3 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | >65yrs | 3 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | <40yrs | 1 | 289 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | 40-50yrs | 1 | 282 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | 50-65yrs | 9 | 1016 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | >65yrs | 9 | 1259 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | head and neck cancer | 50-65yrs | 1 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | head and neck cancer | >65yrs | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | >65yrs | 1 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | adrenocortical carcinoma | >65yrs | 1 | 26 | 0.02 | 0.01 | 0.00 | 0.09 |
| NRAS | G13R | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thyroid cancer | >65yrs | 2 | 370 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | 50-65yrs | 2 | 525 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | >65yrs | 1 | 601 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | >65yrs | 2 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | <40yrs | 1 | 142 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | sex cord stromal tumor | <40yrs | 1 | 29 | 0.02 | 0.01 | 0.00 | 0.08 |
| NRAS | G13R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G13R | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | 40-50yrs | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13R | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-hodgkin lymphoma | >65yrs | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | 40-50yrs | 0 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | 50-65yrs | 0 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | >65yrs | 0 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | >65yrs | 0 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | >65yrs | 1 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | <40yrs | 0 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | 50-65yrs | 1 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | 50-65yrs | 4 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | >65yrs | 1 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | 40-50yrs | 0 | 282 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | 50-65yrs | 1 | 1016 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | >65yrs | 3 | 1259 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | 50-65yrs | 0 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | >65yrs | 0 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 1 | 83 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 2 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | >65yrs | 2 | 664 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 1 | 16 | 0.04 | 0.02 | 0.00 | 0.18 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | >65yrs | 0 | 413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61H | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | <40yrs | 0 | 565 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | 40-50yrs | 3 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | 50-65yrs | 6 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | >65yrs | 8 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | 50-65yrs | 2 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | >65yrs | 1 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | 40-50yrs | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | 50-65yrs | 0 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | >65yrs | 4 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | <40yrs | 1 | 672 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | 50-65yrs | 1 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | >65yrs | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | leukemia | <40yrs | 2 | 204 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | leukemia | 40-50yrs | 1 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | 50-65yrs | 2 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | >65yrs | 2 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | <40yrs | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | 40-50yrs | 1 | 282 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | 50-65yrs | 15 | 1016 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61H | melanoma | >65yrs | 11 | 1259 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61H | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | 50-65yrs | 1 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | 50-65yrs | 2 | 1046 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | >65yrs | 2 | 987 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | 50-65yrs | 0 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | >65yrs | 0 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cervical cancer | 50-65yrs | 1 | 144 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | mature t and nk neoplasms | 50-65yrs | 1 | 76 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cns cancer | <40yrs | 0 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | 40-50yrs | 0 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | 50-65yrs | 0 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | >65yrs | 2 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | <40yrs | 2 | 142 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | germ cell tumor | <40yrs | 2 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | 40-50yrs | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61H | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | lung cancer | >65yrs | 1 | 18 | 0.06 | 0.05 | 0.00 | 0.20 |
| NRAS | Q61H | peritoneal cancer | >65yrs | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | Q61K | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | colorectal cancer | <40yrs | 5 | 565 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | colorectal cancer | 40-50yrs | 12 | 1280 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | colorectal cancer | 50-65yrs | 30 | 2814 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | colorectal cancer | >65yrs | 18 | 2052 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | <40yrs | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | 40-50yrs | 2 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | 50-65yrs | 2 | 810 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | >65yrs | 2 | 796 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-small cell lung cancer | <40yrs | 1 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-small cell lung cancer | 40-50yrs | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | 50-65yrs | 2 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | >65yrs | 4 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | soft tissue sarcoma | <40yrs | 9 | 672 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | soft tissue sarcoma | 40-50yrs | 2 | 367 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | 50-65yrs | 1 | 951 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | >65yrs | 3 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | >65yrs | 2 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | leukemia | <40yrs | 0 | 204 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | 40-50yrs | 3 | 128 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | leukemia | 50-65yrs | 3 | 515 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61K | leukemia | >65yrs | 8 | 720 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | melanoma | <40yrs | 14 | 289 | 0.06 | 0.06 | 0.04 | 0.08 |
| NRAS | Q61K | melanoma | 40-50yrs | 17 | 282 | 0.07 | 0.07 | 0.05 | 0.08 |
| NRAS | Q61K | melanoma | 50-65yrs | 83 | 1016 | 0.08 | 0.08 | 0.06 | 0.09 |
| NRAS | Q61K | melanoma | >65yrs | 85 | 1259 | 0.07 | 0.07 | 0.06 | 0.08 |
| NRAS | Q61K | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | head and neck cancer | 40-50yrs | 1 | 216 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | head and neck cancer | 50-65yrs | 2 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | 50-65yrs | 3 | 1046 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | >65yrs | 3 | 987 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | 40-50yrs | 2 | 253 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | 50-65yrs | 2 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | ovarian cancer | >65yrs | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | >65yrs | 1 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | thyroid cancer | <40yrs | 3 | 150 | 0.03 | 0.03 | 0.01 | 0.04 |
| NRAS | Q61K | thyroid cancer | 40-50yrs | 2 | 122 | 0.03 | 0.03 | 0.01 | 0.04 |
| NRAS | Q61K | thyroid cancer | 50-65yrs | 15 | 374 | 0.03 | 0.03 | 0.02 | 0.05 |
| NRAS | Q61K | thyroid cancer | >65yrs | 9 | 370 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61K | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | 50-65yrs | 3 | 525 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | >65yrs | 4 | 601 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | <40yrs | 6 | 1602 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | 40-50yrs | 1 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | >65yrs | 0 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | 50-65yrs | 2 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | <40yrs | 3 | 142 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | thymic tumor | <40yrs | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | thymic tumor | 40-50yrs | 0 | 28 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | thymic tumor | >65yrs | 1 | 40 | 0.01 | 0.01 | 0.00 | 0.06 |
| NRAS | Q61K | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | small cell lung cancer | 50-65yrs | 1 | 144 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | 40-50yrs | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | germ cell tumor | 50-65yrs | 1 | 92 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | 40-50yrs | 1 | 105 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | b cell lymphoma | 50-65yrs | 1 | 357 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61L | appendiceal cancer | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | 40-50yrs | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | >65yrs | 0 | 90 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | <40yrs | 2 | 565 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | 40-50yrs | 4 | 1280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | 50-65yrs | 11 | 2814 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | >65yrs | 5 | 2052 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | <40yrs | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | 40-50yrs | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | 50-65yrs | 0 | 810 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | >65yrs | 1 | 796 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | 40-50yrs | 2 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | 50-65yrs | 15 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | >65yrs | 15 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | <40yrs | 2 | 672 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | 50-65yrs | 0 | 951 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | >65yrs | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | 50-65yrs | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | >65yrs | 0 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | leukemia | <40yrs | 0 | 204 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | 40-50yrs | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | 50-65yrs | 3 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | >65yrs | 3 | 720 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | melanoma | <40yrs | 5 | 289 | 0.02 | 0.02 | 0.01 | 0.04 |
| NRAS | Q61L | melanoma | 40-50yrs | 7 | 282 | 0.03 | 0.02 | 0.01 | 0.04 |
| NRAS | Q61L | melanoma | 50-65yrs | 18 | 1016 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | Q61L | melanoma | >65yrs | 58 | 1259 | 0.04 | 0.04 | 0.03 | 0.06 |
| NRAS | Q61L | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | 40-50yrs | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | 50-65yrs | 4 | 1046 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | >65yrs | 2 | 987 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 0 | 373 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | >65yrs | 0 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | <40yrs | 0 | 141 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | 40-50yrs | 0 | 253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | 50-65yrs | 1 | 1092 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | >65yrs | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | 40-50yrs | 0 | 200 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | 50-65yrs | 0 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | >65yrs | 1 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | <40yrs | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | 40-50yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | 50-65yrs | 0 | 374 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | >65yrs | 0 | 370 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | <40yrs | 0 | 85 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | <40yrs | 0 | 137 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | 40-50yrs | 0 | 110 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | 50-65yrs | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | >65yrs | 0 | 601 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | 50-65yrs | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | <40yrs | 1 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | 40-50yrs | 1 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | >65yrs | 2 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | >65yrs | 0 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | <40yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | 40-50yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | 50-65yrs | 0 | 511 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | >65yrs | 0 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | >65yrs | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | small cell lung cancer | >65yrs | 1 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | >65yrs | 0 | 316 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | <40yrs | 1 | 650 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | 40-50yrs | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | germ cell tumor | 50-65yrs | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | germ cell tumor | >65yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | nerve sheath tumor | <40yrs | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | 50-65yrs | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | >65yrs | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | b cell lymphoma | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | 50-65yrs | 0 | 357 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b cell lymphoma | >65yrs | 1 | 413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | appendiceal cancer | <40yrs | 0 | 28 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | appendiceal cancer | 40-50yrs | 2 | 62 | 0.02 | 0.02 | 0.00 | 0.05 |
| NRAS | Q61R | appendiceal cancer | 50-65yrs | 2 | 161 | 0.02 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | appendiceal cancer | >65yrs | 1 | 90 | 0.02 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | colorectal cancer | <40yrs | 3 | 565 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | 40-50yrs | 13 | 1280 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | 50-65yrs | 19 | 2814 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | >65yrs | 11 | 2052 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | <40yrs | 2 | 167 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cancer of unknown primary | 40-50yrs | 1 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | 50-65yrs | 4 | 810 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | >65yrs | 1 | 796 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-small cell lung cancer | <40yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | 40-50yrs | 2 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | 50-65yrs | 6 | 3677 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | >65yrs | 7 | 5698 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | <40yrs | 0 | 840 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | 40-50yrs | 0 | 1910 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | 50-65yrs | 0 | 3989 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | >65yrs | 0 | 2583 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Age:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | <40yrs | 3 | 672 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | soft tissue sarcoma | 40-50yrs | 0 | 367 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | 50-65yrs | 3 | 951 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | soft tissue sarcoma | >65yrs | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | pancreatic cancer | <40yrs | 1 | 87 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pancreatic cancer | 40-50yrs | 2 | 200 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pancreatic cancer | 50-65yrs | 3 | 999 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | pancreatic cancer | >65yrs | 1 | 1205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | leukemia | <40yrs | 5 | 204 | 0.01 | 0.01 | 0.01 | 0.03 |
| NRAS | Q61R | leukemia | 40-50yrs | 1 | 128 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | leukemia | 50-65yrs | 5 | 515 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | leukemia | >65yrs | 6 | 720 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | melanoma | <40yrs | 18 | 289 | 0.08 | 0.08 | 0.06 | 0.10 |
| NRAS | Q61R | melanoma | 40-50yrs | 28 | 282 | 0.09 | 0.09 | 0.07 | 0.12 |
| NRAS | Q61R | melanoma | 50-65yrs | 92 | 1016 | 0.09 | 0.09 | 0.08 | 0.10 |
| NRAS | Q61R | melanoma | >65yrs | 108 | 1259 | 0.09 | 0.09 | 0.07 | 0.10 |
| NRAS | Q61R | head and neck cancer | <40yrs | 0 | 140 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | 40-50yrs | 0 | 216 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | 50-65yrs | 0 | 799 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | >65yrs | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | uterine cancer | <40yrs | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | uterine cancer | 40-50yrs | 3 | 162 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | uterine cancer | 50-65yrs | 5 | 1046 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | >65yrs | 1 | 987 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-melanoma skin cancers | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | 40-50yrs | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | 50-65yrs | 0 | 149 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | >65yrs | 0 | 317 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | <40yrs | 0 | 87 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | 40-50yrs | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | 50-65yrs | 1 | 373 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | >65yrs | 1 | 664 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | adrenocortical carcinoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | adrenocortical carcinoma | 40-50yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | adrenocortical carcinoma | 50-65yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | adrenocortical carcinoma | >65yrs | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ovarian cancer | <40yrs | 2 | 141 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | ovarian cancer | 40-50yrs | 1 | 253 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | ovarian cancer | 50-65yrs | 14 | 1092 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | ovarian cancer | >65yrs | 8 | 849 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | esophagogastric cancer | <40yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | esophagogastric cancer | 40-50yrs | 1 | 200 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | esophagogastric cancer | 50-65yrs | 1 | 752 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | esophagogastric cancer | >65yrs | 1 | 725 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thyroid cancer | <40yrs | 8 | 150 | 0.08 | 0.08 | 0.04 | 0.11 |
| NRAS | Q61R | thyroid cancer | 40-50yrs | 15 | 122 | 0.10 | 0.10 | 0.07 | 0.15 |
| NRAS | Q61R | thyroid cancer | 50-65yrs | 31 | 374 | 0.09 | 0.09 | 0.06 | 0.11 |
| NRAS | Q61R | thyroid cancer | >65yrs | 41 | 370 | 0.10 | 0.10 | 0.08 | 0.13 |
| NRAS | Q61R | cervical cancer | <40yrs | 1 | 85 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | cervical cancer | 40-50yrs | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cervical cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cervical cancer | >65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | hepatobiliary cancer | <40yrs | 0 | 137 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | 40-50yrs | 1 | 110 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | hepatobiliary cancer | 50-65yrs | 4 | 525 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | >65yrs | 4 | 601 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | kidney cancer | <40yrs | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | 40-50yrs | 0 | 159 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | 50-65yrs | 0 | 628 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | >65yrs | 0 | 440 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mature t and nk neoplasms | <40yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | mature t and nk neoplasms | 40-50yrs | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | mature t and nk neoplasms | 50-65yrs | 1 | 76 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | mature t and nk neoplasms | >65yrs | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cns cancer | <40yrs | 4 | 1602 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | 40-50yrs | 1 | 687 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | 50-65yrs | 1 | 1439 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | >65yrs | 1 | 836 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | 40-50yrs | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | 50-65yrs | 0 | 960 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | >65yrs | 1 | 1402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | anal cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | anal cancer | 50-65yrs | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | anal cancer | >65yrs | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | neuroendocrine tumors | <40yrs | 1 | 22 | 0.02 | 0.01 | 0.00 | 0.12 |
| NRAS | Q61R | neuroendocrine tumors | 40-50yrs | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | neuroendocrine tumors | 50-65yrs | 0 | 161 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | neuroendocrine tumors | >65yrs | 0 | 121 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | <40yrs | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | 40-50yrs | 1 | 78 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | bladder cancer | 50-65yrs | 1 | 511 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | >65yrs | 1 | 961 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | <40yrs | 2 | 142 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | 40-50yrs | 0 | 16 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | 50-65yrs | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | >65yrs | 0 | 42 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | small bowel cancer | 40-50yrs | 0 | 29 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | small bowel cancer | 50-65yrs | 1 | 96 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | small bowel cancer | >65yrs | 1 | 78 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | sex cord stromal tumor | <40yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | sex cord stromal tumor | 40-50yrs | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | sex cord stromal tumor | 50-65yrs | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | sex cord stromal tumor | >65yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bone cancer | <40yrs | 0 | 342 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | 40-50yrs | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | 50-65yrs | 0 | 96 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | >65yrs | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | vaginal cancer | 50-65yrs | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | vaginal cancer | >65yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | thymic tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | 40-50yrs | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | 50-65yrs | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | >65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ampullary cancer | 40-50yrs | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | ampullary cancer | 50-65yrs | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ampullary cancer | >65yrs | 0 | 50 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | 40-50yrs | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | 50-65yrs | 0 | 144 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | >65yrs | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mesothelioma | <40yrs | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | mesothelioma | 40-50yrs | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | mesothelioma | 50-65yrs | 0 | 122 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | mesothelioma | >65yrs | 1 | 316 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | <40yrs | 0 | 650 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | 40-50yrs | 2 | 131 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | germ cell tumor | 50-65yrs | 1 | 92 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | germ cell tumor | >65yrs | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | nerve sheath tumor | <40yrs | 0 | 77 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | nerve sheath tumor | 40-50yrs | 0 | 27 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | nerve sheath tumor | 50-65yrs | 1 | 37 | 0.02 | 0.01 | 0.00 | 0.07 |
| NRAS | Q61R | nerve sheath tumor | >65yrs | 1 | 13 | 0.03 | 0.02 | 0.00 | 0.16 |
| NRAS | Q61R | penile cancer | 50-65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | penile cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pineal tumor | <40yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | b cell lymphoma | <40yrs | 0 | 87 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | b cell lymphoma | 40-50yrs | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | b cell lymphoma | 50-65yrs | 4 | 357 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | b cell lymphoma | >65yrs | 2 | 413 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-hodgkin lymphoma | >65yrs | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | <40yrs | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | retinoblastoma | <40yrs | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | hodgkin lymphoma | <40yrs | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | lung cancer | >65yrs | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | peritoneal cancer | >65yrs | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12A | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | appendiceal cancer | Race:NA | 1 | 33 | 0.02 | 0.01 | 0.00 | 0.09 |
| KRAS | G12A | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | colorectal cancer | Asian | 5 | 313 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12A | colorectal cancer | Black | 16 | 515 | 0.03 | 0.02 | 0.02 | 0.04 |
| KRAS | G12A | colorectal cancer | Race:NA | 19 | 804 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | Native American | 0 | 17 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12A | colorectal cancer | Race:Other | 7 | 139 | 0.03 | 0.02 | 0.02 | 0.05 |
| KRAS | G12A | colorectal cancer | White | 98 | 4925 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12A | cancer of unknown primary | Asian | 0 | 73 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | Black | 1 | 123 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | cancer of unknown primary | Race:NA | 1 | 286 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | Race:Other | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | cancer of unknown primary | White | 12 | 1465 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | non-small cell lung cancer | Asian | 2 | 624 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | Black | 13 | 717 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12A | non-small cell lung cancer | Race:NA | 12 | 849 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | Native American | 0 | 17 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12A | non-small cell lung cancer | Race:Other | 3 | 165 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12A | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G12A | non-small cell lung cancer | White | 196 | 7745 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Race:NA | 3 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | White | 3 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | pancreatic cancer | Asian | 1 | 100 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | Race:NA | 2 | 231 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | Race:Other | 0 | 34 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | White | 10 | 2038 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Race:NA | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | White | 3 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | White | 1 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | uterine cancer | Asian | 1 | 108 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | uterine cancer | Race:Other | 0 | 37 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | uterine cancer | White | 30 | 1754 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12A | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Race:NA | 1 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ovarian cancer | Asian | 2 | 134 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | Race:Other | 0 | 36 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | ovarian cancer | White | 12 | 1852 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Race:NA | 2 | 191 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | White | 4 | 1379 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cervical cancer | Asian | 1 | 27 | 0.02 | 0.01 | 0.00 | 0.09 |
| KRAS | G12A | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Asian | 1 | 98 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Race:NA | 2 | 235 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Race:Other | 0 | 25 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | hepatobiliary cancer | White | 4 | 948 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Race:Other | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cns cancer | White | 5 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | anal cancer | Race:NA | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12A | anal cancer | White | 1 | 126 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Race:NA | 1 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | White | 2 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Asian | 1 | 17 | 0.04 | 0.02 | 0.00 | 0.17 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | small bowel cancer | Black | 0 | 25 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G12A | small bowel cancer | Race:NA | 0 | 22 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G12A | small bowel cancer | White | 4 | 150 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12A | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | bone cancer | White | 2 | 391 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | vaginal cancer | White | 1 | 68 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12A | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ampullary cancer | White | 1 | 86 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12A | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | small cell lung cancer | Race:NA | 1 | 30 | 0.02 | 0.01 | 0.00 | 0.10 |
| KRAS | G12A | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | germ cell tumor | Asian | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | Black | 0 | 23 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | Race:NA | 1 | 179 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | Race:Other | 0 | 37 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | White | 6 | 603 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | nerve sheath tumor | Black | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | nerve sheath tumor | Race:NA | 0 | 26 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | nerve sheath tumor | White | 1 | 105 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b cell lymphoma | White | 2 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | appendiceal cancer | Black | 0 | 17 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12C | appendiceal cancer | Race:NA | 0 | 33 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12C | appendiceal cancer | White | 7 | 280 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12C | colorectal cancer | Asian | 8 | 313 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | colorectal cancer | Black | 15 | 515 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | colorectal cancer | Race:NA | 30 | 804 | 0.03 | 0.03 | 0.03 | 0.04 |
| KRAS | G12C | colorectal cancer | Native American | 2 | 17 | 0.03 | 0.03 | 0.02 | 0.05 |
| KRAS | G12C | colorectal cancer | Race:Other | 4 | 139 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | colorectal cancer | White | 152 | 4925 | 0.03 | 0.03 | 0.03 | 0.04 |
| KRAS | G12C | cancer of unknown primary | Asian | 1 | 73 | 0.03 | 0.03 | 0.01 | 0.04 |
| KRAS | G12C | cancer of unknown primary | Black | 5 | 123 | 0.03 | 0.03 | 0.02 | 0.05 |
| KRAS | G12C | cancer of unknown primary | Race:NA | 7 | 286 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | cancer of unknown primary | Race:Other | 0 | 36 | 0.03 | 0.03 | 0.01 | 0.04 |
| KRAS | G12C | cancer of unknown primary | White | 48 | 1465 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | non-small cell lung cancer | Asian | 21 | 624 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12C | non-small cell lung cancer | Black | 78 | 717 | 0.11 | 0.11 | 0.09 | 0.13 |
| KRAS | G12C | non-small cell lung cancer | Race:NA | 76 | 849 | 0.09 | 0.09 | 0.07 | 0.11 |
| KRAS | G12C | non-small cell lung cancer | Native American | 1 | 17 | 0.08 | 0.07 | 0.02 | 0.17 |
| KRAS | G12C | non-small cell lung cancer | Race:Other | 10 | 165 | 0.06 | 0.06 | 0.04 | 0.10 |
| KRAS | G12C | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.07 | 0.06 | 0.01 | 0.16 |
| KRAS | G12C | non-small cell lung cancer | White | 1026 | 7745 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12C | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Race:NA | 2 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | White | 6 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | Black | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | soft tissue sarcoma | Race:NA | 1 | 350 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | soft tissue sarcoma | White | 3 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | pancreatic cancer | Asian | 0 | 100 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | Black | 1 | 88 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | Race:NA | 3 | 231 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | Race:Other | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | White | 18 | 2038 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G12C | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | White | 2 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | head and neck cancer | Black | 1 | 62 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | head and neck cancer | Race:NA | 1 | 292 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | uterine cancer | Asian | 2 | 108 | 0.01 | 0.01 | 0.01 | 0.03 |
| KRAS | G12C | uterine cancer | Black | 1 | 163 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | uterine cancer | Race:NA | 1 | 190 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | uterine cancer | Race:Other | 1 | 37 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12C | uterine cancer | White | 21 | 1754 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ovarian cancer | Asian | 1 | 134 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Race:NA | 2 | 239 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | White | 7 | 1852 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Race:NA | 1 | 191 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | White | 4 | 1379 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | White | 2 | 803 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | cervical cancer | White | 1 | 228 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | Asian | 0 | 98 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | Black | 0 | 64 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | hepatobiliary cancer | Race:NA | 1 | 235 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | Race:Other | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | hepatobiliary cancer | White | 9 | 948 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | White | 1 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | neuroendocrine tumors | Black | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | neuroendocrine tumors | Race:NA | 1 | 45 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G12C | neuroendocrine tumors | White | 1 | 283 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | White | 7 | 1311 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | small bowel cancer | Black | 3 | 25 | 0.07 | 0.06 | 0.02 | 0.22 |
| KRAS | G12C | small bowel cancer | Race:NA | 1 | 22 | 0.04 | 0.03 | 0.00 | 0.13 |
| KRAS | G12C | small bowel cancer | White | 2 | 150 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12C | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ampullary cancer | White | 2 | 86 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | G12C | small cell lung cancer | Asian | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12C | small cell lung cancer | Race:NA | 0 | 30 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12C | small cell lung cancer | White | 3 | 337 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | White | 4 | 603 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12C | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | lung cancer | White | 1 | 17 | 0.07 | 0.05 | 0.00 | 0.22 |
| KRAS | G12C | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12C | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | appendiceal cancer | Black | 5 | 17 | 0.28 | 0.27 | 0.18 | 0.42 |
| KRAS | G12D | appendiceal cancer | Race:NA | 12 | 33 | 0.30 | 0.29 | 0.21 | 0.44 |
| KRAS | G12D | appendiceal cancer | White | 71 | 280 | 0.26 | 0.26 | 0.21 | 0.31 |
| KRAS | G12D | colorectal cancer | Asian | 45 | 313 | 0.14 | 0.14 | 0.12 | 0.16 |
| KRAS | G12D | colorectal cancer | Black | 79 | 515 | 0.14 | 0.14 | 0.12 | 0.17 |
| KRAS | G12D | colorectal cancer | Race:NA | 104 | 804 | 0.13 | 0.13 | 0.12 | 0.15 |
| KRAS | G12D | colorectal cancer | Native American | 4 | 17 | 0.14 | 0.13 | 0.11 | 0.18 |
| KRAS | G12D | colorectal cancer | Race:Other | 15 | 139 | 0.13 | 0.13 | 0.10 | 0.16 |
| KRAS | G12D | colorectal cancer | White | 634 | 4925 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12D | cancer of unknown primary | Asian | 5 | 73 | 0.06 | 0.06 | 0.04 | 0.08 |
| KRAS | G12D | cancer of unknown primary | Black | 7 | 123 | 0.06 | 0.05 | 0.04 | 0.08 |
| KRAS | G12D | cancer of unknown primary | Race:NA | 14 | 286 | 0.05 | 0.05 | 0.04 | 0.07 |
| KRAS | G12D | cancer of unknown primary | Race:Other | 3 | 36 | 0.06 | 0.06 | 0.04 | 0.09 |
| KRAS | G12D | cancer of unknown primary | White | 78 | 1465 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12D | non-small cell lung cancer | Asian | 15 | 624 | 0.04 | 0.04 | 0.02 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | Black | 27 | 717 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | Race:NA | 40 | 849 | 0.04 | 0.04 | 0.04 | 0.06 |
| KRAS | G12D | non-small cell lung cancer | Native American | 1 | 17 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G12D | non-small cell lung cancer | Race:Other | 7 | 165 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | non-small cell lung cancer | Race:Undefined | 1 | 10 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G12D | non-small cell lung cancer | White | 340 | 7745 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12D | breast cancer | Asian | 1 | 334 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | Race:NA | 3 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | breast cancer | Race:Other | 2 | 176 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | breast cancer | White | 5 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Race:NA | 2 | 350 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | White | 9 | 2005 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | pancreatic cancer | Asian | 24 | 100 | 0.29 | 0.30 | 0.22 | 0.34 |
| KRAS | G12D | pancreatic cancer | Black | 24 | 88 | 0.30 | 0.30 | 0.24 | 0.35 |
| KRAS | G12D | pancreatic cancer | Race:NA | 78 | 231 | 0.32 | 0.32 | 0.28 | 0.37 |
| KRAS | G12D | pancreatic cancer | Race:Other | 12 | 34 | 0.32 | 0.31 | 0.25 | 0.39 |
| KRAS | G12D | pancreatic cancer | White | 642 | 2038 | 0.31 | 0.31 | 0.30 | 0.33 |
| KRAS | G12D | leukemia | Asian | 1 | 37 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12D | leukemia | Black | 0 | 69 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | leukemia | Race:NA | 14 | 777 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12D | leukemia | Race:Other | 0 | 13 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | leukemia | White | 6 | 662 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | melanoma | Black | 1 | 34 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G12D | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | melanoma | White | 13 | 2348 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | White | 4 | 1264 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | uterine cancer | Asian | 4 | 108 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | uterine cancer | Black | 4 | 163 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | uterine cancer | Race:NA | 10 | 190 | 0.05 | 0.04 | 0.03 | 0.07 |
| KRAS | G12D | uterine cancer | Race:Other | 2 | 37 | 0.05 | 0.04 | 0.03 | 0.07 |
| KRAS | G12D | uterine cancer | White | 82 | 1754 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12D | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | non-melanoma skin cancers | Race:NA | 1 | 53 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12D | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Race:NA | 2 | 571 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | White | 2 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ovarian cancer | Asian | 5 | 134 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | ovarian cancer | Black | 5 | 74 | 0.04 | 0.04 | 0.03 | 0.09 |
| KRAS | G12D | ovarian cancer | Race:NA | 8 | 239 | 0.04 | 0.04 | 0.02 | 0.05 |
| KRAS | G12D | ovarian cancer | Race:Other | 4 | 36 | 0.05 | 0.04 | 0.03 | 0.12 |
| KRAS | G12D | ovarian cancer | White | 60 | 1852 | 0.03 | 0.03 | 0.03 | 0.04 |
| KRAS | G12D | esophagogastric cancer | Asian | 1 | 115 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | Black | 1 | 68 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | Race:NA | 3 | 191 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | Race:Other | 1 | 46 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | White | 27 | 1379 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | White | 3 | 803 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | cervical cancer | Asian | 0 | 27 | 0.03 | 0.02 | 0.00 | 0.05 |
| KRAS | G12D | cervical cancer | Black | 1 | 19 | 0.03 | 0.03 | 0.01 | 0.08 |
| KRAS | G12D | cervical cancer | Race:NA | 3 | 77 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | cervical cancer | Race:Other | 0 | 15 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G12D | cervical cancer | White | 6 | 228 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12D | hepatobiliary cancer | Asian | 7 | 98 | 0.05 | 0.04 | 0.03 | 0.09 |
| KRAS | G12D | hepatobiliary cancer | Black | 0 | 64 | 0.03 | 0.04 | 0.00 | 0.06 |
| KRAS | G12D | hepatobiliary cancer | Race:NA | 11 | 235 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | hepatobiliary cancer | Race:Other | 1 | 25 | 0.04 | 0.04 | 0.02 | 0.08 |
| KRAS | G12D | hepatobiliary cancer | White | 36 | 948 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | kidney cancer | Black | 1 | 77 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | kidney cancer | Race:NA | 2 | 169 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | kidney cancer | White | 2 | 1113 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | cns cancer | White | 7 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | prostate cancer | Black | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | anal cancer | Race:NA | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12D | anal cancer | White | 1 | 126 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | neuroendocrine tumors | Black | 0 | 23 | 0.03 | 0.03 | 0.00 | 0.08 |
| KRAS | G12D | neuroendocrine tumors | Race:NA | 5 | 45 | 0.08 | 0.07 | 0.02 | 0.18 |
| KRAS | G12D | neuroendocrine tumors | White | 9 | 283 | 0.04 | 0.03 | 0.02 | 0.06 |
| KRAS | G12D | bladder cancer | Asian | 0 | 40 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12D | bladder cancer | Black | 1 | 43 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12D | bladder cancer | Race:NA | 2 | 169 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12D | bladder cancer | Race:Other | 0 | 14 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12D | bladder cancer | White | 28 | 1311 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.03 | 0.03 | 0.00 | 0.08 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Race:NA | 5 | 92 | 0.04 | 0.04 | 0.02 | 0.09 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | White | 3 | 125 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | small bowel cancer | Black | 3 | 25 | 0.12 | 0.12 | 0.06 | 0.21 |
| KRAS | G12D | small bowel cancer | Race:NA | 3 | 22 | 0.13 | 0.12 | 0.06 | 0.22 |
| KRAS | G12D | small bowel cancer | White | 18 | 150 | 0.12 | 0.12 | 0.08 | 0.17 |
| KRAS | G12D | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | Race:Other | 1 | 29 | 0.01 | 0.00 | 0.00 | 0.06 |
| KRAS | G12D | bone cancer | White | 1 | 391 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ampullary cancer | White | 22 | 86 | 0.26 | 0.26 | 0.17 | 0.35 |
| KRAS | G12D | small cell lung cancer | Asian | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | small cell lung cancer | Race:NA | 0 | 30 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | small cell lung cancer | White | 3 | 337 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | germ cell tumor | Asian | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Black | 0 | 23 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Race:NA | 1 | 179 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Race:Other | 1 | 37 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12D | germ cell tumor | White | 7 | 603 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | b cell lymphoma | White | 3 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12D | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Black | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Race:NA | 1 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | White | 0 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | cancer of unknown primary | White | 3 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Black | 5 | 717 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | Race:NA | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | Race:Other | 1 | 165 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | White | 25 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | White | 1 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | White | 0 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Race:NA | 1 | 239 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | White | 0 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12F | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | appendiceal cancer | Black | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | appendiceal cancer | Race:NA | 0 | 33 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | appendiceal cancer | White | 3 | 280 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | colorectal cancer | Asian | 1 | 313 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | Black | 1 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | Race:NA | 10 | 804 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | colorectal cancer | Native American | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | White | 22 | 4925 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | Asian | 0 | 73 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | cancer of unknown primary | Black | 3 | 123 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | cancer of unknown primary | Race:NA | 4 | 286 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | cancer of unknown primary | Race:Other | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | cancer of unknown primary | White | 10 | 1465 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Asian | 1 | 624 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Black | 1 | 717 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Race:NA | 4 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Native American | 1 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | non-small cell lung cancer | Race:Other | 2 | 165 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | White | 27 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Black | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | White | 3 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | White | 3 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | pancreatic cancer | Asian | 8 | 100 | 0.10 | 0.10 | 0.07 | 0.13 |
| KRAS | G12R | pancreatic cancer | Black | 10 | 88 | 0.11 | 0.11 | 0.08 | 0.14 |
| KRAS | G12R | pancreatic cancer | Race:NA | 22 | 231 | 0.10 | 0.10 | 0.08 | 0.13 |
| KRAS | G12R | pancreatic cancer | Race:Other | 3 | 34 | 0.11 | 0.11 | 0.07 | 0.14 |
| KRAS | G12R | pancreatic cancer | White | 233 | 2038 | 0.11 | 0.11 | 0.10 | 0.13 |
| KRAS | G12R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | Race:NA | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | leukemia | White | 1 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | melanoma | White | 3 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | White | 2 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Race:NA | 1 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | Black | 1 | 74 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | White | 9 | 1852 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | Asian | 1 | 115 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | Race:NA | 1 | 191 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | White | 1 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | cervical cancer | Race:NA | 1 | 77 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | White | 3 | 948 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | White | 2 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | prostate cancer | White | 3 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | neuroendocrine tumors | Black | 1 | 23 | 0.02 | 0.01 | 0.00 | 0.09 |
| KRAS | G12R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | White | 3 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small bowel cancer | Black | 1 | 25 | 0.02 | 0.01 | 0.00 | 0.08 |
| KRAS | G12R | small bowel cancer | Race:NA | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | small bowel cancer | White | 1 | 150 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ampullary cancer | White | 3 | 86 | 0.04 | 0.03 | 0.01 | 0.08 |
| KRAS | G12R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | germ cell tumor | Asian | 0 | 36 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | Black | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | germ cell tumor | Race:Other | 0 | 37 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | White | 8 | 603 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | appendiceal cancer | White | 1 | 280 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | colorectal cancer | Asian | 8 | 313 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12S | colorectal cancer | Black | 14 | 515 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12S | colorectal cancer | Race:NA | 14 | 804 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12S | colorectal cancer | Native American | 0 | 17 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12S | colorectal cancer | Race:Other | 4 | 139 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12S | colorectal cancer | White | 85 | 4925 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12S | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | Black | 2 | 123 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | White | 3 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-small cell lung cancer | Asian | 5 | 624 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Black | 5 | 717 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Race:NA | 5 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Native American | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Race:Other | 1 | 165 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | White | 36 | 7745 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Black | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | White | 4 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | White | 0 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Race:NA | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | White | 1 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | uterine cancer | Asian | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | White | 5 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | White | 2 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Race:NA | 1 | 239 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | Race:NA | 1 | 191 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | White | 3 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cervical cancer | Asian | 1 | 27 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G12S | cervical cancer | Black | 0 | 19 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12S | cervical cancer | Race:NA | 0 | 77 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | cervical cancer | Race:Other | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12S | cervical cancer | White | 2 | 228 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | White | 2 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | White | 1 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bladder cancer | Black | 1 | 43 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | bladder cancer | White | 1 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small bowel cancer | Black | 1 | 25 | 0.02 | 0.01 | 0.00 | 0.08 |
| KRAS | G12S | small bowel cancer | Race:NA | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | small bowel cancer | White | 1 | 150 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12S | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | germ cell tumor | Asian | 1 | 36 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | germ cell tumor | Black | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | germ cell tumor | Race:NA | 1 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | germ cell tumor | White | 2 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | b cell lymphoma | White | 3 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.03 | 0.02 | 0.00 | 0.12 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | White | 1 | 23 | 0.04 | 0.03 | 0.00 | 0.13 |
| KRAS | G12S | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12S | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | appendiceal cancer | Black | 1 | 17 | 0.10 | 0.10 | 0.02 | 0.18 |
| KRAS | G12V | appendiceal cancer | Race:NA | 2 | 33 | 0.10 | 0.10 | 0.02 | 0.17 |
| KRAS | G12V | appendiceal cancer | White | 38 | 280 | 0.13 | 0.13 | 0.09 | 0.17 |
| KRAS | G12V | colorectal cancer | Asian | 31 | 313 | 0.10 | 0.10 | 0.08 | 0.12 |
| KRAS | G12V | colorectal cancer | Black | 64 | 515 | 0.11 | 0.11 | 0.09 | 0.14 |
| KRAS | G12V | colorectal cancer | Race:NA | 72 | 804 | 0.09 | 0.09 | 0.08 | 0.11 |
| KRAS | G12V | colorectal cancer | Native American | 3 | 17 | 0.10 | 0.10 | 0.07 | 0.16 |
| KRAS | G12V | colorectal cancer | Race:Other | 13 | 139 | 0.10 | 0.10 | 0.07 | 0.13 |
| KRAS | G12V | colorectal cancer | White | 435 | 4925 | 0.09 | 0.09 | 0.08 | 0.10 |
| KRAS | G12V | cancer of unknown primary | Asian | 3 | 73 | 0.05 | 0.05 | 0.03 | 0.08 |
| KRAS | G12V | cancer of unknown primary | Black | 5 | 123 | 0.05 | 0.05 | 0.03 | 0.07 |
| KRAS | G12V | cancer of unknown primary | Race:NA | 11 | 286 | 0.05 | 0.05 | 0.03 | 0.06 |
| KRAS | G12V | cancer of unknown primary | Race:Other | 4 | 36 | 0.06 | 0.06 | 0.04 | 0.11 |
| KRAS | G12V | cancer of unknown primary | White | 84 | 1465 | 0.06 | 0.06 | 0.04 | 0.07 |
| KRAS | G12V | non-small cell lung cancer | Asian | 10 | 624 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12V | non-small cell lung cancer | Black | 43 | 717 | 0.06 | 0.06 | 0.04 | 0.08 |
| KRAS | G12V | non-small cell lung cancer | Race:NA | 45 | 849 | 0.05 | 0.05 | 0.04 | 0.07 |
| KRAS | G12V | non-small cell lung cancer | Native American | 1 | 17 | 0.05 | 0.04 | 0.02 | 0.12 |
| KRAS | G12V | non-small cell lung cancer | Race:Other | 6 | 165 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G12V | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.04 | 0.04 | 0.01 | 0.10 |
| KRAS | G12V | non-small cell lung cancer | White | 443 | 7745 | 0.06 | 0.06 | 0.05 | 0.06 |
| KRAS | G12V | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | Black | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | Race:NA | 12 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | White | 17 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | Race:NA | 1 | 350 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | soft tissue sarcoma | Race:Other | 1 | 73 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | soft tissue sarcoma | White | 2 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | pancreatic cancer | Asian | 28 | 100 | 0.24 | 0.24 | 0.20 | 0.31 |
| KRAS | G12V | pancreatic cancer | Black | 23 | 88 | 0.24 | 0.24 | 0.20 | 0.30 |
| KRAS | G12V | pancreatic cancer | Race:NA | 49 | 231 | 0.23 | 0.23 | 0.18 | 0.26 |
| KRAS | G12V | pancreatic cancer | Race:Other | 4 | 34 | 0.22 | 0.23 | 0.14 | 0.27 |
| KRAS | G12V | pancreatic cancer | White | 479 | 2038 | 0.23 | 0.23 | 0.22 | 0.25 |
| KRAS | G12V | leukemia | Asian | 1 | 37 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | leukemia | Black | 0 | 69 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | leukemia | Race:NA | 10 | 777 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | leukemia | Race:Other | 0 | 13 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | leukemia | White | 5 | 662 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | White | 2 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | uterine cancer | Asian | 7 | 108 | 0.05 | 0.05 | 0.04 | 0.08 |
| KRAS | G12V | uterine cancer | Black | 5 | 163 | 0.05 | 0.05 | 0.03 | 0.06 |
| KRAS | G12V | uterine cancer | Race:NA | 11 | 190 | 0.05 | 0.05 | 0.04 | 0.07 |
| KRAS | G12V | uterine cancer | Race:Other | 1 | 37 | 0.05 | 0.05 | 0.03 | 0.07 |
| KRAS | G12V | uterine cancer | White | 88 | 1754 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-melanoma skin cancers | White | 1 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Race:NA | 1 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ovarian cancer | Asian | 4 | 134 | 0.04 | 0.03 | 0.02 | 0.06 |
| KRAS | G12V | ovarian cancer | Black | 5 | 74 | 0.04 | 0.04 | 0.02 | 0.09 |
| KRAS | G12V | ovarian cancer | Race:NA | 4 | 239 | 0.03 | 0.03 | 0.01 | 0.04 |
| KRAS | G12V | ovarian cancer | Race:Other | 3 | 36 | 0.04 | 0.04 | 0.02 | 0.10 |
| KRAS | G12V | ovarian cancer | White | 67 | 1852 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | G12V | esophagogastric cancer | Asian | 1 | 115 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | Black | 0 | 68 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | Race:NA | 0 | 191 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | esophagogastric cancer | Race:Other | 1 | 46 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | esophagogastric cancer | White | 13 | 1379 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | thyroid cancer | White | 6 | 803 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | cervical cancer | Asian | 1 | 27 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | G12V | cervical cancer | Black | 0 | 19 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G12V | cervical cancer | Race:NA | 1 | 77 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12V | cervical cancer | Race:Other | 0 | 15 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G12V | cervical cancer | White | 9 | 228 | 0.03 | 0.03 | 0.02 | 0.06 |
| KRAS | G12V | hepatobiliary cancer | Asian | 1 | 98 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | Black | 0 | 64 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | Race:NA | 5 | 235 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | Race:Other | 0 | 25 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | White | 32 | 948 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | Black | 1 | 77 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | White | 3 | 1113 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | mature t and nk neoplasms | Asian | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12V | mature t and nk neoplasms | Black | 1 | 18 | 0.03 | 0.01 | 0.00 | 0.15 |
| KRAS | G12V | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12V | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | cns cancer | White | 7 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | White | 2 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | neuroendocrine tumors | Black | 0 | 23 | 0.01 | 0.01 | 0.00 | 0.07 |
| KRAS | G12V | neuroendocrine tumors | Race:NA | 4 | 45 | 0.07 | 0.06 | 0.01 | 0.17 |
| KRAS | G12V | neuroendocrine tumors | White | 2 | 283 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | bladder cancer | Asian | 0 | 40 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | bladder cancer | Black | 0 | 43 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | bladder cancer | Race:NA | 0 | 169 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | bladder cancer | Race:Other | 1 | 14 | 0.03 | 0.01 | 0.00 | 0.15 |
| KRAS | G12V | bladder cancer | White | 18 | 1311 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | White | 1 | 125 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | small bowel cancer | Black | 4 | 25 | 0.13 | 0.12 | 0.07 | 0.23 |
| KRAS | G12V | small bowel cancer | Race:NA | 2 | 22 | 0.12 | 0.12 | 0.05 | 0.20 |
| KRAS | G12V | small bowel cancer | White | 18 | 150 | 0.12 | 0.12 | 0.08 | 0.17 |
| KRAS | G12V | sex cord stromal tumor | Race:NA | 1 | 23 | 0.03 | 0.02 | 0.00 | 0.11 |
| KRAS | G12V | sex cord stromal tumor | White | 1 | 69 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ampullary cancer | White | 11 | 86 | 0.13 | 0.13 | 0.07 | 0.21 |
| KRAS | G12V | small cell lung cancer | Asian | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | small cell lung cancer | Race:NA | 0 | 30 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | small cell lung cancer | White | 3 | 337 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | germ cell tumor | Asian | 1 | 36 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12V | germ cell tumor | Black | 0 | 23 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | germ cell tumor | Race:NA | 2 | 179 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12V | germ cell tumor | Race:Other | 0 | 37 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | germ cell tumor | White | 15 | 603 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12V | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | b cell lymphoma | Race:Other | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b cell lymphoma | White | 3 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | lung cancer | White | 2 | 17 | 0.12 | 0.11 | 0.02 | 0.31 |
| KRAS | G12V | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12V | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | colorectal cancer | Asian | 1 | 313 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Black | 3 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Race:NA | 3 | 804 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Race:Other | 1 | 139 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | White | 16 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | White | 8 | 1465 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Asian | 3 | 624 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Black | 11 | 717 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | Race:NA | 5 | 849 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Native American | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | Race:Other | 1 | 165 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | White | 89 | 7745 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13C | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | White | 1 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | White | 0 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | leukemia | White | 1 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | Race:NA | 1 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | White | 4 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | White | 1 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | anal cancer | Race:NA | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G13C | anal cancer | White | 1 | 126 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13C | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | White | 0 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | vaginal cancer | White | 1 | 68 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G13C | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13C | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | appendiceal cancer | Black | 1 | 17 | 0.05 | 0.04 | 0.02 | 0.12 |
| KRAS | G13D | appendiceal cancer | Race:NA | 2 | 33 | 0.05 | 0.04 | 0.02 | 0.11 |
| KRAS | G13D | appendiceal cancer | White | 11 | 280 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | colorectal cancer | Asian | 21 | 313 | 0.07 | 0.07 | 0.05 | 0.10 |
| KRAS | G13D | colorectal cancer | Black | 60 | 515 | 0.10 | 0.10 | 0.08 | 0.13 |
| KRAS | G13D | colorectal cancer | Race:NA | 69 | 804 | 0.08 | 0.08 | 0.07 | 0.10 |
| KRAS | G13D | colorectal cancer | Native American | 0 | 17 | 0.08 | 0.08 | 0.04 | 0.12 |
| KRAS | G13D | colorectal cancer | Race:Other | 12 | 139 | 0.08 | 0.08 | 0.06 | 0.12 |
| KRAS | G13D | colorectal cancer | White | 338 | 4925 | 0.07 | 0.07 | 0.06 | 0.08 |
| KRAS | G13D | cancer of unknown primary | Asian | 2 | 73 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | cancer of unknown primary | Black | 2 | 123 | 0.02 | 0.01 | 0.01 | 0.03 |
| KRAS | G13D | cancer of unknown primary | Race:NA | 6 | 286 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | cancer of unknown primary | Race:Other | 1 | 36 | 0.02 | 0.01 | 0.01 | 0.04 |
| KRAS | G13D | cancer of unknown primary | White | 15 | 1465 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | non-small cell lung cancer | Asian | 1 | 624 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Black | 1 | 717 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Race:NA | 7 | 849 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Native American | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | non-small cell lung cancer | Race:Other | 1 | 165 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | non-small cell lung cancer | Race:Undefined | 1 | 10 | 0.02 | 0.01 | 0.00 | 0.12 |
| KRAS | G13D | non-small cell lung cancer | White | 76 | 7745 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Black | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | White | 3 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | pancreatic cancer | Asian | 1 | 100 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | pancreatic cancer | Black | 0 | 88 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | Race:NA | 1 | 231 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | Race:Other | 0 | 34 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | White | 12 | 2038 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | leukemia | Asian | 1 | 37 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | leukemia | Black | 2 | 69 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | leukemia | Race:NA | 10 | 777 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G13D | leukemia | Race:Other | 0 | 13 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | leukemia | White | 12 | 662 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | melanoma | White | 6 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | head and neck cancer | White | 3 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | uterine cancer | Asian | 3 | 108 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | uterine cancer | Black | 0 | 163 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G13D | uterine cancer | Race:NA | 4 | 190 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | uterine cancer | Race:Other | 1 | 37 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G13D | uterine cancer | White | 38 | 1754 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G13D | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Race:NA | 6 | 571 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ovarian cancer | Asian | 2 | 134 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | Race:NA | 2 | 239 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | ovarian cancer | White | 6 | 1852 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | esophagogastric cancer | Asian | 1 | 115 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Black | 1 | 68 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Race:NA | 1 | 191 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Race:Other | 1 | 46 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | esophagogastric cancer | White | 18 | 1379 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cervical cancer | Asian | 2 | 27 | 0.03 | 0.02 | 0.00 | 0.12 |
| KRAS | G13D | cervical cancer | Black | 0 | 19 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G13D | cervical cancer | Race:NA | 1 | 77 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G13D | cervical cancer | Race:Other | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G13D | cervical cancer | White | 1 | 228 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | Asian | 0 | 98 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | hepatobiliary cancer | Black | 1 | 64 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | Race:NA | 1 | 235 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | hepatobiliary cancer | Race:Other | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | White | 7 | 948 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | anal cancer | Race:NA | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | anal cancer | White | 1 | 126 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | neuroendocrine tumors | Black | 0 | 23 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G13D | neuroendocrine tumors | Race:NA | 0 | 45 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G13D | neuroendocrine tumors | White | 6 | 283 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | bladder cancer | Race:NA | 1 | 169 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | bladder cancer | Race:Other | 1 | 14 | 0.02 | 0.00 | 0.00 | 0.12 |
| KRAS | G13D | bladder cancer | White | 2 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.03 | 0.03 | 0.00 | 0.07 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Race:NA | 2 | 92 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | White | 6 | 125 | 0.04 | 0.04 | 0.02 | 0.08 |
| KRAS | G13D | small bowel cancer | Black | 1 | 25 | 0.06 | 0.06 | 0.01 | 0.12 |
| KRAS | G13D | small bowel cancer | Race:NA | 3 | 22 | 0.08 | 0.07 | 0.03 | 0.20 |
| KRAS | G13D | small bowel cancer | White | 8 | 150 | 0.06 | 0.06 | 0.03 | 0.10 |
| KRAS | G13D | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ampullary cancer | White | 4 | 86 | 0.05 | 0.04 | 0.01 | 0.10 |
| KRAS | G13D | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | White | 1 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | pineal tumor | White | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| KRAS | G13D | b cell lymphoma | Asian | 0 | 21 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | Black | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | Race:NA | 0 | 42 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | Race:Other | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | b cell lymphoma | White | 7 | 859 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Black | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Race:NA | 1 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | White | 1 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | White | 1 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | White | 6 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | White | 0 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | White | 0 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | White | 0 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13V | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Black | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | White | 2 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | White | 0 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | White | 4 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | White | 2 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | White | 0 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | White | 0 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | germ cell tumor | White | 1 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13V | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G13V | parathyroid cancer | White | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| KRAS | Q61H | appendiceal cancer | Black | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | Q61H | appendiceal cancer | Race:NA | 2 | 33 | 0.04 | 0.02 | 0.00 | 0.13 |
| KRAS | Q61H | appendiceal cancer | White | 1 | 280 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | colorectal cancer | Asian | 1 | 313 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | colorectal cancer | Black | 4 | 515 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | colorectal cancer | Race:NA | 11 | 804 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | colorectal cancer | Native American | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | colorectal cancer | Race:Other | 1 | 139 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | colorectal cancer | White | 47 | 4925 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Asian | 0 | 73 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Race:NA | 1 | 286 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Race:Other | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | cancer of unknown primary | White | 14 | 1465 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | non-small cell lung cancer | Asian | 4 | 624 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Black | 12 | 717 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Race:NA | 6 | 849 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Native American | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Race:Other | 1 | 165 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Race:Undefined | 1 | 10 | 0.02 | 0.01 | 0.01 | 0.04 |
| KRAS | Q61H | non-small cell lung cancer | White | 107 | 7745 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Race:Other | 1 | 73 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | pancreatic cancer | Asian | 3 | 100 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | Q61H | pancreatic cancer | Black | 4 | 88 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | Q61H | pancreatic cancer | Race:NA | 7 | 231 | 0.04 | 0.03 | 0.02 | 0.05 |
| KRAS | Q61H | pancreatic cancer | Race:Other | 4 | 34 | 0.04 | 0.04 | 0.03 | 0.11 |
| KRAS | Q61H | pancreatic cancer | White | 68 | 2038 | 0.03 | 0.03 | 0.03 | 0.04 |
| KRAS | Q61H | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | Race:NA | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | White | 2 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | melanoma | Black | 1 | 34 | 0.01 | 0.00 | 0.00 | 0.06 |
| KRAS | Q61H | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | melanoma | White | 1 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | uterine cancer | Asian | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | White | 5 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | Race:NA | 3 | 239 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | White | 6 | 1852 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | White | 2 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | hepatobiliary cancer | Asian | 0 | 98 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | Black | 1 | 64 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | hepatobiliary cancer | Race:NA | 1 | 235 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | Race:Other | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | White | 12 | 948 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | kidney cancer | White | 1 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mature t and nk neoplasms | Asian | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | mature t and nk neoplasms | Black | 0 | 18 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | mature t and nk neoplasms | White | 2 | 188 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Race:NA | 2 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | White | 3 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Race:NA | 2 | 92 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | White | 1 | 125 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | small bowel cancer | Black | 2 | 25 | 0.04 | 0.03 | 0.01 | 0.15 |
| KRAS | Q61H | small bowel cancer | Race:NA | 0 | 22 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | Q61H | small bowel cancer | White | 3 | 150 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | Q61H | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | bone cancer | Asian | 1 | 30 | 0.02 | 0.00 | 0.00 | 0.08 |
| KRAS | Q61H | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ampullary cancer | White | 2 | 86 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | Q61H | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61H | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | b cell lymphoma | Asian | 0 | 21 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | b cell lymphoma | Black | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | b cell lymphoma | Race:Other | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | b cell lymphoma | White | 9 | 859 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | Q61H | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Black | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | White | 12 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Asian | 1 | 73 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | cancer of unknown primary | White | 0 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Race:NA | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | White | 1 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | Asian | 1 | 100 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | pancreatic cancer | White | 2 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | White | 1 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | White | 1 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | White | 1 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | anal cancer | Race:NA | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61K | anal cancer | White | 1 | 126 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61K | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | White | 0 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61K | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | appendiceal cancer | White | 1 | 280 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Asian | 2 | 313 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Black | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Race:NA | 7 | 804 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | White | 15 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | Asian | 1 | 73 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | cancer of unknown primary | White | 2 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | Asian | 3 | 624 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Black | 1 | 717 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Race:NA | 4 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Race:Other | 1 | 165 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | White | 28 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | White | 1 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | White | 6 | 2038 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Race:Other | 1 | 13 | 0.06 | 0.03 | 0.00 | 0.24 |
| KRAS | Q61L | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | melanoma | White | 2 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | uterine cancer | Black | 1 | 163 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | uterine cancer | Race:NA | 1 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | uterine cancer | White | 0 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | White | 1 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hepatobiliary cancer | Race:NA | 1 | 235 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hepatobiliary cancer | White | 1 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bladder cancer | White | 1 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | penile cancer | White | 1 | 20 | 0.06 | 0.04 | 0.00 | 0.18 |
| KRAS | Q61L | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61L | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | Q61L | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | appendiceal cancer | Race:NA | 1 | 33 | 0.02 | 0.01 | 0.00 | 0.09 |
| KRAS | Q61R | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | Asian | 2 | 313 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | Black | 0 | 515 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | colorectal cancer | Race:NA | 3 | 804 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | White | 15 | 4925 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | cancer of unknown primary | White | 3 | 1465 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-small cell lung cancer | Race:Other | 1 | 165 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-small cell lung cancer | White | 6 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Black | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | pancreatic cancer | Asian | 0 | 100 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61R | pancreatic cancer | Black | 1 | 88 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61R | pancreatic cancer | Race:NA | 1 | 231 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61R | pancreatic cancer | Race:Other | 1 | 34 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61R | pancreatic cancer | White | 35 | 2038 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | Q61R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | Race:NA | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | melanoma | White | 3 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | White | 0 | 1754 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | White | 2 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thyroid cancer | Asian | 0 | 66 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61R | thyroid cancer | Black | 1 | 40 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | Q61R | thyroid cancer | Race:NA | 4 | 79 | 0.03 | 0.02 | 0.01 | 0.08 |
| KRAS | Q61R | thyroid cancer | Race:Other | 0 | 26 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61R | thyroid cancer | White | 10 | 803 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | Asian | 0 | 98 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hepatobiliary cancer | White | 2 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | White | 3 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | prostate cancer | Black | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | bladder cancer | White | 1 | 1311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | sex cord stromal tumor | White | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ampullary cancer | White | 2 | 86 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | Q61R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | b cell lymphoma | White | 3 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | White | 2 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | non-melanoma skin cancers | White | 1 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | bladder cancer | Race:NA | 1 | 169 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | bladder cancer | Race:Other | 1 | 14 | 0.02 | 0.00 | 0.00 | 0.14 |
| HRAS | G12C | bladder cancer | White | 1 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | small cell lung cancer | White | 1 | 337 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12C | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12C | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12C | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Black | 2 | 514 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | White | 1 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | White | 1 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | White | 3 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | melanoma | Black | 1 | 34 | 0.01 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | melanoma | White | 6 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | Race:Other | 1 | 28 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | G12D | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | White | 2 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | non-melanoma skin cancers | Race:NA | 1 | 53 | 0.01 | 0.01 | 0.00 | 0.05 |
| HRAS | G12D | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | White | 1 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thyroid cancer | Race:NA | 1 | 79 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bladder cancer | Asian | 2 | 40 | 0.02 | 0.01 | 0.00 | 0.10 |
| HRAS | G12D | bladder cancer | Black | 0 | 43 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bladder cancer | Race:Other | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | bladder cancer | White | 7 | 1310 | 0.01 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12D | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | bladder cancer | White | 1 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12F | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | White | 1 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | White | 1 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Asian | 1 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | White | 1 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | head and neck cancer | White | 11 | 1264 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12S | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | White | 2 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-melanoma skin cancers | Asian | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.05 |
| HRAS | G12S | non-melanoma skin cancers | Black | 1 | 13 | 0.03 | 0.01 | 0.00 | 0.16 |
| HRAS | G12S | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | non-melanoma skin cancers | White | 1 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | White | 1 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bladder cancer | Race:NA | 1 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bladder cancer | White | 2 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | vaginal cancer | White | 1 | 68 | 0.02 | 0.01 | 0.00 | 0.06 |
| HRAS | G12S | thymic tumor | Asian | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | thymic tumor | Race:NA | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | thymic tumor | White | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | G12S | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12S | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | White | 1 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | White | 1 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Black | 1 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | White | 1 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | cervical cancer | White | 1 | 228 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12V | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | White | 1 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | White | 1 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13C | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | melanoma | White | 6 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | White | 1 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Asian | 1 | 115 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Race:NA | 1 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | White | 2 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thymic tumor | Asian | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | thymic tumor | Race:NA | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | thymic tumor | White | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | G13D | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13D | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cancer of unknown primary | White | 3 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | White | 4 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Black | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | White | 3 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | White | 1 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Asian | 1 | 33 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | G13R | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | melanoma | White | 1 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | head and neck cancer | Asian | 1 | 94 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | G13R | head and neck cancer | Black | 3 | 62 | 0.02 | 0.02 | 0.00 | 0.08 |
| HRAS | G13R | head and neck cancer | Race:NA | 1 | 292 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | Race:Other | 0 | 28 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | G13R | head and neck cancer | White | 5 | 1264 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | White | 1 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | soft tissue sarcoma | Race:NA | 3 | 347 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | soft tissue sarcoma | White | 1 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | White | 2 | 803 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | bladder cancer | Race:NA | 2 | 169 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | G13R | bladder cancer | Race:Other | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | bladder cancer | White | 6 | 1310 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | Race:NA | 1 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13V | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | cancer of unknown primary | Black | 1 | 123 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | White | 6 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | White | 1 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | melanoma | Race:NA | 1 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | melanoma | White | 2 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | head and neck cancer | Asian | 1 | 94 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | White | 2 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | White | 1 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-melanoma skin cancers | Asian | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | non-melanoma skin cancers | White | 2 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | White | 3 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | small cell lung cancer | White | 1 | 337 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13V | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G13V | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Race:NA | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | White | 1 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | White | 1 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61H | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | cancer of unknown primary | White | 3 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | White | 1 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | White | 1 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | White | 8 | 2348 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | White | 5 | 1264 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | White | 2 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Race:NA | 0 | 347 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | White | 1 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thyroid cancer | Asian | 2 | 66 | 0.02 | 0.01 | 0.01 | 0.05 |
| HRAS | Q61K | thyroid cancer | Black | 1 | 40 | 0.02 | 0.01 | 0.00 | 0.04 |
| HRAS | Q61K | thyroid cancer | Race:NA | 1 | 79 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | Q61K | thyroid cancer | Race:Other | 1 | 26 | 0.02 | 0.01 | 0.00 | 0.06 |
| HRAS | Q61K | thyroid cancer | White | 7 | 803 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61K | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | hepatobiliary cancer | White | 1 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | prostate cancer | Asian | 1 | 62 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | prostate cancer | Black | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | prostate cancer | White | 4 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | bladder cancer | White | 5 | 1310 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61K | parathyroid cancer | White | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| HRAS | Q61L | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Race:NA | 1 | 347 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | White | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61L | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | Q61L | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | White | 0 | 1461 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Race:NA | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | White | 2 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Asian | 1 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | White | 2 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | White | 0 | 655 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | melanoma | White | 5 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | Black | 1 | 62 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | head and neck cancer | Race:NA | 1 | 292 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | Race:Other | 0 | 28 | 0.01 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | White | 7 | 1264 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | Black | 0 | 162 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | Race:NA | 0 | 189 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | White | 0 | 1750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | non-melanoma skin cancers | Race:NA | 1 | 53 | 0.01 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Black | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Race:NA | 1 | 347 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | White | 0 | 1976 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | thyroid cancer | Asian | 2 | 66 | 0.03 | 0.03 | 0.01 | 0.05 |
| HRAS | Q61R | thyroid cancer | Black | 0 | 40 | 0.03 | 0.03 | 0.00 | 0.05 |
| HRAS | Q61R | thyroid cancer | Race:NA | 1 | 79 | 0.03 | 0.03 | 0.01 | 0.04 |
| HRAS | Q61R | thyroid cancer | Race:Other | 1 | 26 | 0.03 | 0.03 | 0.01 | 0.06 |
| HRAS | Q61R | thyroid cancer | White | 26 | 803 | 0.03 | 0.03 | 0.02 | 0.04 |
| HRAS | Q61R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | White | 0 | 3330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | Black | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | Race:NA | 1 | 289 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | White | 4 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | bladder cancer | Asian | 0 | 40 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Black | 0 | 43 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Race:NA | 1 | 169 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Race:Other | 1 | 14 | 0.02 | 0.01 | 0.00 | 0.08 |
| HRAS | Q61R | bladder cancer | White | 14 | 1310 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Black | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | White | 0 | 379 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | thymic tumor | Asian | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | thymic tumor | Race:NA | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | thymic tumor | White | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| HRAS | Q61R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | White | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Black | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | White | 0 | 858 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | White | 5 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | White | 0 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | White | 2 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | leukemia | Asian | 0 | 37 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Black | 0 | 69 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Race:NA | 7 | 777 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Race:Other | 1 | 13 | 0.01 | 0.01 | 0.00 | 0.06 |
| NRAS | G12A | leukemia | White | 6 | 662 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | melanoma | Race:Other | 1 | 26 | 0.01 | 0.00 | 0.00 | 0.08 |
| NRAS | G12A | melanoma | White | 4 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | White | 0 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Race:NA | 3 | 571 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | White | 2 | 125 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G12A | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | Asian | 1 | 36 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G12A | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | appendiceal cancer | White | 1 | 280 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | colorectal cancer | Asian | 2 | 313 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | colorectal cancer | Black | 1 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | Race:NA | 2 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | White | 11 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | Race:NA | 1 | 286 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | White | 1 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Race:NA | 2 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | non-small cell lung cancer | White | 1 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | White | 1 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Race:NA | 3 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Race:Other | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | leukemia | White | 5 | 662 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | melanoma | Black | 1 | 34 | 0.01 | 0.00 | 0.00 | 0.06 |
| NRAS | G12C | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | melanoma | White | 11 | 2348 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | White | 5 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Race:NA | 1 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hepatobiliary cancer | Race:NA | 1 | 235 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hepatobiliary cancer | White | 1 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Race:Other | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bladder cancer | White | 1 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | White | 1 | 125 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | Race:NA | 1 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12C | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | colorectal cancer | Asian | 1 | 313 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | colorectal cancer | Black | 3 | 514 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | colorectal cancer | Race:NA | 5 | 804 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | colorectal cancer | Native American | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12D | colorectal cancer | Race:Other | 3 | 139 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12D | colorectal cancer | White | 41 | 4922 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | G12D | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | cancer of unknown primary | White | 3 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Asian | 2 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Race:NA | 1 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | White | 5 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Race:NA | 1 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | White | 1 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | White | 1 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | leukemia | Asian | 0 | 37 | 0.04 | 0.04 | 0.00 | 0.06 |
| NRAS | G12D | leukemia | Black | 4 | 69 | 0.05 | 0.05 | 0.02 | 0.08 |
| NRAS | G12D | leukemia | Race:NA | 30 | 777 | 0.04 | 0.04 | 0.03 | 0.06 |
| NRAS | G12D | leukemia | Race:Other | 0 | 13 | 0.04 | 0.04 | 0.01 | 0.08 |
| NRAS | G12D | leukemia | White | 37 | 662 | 0.05 | 0.05 | 0.04 | 0.07 |
| NRAS | G12D | melanoma | Asian | 0 | 33 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12D | melanoma | Black | 1 | 34 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G12D | melanoma | Race:NA | 3 | 398 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | Race:Other | 0 | 26 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12D | melanoma | White | 13 | 2348 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | Asian | 1 | 94 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | White | 2 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | uterine cancer | Asian | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | White | 7 | 1753 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | White | 1 | 436 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.02 | 0.02 | 0.00 | 0.03 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Race:NA | 10 | 571 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | White | 10 | 584 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G12D | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | White | 2 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | Black | 1 | 64 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | White | 2 | 948 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | White | 1 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.04 | 0.03 | 0.00 | 0.08 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Race:NA | 5 | 92 | 0.04 | 0.04 | 0.02 | 0.08 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | White | 4 | 125 | 0.04 | 0.04 | 0.01 | 0.07 |
| NRAS | G12D | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | White | 2 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.03 | 0.02 | 0.00 | 0.12 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | White | 1 | 23 | 0.04 | 0.03 | 0.00 | 0.13 |
| NRAS | G12D | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12D | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | White | 0 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Race:NA | 0 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | White | 0 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | White | 0 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12F | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | White | 0 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | leukemia | Race:NA | 3 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | melanoma | Black | 1 | 34 | 0.01 | 0.00 | 0.00 | 0.06 |
| NRAS | G12R | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | melanoma | White | 2 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | White | 1 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Race:NA | 3 | 571 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | White | 2 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.00 | 0.00 | 0.06 |
| NRAS | G12R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Race:NA | 1 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | White | 1 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Black | 1 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | White | 1 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Race:NA | 1 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | Race:NA | 4 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | White | 2 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | White | 6 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | White | 2 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Race:NA | 2 | 571 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | White | 6 | 584 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12S | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | Asian | 1 | 97 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | hepatobiliary cancer | White | 1 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | White | 1 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | White | 4 | 125 | 0.03 | 0.02 | 0.01 | 0.06 |
| NRAS | G12S | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | germ cell tumor | Asian | 1 | 36 | 0.02 | 0.01 | 0.00 | 0.08 |
| NRAS | G12S | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | White | 2 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.03 | 0.02 | 0.00 | 0.12 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | White | 1 | 23 | 0.04 | 0.03 | 0.00 | 0.13 |
| NRAS | G12S | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12S | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Race:NA | 1 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | White | 6 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | cancer of unknown primary | White | 3 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | White | 3 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | White | 1 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | leukemia | Asian | 1 | 37 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | leukemia | Black | 1 | 69 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | leukemia | Race:NA | 4 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | leukemia | Race:Other | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | leukemia | White | 1 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | melanoma | Race:NA | 1 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | melanoma | White | 2 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | White | 1 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Race:NA | 3 | 571 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | hepatobiliary cancer | White | 1 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | White | 2 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G12V | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-hodgkin lymphoma | White | 1 | 19 | 0.06 | 0.04 | 0.00 | 0.19 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12V | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | White | 3 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | White | 0 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Race:NA | 1 | 777 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | leukemia | White | 0 | 662 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | melanoma | White | 4 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | White | 0 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Race:NA | 3 | 571 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | White | 2 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13C | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Black | 1 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Race:NA | 3 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | White | 8 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | White | 0 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Black | 1 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Race:NA | 3 | 350 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | leukemia | Asian | 0 | 37 | 0.02 | 0.02 | 0.00 | 0.03 |
| NRAS | G13D | leukemia | Black | 1 | 69 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | Race:NA | 16 | 777 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | Race:Other | 0 | 13 | 0.02 | 0.02 | 0.01 | 0.04 |
| NRAS | G13D | leukemia | White | 15 | 662 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | melanoma | Black | 1 | 34 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | melanoma | Race:NA | 2 | 398 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | melanoma | White | 5 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Black | 1 | 163 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | uterine cancer | White | 0 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Race:NA | 6 | 571 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | White | 3 | 584 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13D | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | esophagogastric cancer | Race:NA | 1 | 191 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Asian | 1 | 17 | 0.03 | 0.02 | 0.01 | 0.10 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Race:NA | 1 | 92 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | White | 3 | 125 | 0.02 | 0.02 | 0.01 | 0.05 |
| NRAS | G13D | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | germ cell tumor | Race:NA | 1 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13D | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13R | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | White | 1 | 280 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | Race:NA | 2 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | White | 17 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Black | 1 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Race:NA | 1 | 286 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | White | 3 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | White | 2 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | leukemia | Asian | 1 | 37 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | Race:NA | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | Race:Other | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | leukemia | White | 4 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Asian | 0 | 33 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13R | melanoma | Black | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13R | melanoma | Race:NA | 2 | 398 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Race:Other | 0 | 26 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13R | melanoma | White | 18 | 2348 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | White | 2 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | White | 0 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | adrenocortical carcinoma | White | 1 | 103 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G13R | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | Race:NA | 1 | 79 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | White | 1 | 803 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | Race:NA | 1 | 235 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | White | 2 | 948 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bladder cancer | White | 2 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | White | 1 | 125 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | White | 2 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.03 | 0.02 | 0.00 | 0.12 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | White | 1 | 23 | 0.04 | 0.03 | 0.00 | 0.13 |
| NRAS | G13R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13R | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13V | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Black | 0 | 514 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Race:NA | 0 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | White | 0 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | White | 0 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Asian | 1 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | non-small cell lung cancer | White | 0 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | White | 0 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | White | 1 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | Black | 1 | 69 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | leukemia | Race:NA | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | White | 2 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | Black | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | Race:NA | 0 | 398 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | White | 4 | 2348 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | White | 0 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Race:NA | 4 | 571 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Race:NA | 1 | 92 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13V | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | White | 0 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G13V | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Black | 2 | 514 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | colorectal cancer | Race:NA | 3 | 804 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | colorectal cancer | Race:Other | 0 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | White | 12 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | Race:Other | 1 | 36 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61H | cancer of unknown primary | White | 2 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | White | 4 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | White | 3 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | leukemia | Asian | 1 | 37 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | Race:NA | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | Race:Other | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | leukemia | White | 4 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | Asian | 0 | 33 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | melanoma | Black | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | melanoma | Race:NA | 2 | 398 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | Race:Other | 0 | 26 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | melanoma | White | 25 | 2348 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61H | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | White | 1 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | uterine cancer | White | 4 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | White | 1 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | White | 0 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | White | 0 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cervical cancer | White | 1 | 228 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mature t and nk neoplasms | Asian | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | mature t and nk neoplasms | Black | 0 | 18 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | mature t and nk neoplasms | White | 1 | 188 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Race:NA | 0 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | White | 0 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | White | 2 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Race:NA | 1 | 92 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | White | 1 | 125 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | Race:NA | 1 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | White | 2 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | non-hodgkin lymphoma | White | 1 | 19 | 0.06 | 0.04 | 0.00 | 0.20 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61H | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | colorectal cancer | Asian | 1 | 313 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61K | colorectal cancer | Black | 7 | 514 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61K | colorectal cancer | Race:NA | 8 | 804 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | colorectal cancer | Native American | 1 | 17 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61K | colorectal cancer | Race:Other | 0 | 139 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61K | colorectal cancer | White | 48 | 4922 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Race:Other | 1 | 36 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61K | cancer of unknown primary | White | 5 | 1464 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Black | 1 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Race:NA | 0 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | White | 7 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | Race:NA | 5 | 350 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | White | 10 | 2005 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | pancreatic cancer | Black | 1 | 88 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | pancreatic cancer | White | 1 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | leukemia | Asian | 0 | 37 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | Black | 0 | 69 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | Race:NA | 7 | 777 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | Race:Other | 1 | 13 | 0.01 | 0.01 | 0.00 | 0.06 |
| NRAS | Q61K | leukemia | White | 6 | 662 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | melanoma | Asian | 1 | 33 | 0.06 | 0.07 | 0.02 | 0.09 |
| NRAS | Q61K | melanoma | Black | 2 | 34 | 0.07 | 0.07 | 0.03 | 0.10 |
| NRAS | Q61K | melanoma | Race:NA | 31 | 398 | 0.07 | 0.07 | 0.06 | 0.09 |
| NRAS | Q61K | melanoma | Race:Other | 0 | 26 | 0.06 | 0.07 | 0.01 | 0.09 |
| NRAS | Q61K | melanoma | White | 165 | 2348 | 0.07 | 0.07 | 0.06 | 0.08 |
| NRAS | Q61K | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | head and neck cancer | White | 3 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | uterine cancer | Asian | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | White | 5 | 1753 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | Race:NA | 1 | 239 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | White | 4 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | Asian | 1 | 115 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | thyroid cancer | Asian | 3 | 66 | 0.04 | 0.03 | 0.02 | 0.08 |
| NRAS | Q61K | thyroid cancer | Black | 4 | 40 | 0.05 | 0.04 | 0.02 | 0.14 |
| NRAS | Q61K | thyroid cancer | Race:NA | 1 | 79 | 0.03 | 0.03 | 0.01 | 0.05 |
| NRAS | Q61K | thyroid cancer | Race:Other | 2 | 26 | 0.04 | 0.04 | 0.02 | 0.12 |
| NRAS | Q61K | thyroid cancer | White | 19 | 803 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61K | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | Race:NA | 3 | 235 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | hepatobiliary cancer | Race:Other | 0 | 25 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | hepatobiliary cancer | White | 4 | 948 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | Asian | 0 | 154 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | Black | 1 | 131 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | Race:NA | 4 | 817 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | White | 3 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | White | 3 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Race:NA | 1 | 92 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | White | 2 | 125 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | thymic tumor | Asian | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | thymic tumor | Race:NA | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | thymic tumor | White | 1 | 108 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61K | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | small cell lung cancer | White | 1 | 337 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | White | 3 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61K | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | b cell lymphoma | White | 3 | 859 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61K | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | appendiceal cancer | Black | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | Race:NA | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | White | 0 | 280 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | Asian | 0 | 313 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Black | 4 | 514 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Race:NA | 2 | 804 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Race:Other | 2 | 139 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | colorectal cancer | White | 14 | 4922 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Black | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Race:NA | 0 | 286 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | White | 1 | 1464 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Asian | 2 | 624 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | Black | 0 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Race:NA | 3 | 849 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | White | 27 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Asian | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | White | 4 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Asian | 0 | 100 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Black | 0 | 88 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Race:Other | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | White | 0 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | leukemia | Asian | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | Black | 0 | 69 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | Race:NA | 2 | 777 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | Race:Other | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | leukemia | White | 4 | 662 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | melanoma | Asian | 0 | 33 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | Q61L | melanoma | Black | 0 | 34 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | Q61L | melanoma | Race:NA | 7 | 398 | 0.02 | 0.02 | 0.01 | 0.04 |
| NRAS | Q61L | melanoma | Race:Other | 0 | 26 | 0.02 | 0.02 | 0.00 | 0.05 |
| NRAS | Q61L | melanoma | White | 81 | 2348 | 0.03 | 0.03 | 0.03 | 0.04 |
| NRAS | Q61L | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | Race:NA | 0 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | White | 6 | 1753 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | White | 0 | 584 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Asian | 0 | 134 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Black | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Race:NA | 0 | 239 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | White | 1 | 1852 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | White | 1 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Asian | 0 | 66 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Black | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Race:NA | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Race:Other | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | White | 0 | 803 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Race:NA | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Asian | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Black | 0 | 64 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Race:NA | 0 | 235 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Race:Other | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | White | 0 | 948 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Black | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | White | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Asian | 1 | 154 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Race:NA | 1 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | White | 3 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | White | 0 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | White | 0 | 283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | White | 0 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 92 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | White | 0 | 125 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | Race:NA | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | small cell lung cancer | White | 1 | 337 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | White | 0 | 434 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | White | 0 | 603 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | Black | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | nerve sheath tumor | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61L | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | b cell lymphoma | Asian | 0 | 21 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | Black | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | Race:NA | 0 | 42 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | Race:Other | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | White | 1 | 859 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61L | parathyroid cancer | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | appendiceal cancer | Black | 0 | 17 | 0.02 | 0.01 | 0.00 | 0.05 |
| NRAS | Q61R | appendiceal cancer | Race:NA | 1 | 33 | 0.02 | 0.02 | 0.00 | 0.06 |
| NRAS | Q61R | appendiceal cancer | White | 4 | 280 | 0.02 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | colorectal cancer | Asian | 5 | 313 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | colorectal cancer | Black | 7 | 514 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | colorectal cancer | Race:NA | 2 | 804 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | Native American | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | colorectal cancer | Race:Other | 1 | 139 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | colorectal cancer | White | 31 | 4922 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Asian | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Black | 1 | 123 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Race:NA | 2 | 286 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Race:Other | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | White | 5 | 1464 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-small cell lung cancer | Asian | 0 | 624 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Black | 2 | 717 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Race:NA | 3 | 849 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Native American | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Race:Other | 0 | 165 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Race:Undefined | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | White | 10 | 7745 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Asian | 0 | 334 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Black | 0 | 525 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Race:NA | 0 | 3112 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Native American | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Race:Other | 0 | 176 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | White | 0 | 5174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Asian | 1 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | soft tissue sarcoma | Black | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Race:NA | 0 | 350 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Race:Other | 0 | 73 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | soft tissue sarcoma | White | 5 | 2005 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | pancreatic cancer | Asian | 1 | 100 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pancreatic cancer | Black | 1 | 88 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pancreatic cancer | Race:NA | 0 | 231 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | pancreatic cancer | Race:Other | 1 | 34 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | pancreatic cancer | White | 4 | 2037 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | leukemia | Asian | 0 | 37 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | leukemia | Black | 1 | 69 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | leukemia | Race:NA | 6 | 777 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | leukemia | Race:Other | 1 | 13 | 0.02 | 0.01 | 0.00 | 0.06 |
| NRAS | Q61R | leukemia | White | 9 | 662 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | melanoma | Asian | 3 | 33 | 0.08 | 0.08 | 0.05 | 0.12 |
| NRAS | Q61R | melanoma | Black | 1 | 34 | 0.08 | 0.08 | 0.04 | 0.11 |
| NRAS | Q61R | melanoma | Race:NA | 33 | 398 | 0.08 | 0.08 | 0.06 | 0.10 |
| NRAS | Q61R | melanoma | Race:Other | 1 | 26 | 0.08 | 0.08 | 0.04 | 0.11 |
| NRAS | Q61R | melanoma | White | 206 | 2348 | 0.09 | 0.09 | 0.08 | 0.10 |
| NRAS | Q61R | head and neck cancer | Asian | 0 | 94 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | Black | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | Race:NA | 0 | 292 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | Race:Other | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | White | 0 | 1264 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | uterine cancer | Asian | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | Black | 0 | 163 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | Race:NA | 1 | 190 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | White | 8 | 1753 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-melanoma skin cancers | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | Black | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | Race:NA | 0 | 53 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | White | 0 | 436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Asian | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Black | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Race:NA | 0 | 571 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | White | 2 | 584 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | adrenocortical carcinoma | Race:NA | 0 | 26 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | adrenocortical carcinoma | White | 0 | 103 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ovarian cancer | Asian | 1 | 134 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | ovarian cancer | Black | 0 | 74 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | ovarian cancer | Race:NA | 2 | 239 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | ovarian cancer | Race:Other | 0 | 36 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | ovarian cancer | White | 22 | 1852 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | esophagogastric cancer | Asian | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | esophagogastric cancer | Black | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | esophagogastric cancer | Race:NA | 0 | 191 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | esophagogastric cancer | Race:Other | 0 | 46 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | esophagogastric cancer | White | 3 | 1379 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thyroid cancer | Asian | 7 | 66 | 0.10 | 0.10 | 0.07 | 0.16 |
| NRAS | Q61R | thyroid cancer | Black | 8 | 40 | 0.12 | 0.11 | 0.08 | 0.24 |
| NRAS | Q61R | thyroid cancer | Race:NA | 7 | 79 | 0.10 | 0.10 | 0.06 | 0.15 |
| NRAS | Q61R | thyroid cancer | Race:Other | 4 | 26 | 0.11 | 0.10 | 0.07 | 0.20 |
| NRAS | Q61R | thyroid cancer | White | 69 | 803 | 0.09 | 0.09 | 0.07 | 0.11 |
| NRAS | Q61R | cervical cancer | Asian | 0 | 27 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cervical cancer | Black | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cervical cancer | Race:NA | 1 | 77 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | cervical cancer | Race:Other | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cervical cancer | White | 0 | 228 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | Asian | 2 | 97 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | hepatobiliary cancer | Black | 0 | 64 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | hepatobiliary cancer | Race:NA | 1 | 235 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | Race:Other | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | hepatobiliary cancer | White | 6 | 948 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | kidney cancer | Asian | 0 | 33 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | Black | 0 | 77 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | Race:NA | 0 | 169 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | White | 0 | 1113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mature t and nk neoplasms | Asian | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | mature t and nk neoplasms | Black | 0 | 18 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | mature t and nk neoplasms | Race:NA | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | mature t and nk neoplasms | White | 1 | 188 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cns cancer | Asian | 1 | 154 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cns cancer | Black | 0 | 131 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Race:NA | 2 | 817 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Race:Other | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Race:Undefined | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cns cancer | White | 4 | 3331 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Asian | 0 | 62 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Black | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Race:NA | 0 | 289 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Race:Other | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | White | 1 | 1882 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | anal cancer | Race:NA | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | anal cancer | White | 0 | 126 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | neuroendocrine tumors | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | neuroendocrine tumors | Race:NA | 0 | 45 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | neuroendocrine tumors | White | 1 | 283 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | Asian | 0 | 40 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | bladder cancer | Black | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | bladder cancer | Race:NA | 2 | 169 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | bladder cancer | Race:Other | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | bladder cancer | White | 1 | 1310 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Asian | 0 | 17 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Race:NA | 1 | 92 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | White | 1 | 125 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | small bowel cancer | Black | 2 | 25 | 0.07 | 0.06 | 0.00 | 0.20 |
| NRAS | Q61R | small bowel cancer | Race:NA | 0 | 22 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | small bowel cancer | White | 0 | 150 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | sex cord stromal tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | sex cord stromal tumor | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Asian | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Black | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Race:NA | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Race:Other | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | White | 0 | 391 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | vaginal cancer | White | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | thymic tumor | Asian | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | Race:NA | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | White | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ampullary cancer | White | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | Asian | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | Race:NA | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | White | 0 | 337 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mesothelioma | Asian | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | mesothelioma | Black | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | mesothelioma | Race:NA | 0 | 32 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | mesothelioma | White | 1 | 434 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Asian | 0 | 36 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Black | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Race:NA | 0 | 179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Race:Other | 0 | 37 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | White | 3 | 603 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | nerve sheath tumor | Black | 0 | 12 | 0.01 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61R | nerve sheath tumor | Race:NA | 1 | 26 | 0.02 | 0.01 | 0.00 | 0.10 |
| NRAS | Q61R | nerve sheath tumor | White | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | penile cancer | White | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | pheochromocytoma | White | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | pineal tumor | White | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | b cell lymphoma | Asian | 0 | 21 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | b cell lymphoma | Black | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | b cell lymphoma | Race:NA | 1 | 42 | 0.01 | 0.01 | 0.00 | 0.05 |
| NRAS | Q61R | b cell lymphoma | Race:Other | 1 | 12 | 0.02 | 0.01 | 0.00 | 0.11 |
| NRAS | Q61R | b cell lymphoma | White | 4 | 859 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | non-hodgkin lymphoma | White | 0 | 19 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | White | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | retinoblastoma | Race:NA | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | retinoblastoma | White | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | hodgkin lymphoma | White | 0 | 30 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | lung cancer | White | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | peritoneal cancer | White | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | parathyroid cancer | White | 2 | 14 | 0.15 | 0.13 | 0.02 | 0.36 |
| KRAS | G12A | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | appendiceal cancer | Male | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | colorectal cancer | Female | 71 | 3028 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | Male | 74 | 3696 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12A | cancer of unknown primary | Female | 8 | 1000 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | Male | 6 | 989 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | non-small cell lung cancer | Female | 147 | 5722 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | non-small cell lung cancer | Male | 79 | 4406 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12A | breast cancer | Female | 6 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | pancreatic cancer | Female | 7 | 1153 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | Male | 6 | 1341 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Female | 2 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Male | 3 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | uterine cancer | Female | 31 | 2254 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12A | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Male | 1 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ovarian cancer | Female | 14 | 2336 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Female | 2 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Male | 4 | 1297 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cervical cancer | Female | 1 | 365 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Female | 1 | 636 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Male | 6 | 739 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Female | 4 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Male | 2 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | anal cancer | Male | 1 | 47 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12A | neuroendocrine tumors | Female | 1 | 166 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Male | 2 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Female | 1 | 106 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | small bowel cancer | Female | 1 | 78 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12A | small bowel cancer | Male | 3 | 132 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12A | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | Female | 2 | 242 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | vaginal cancer | Female | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G12A | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ampullary cancer | Female | 1 | 41 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | G12A | ampullary cancer | Male | 0 | 65 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | small cell lung cancer | Female | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | germ cell tumor | Male | 7 | 711 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | nerve sheath tumor | Female | 1 | 80 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12A | nerve sheath tumor | Male | 0 | 74 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12A | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12A | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | appendiceal cancer | Female | 6 | 174 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12C | appendiceal cancer | Male | 3 | 167 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12C | colorectal cancer | Female | 110 | 3028 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | G12C | colorectal cancer | Male | 102 | 3696 | 0.03 | 0.03 | 0.02 | 0.03 |
| KRAS | G12C | cancer of unknown primary | Female | 39 | 1000 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12C | cancer of unknown primary | Male | 22 | 989 | 0.02 | 0.02 | 0.02 | 0.04 |
| KRAS | G12C | non-small cell lung cancer | Female | 755 | 5722 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12C | non-small cell lung cancer | Male | 458 | 4406 | 0.10 | 0.10 | 0.10 | 0.11 |
| KRAS | G12C | breast cancer | Female | 8 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | soft tissue sarcoma | Female | 4 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | Male | 1 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | pancreatic cancer | Female | 8 | 1153 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | pancreatic cancer | Male | 14 | 1341 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | Male | 1 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | uterine cancer | Female | 26 | 2254 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ovarian cancer | Female | 10 | 2336 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Female | 2 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Male | 3 | 1297 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Male | 1 | 480 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | Female | 1 | 365 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | Female | 4 | 636 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | Male | 6 | 739 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | Male | 1 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | neuroendocrine tumors | Female | 1 | 166 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | neuroendocrine tumors | Male | 1 | 193 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bladder cancer | Male | 7 | 1188 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | small bowel cancer | Female | 2 | 78 | 0.04 | 0.03 | 0.01 | 0.07 |
| KRAS | G12C | small bowel cancer | Male | 6 | 132 | 0.04 | 0.04 | 0.02 | 0.08 |
| KRAS | G12C | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | vaginal cancer | Female | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G12C | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ampullary cancer | Female | 1 | 41 | 0.04 | 0.03 | 0.00 | 0.09 |
| KRAS | G12C | ampullary cancer | Male | 3 | 65 | 0.04 | 0.04 | 0.01 | 0.09 |
| KRAS | G12C | small cell lung cancer | Female | 2 | 193 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | small cell lung cancer | Male | 1 | 205 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | Male | 4 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12C | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | lung cancer | Male | 1 | 16 | 0.07 | 0.05 | 0.00 | 0.23 |
| KRAS | G12C | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12C | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | appendiceal cancer | Female | 45 | 174 | 0.26 | 0.26 | 0.21 | 0.32 |
| KRAS | G12D | appendiceal cancer | Male | 47 | 167 | 0.28 | 0.27 | 0.22 | 0.34 |
| KRAS | G12D | colorectal cancer | Female | 417 | 3028 | 0.14 | 0.14 | 0.12 | 0.15 |
| KRAS | G12D | colorectal cancer | Male | 468 | 3696 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12D | cancer of unknown primary | Female | 58 | 1000 | 0.06 | 0.06 | 0.04 | 0.07 |
| KRAS | G12D | cancer of unknown primary | Male | 49 | 989 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12D | non-small cell lung cancer | Female | 263 | 5722 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | Male | 169 | 4406 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | G12D | breast cancer | Female | 11 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Female | 7 | 1413 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Male | 4 | 1360 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | pancreatic cancer | Female | 374 | 1153 | 0.32 | 0.32 | 0.30 | 0.35 |
| KRAS | G12D | pancreatic cancer | Male | 408 | 1341 | 0.31 | 0.31 | 0.28 | 0.33 |
| KRAS | G12D | leukemia | Female | 8 | 637 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | leukemia | Male | 13 | 930 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | melanoma | Female | 6 | 1104 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | Male | 8 | 1742 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Male | 3 | 1179 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | uterine cancer | Female | 102 | 2254 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12D | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Female | 3 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Male | 1 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ovarian cancer | Female | 82 | 2336 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | G12D | esophagogastric cancer | Female | 13 | 504 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12D | esophagogastric cancer | Male | 20 | 1297 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12D | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thyroid cancer | Male | 3 | 480 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | cervical cancer | Female | 10 | 365 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12D | hepatobiliary cancer | Female | 28 | 636 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | hepatobiliary cancer | Male | 27 | 739 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | kidney cancer | Female | 1 | 420 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | kidney cancer | Male | 4 | 1002 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Female | 4 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Male | 4 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | anal cancer | Male | 1 | 47 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12D | neuroendocrine tumors | Female | 5 | 166 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | neuroendocrine tumors | Male | 9 | 193 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G12D | bladder cancer | Female | 9 | 393 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12D | bladder cancer | Male | 23 | 1188 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Female | 6 | 106 | 0.05 | 0.04 | 0.02 | 0.09 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Male | 2 | 142 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12D | small bowel cancer | Female | 8 | 78 | 0.11 | 0.11 | 0.06 | 0.17 |
| KRAS | G12D | small bowel cancer | Male | 17 | 132 | 0.12 | 0.12 | 0.08 | 0.18 |
| KRAS | G12D | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | bone cancer | Female | 1 | 242 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | Male | 1 | 328 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | vaginal cancer | Female | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G12D | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ampullary cancer | Female | 12 | 41 | 0.27 | 0.27 | 0.18 | 0.40 |
| KRAS | G12D | ampullary cancer | Male | 16 | 65 | 0.26 | 0.26 | 0.17 | 0.35 |
| KRAS | G12D | small cell lung cancer | Female | 1 | 193 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | small cell lung cancer | Male | 3 | 205 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Male | 9 | 711 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | b cell lymphoma | Female | 2 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12D | blastic plasmacytoid dendritic cell neoplasm | Male | 1 | 11 | 0.10 | 0.08 | 0.00 | 0.32 |
| KRAS | G12D | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Female | 1 | 3028 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Male | 0 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Female | 2 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Male | 1 | 989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Female | 18 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Male | 14 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Female | 0 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Female | 1 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Male | 0 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Female | 0 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Male | 0 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | appendiceal cancer | Female | 2 | 174 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | appendiceal cancer | Male | 1 | 167 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | colorectal cancer | Female | 19 | 3028 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | Male | 15 | 3696 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | Female | 7 | 1000 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | Male | 10 | 989 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | non-small cell lung cancer | Female | 24 | 5722 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Male | 12 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Female | 4 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | soft tissue sarcoma | Female | 2 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Male | 1 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | pancreatic cancer | Female | 131 | 1153 | 0.11 | 0.11 | 0.10 | 0.13 |
| KRAS | G12R | pancreatic cancer | Male | 145 | 1341 | 0.11 | 0.11 | 0.10 | 0.12 |
| KRAS | G12R | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | Male | 2 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Male | 3 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Female | 2 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Male | 2 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | Female | 10 | 2336 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | Female | 2 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cervical cancer | Female | 1 | 365 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Female | 2 | 636 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Male | 1 | 739 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Female | 1 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Male | 3 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | neuroendocrine tumors | Female | 1 | 166 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | neuroendocrine tumors | Male | 1 | 193 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | Male | 2 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small bowel cancer | Female | 0 | 78 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | small bowel cancer | Male | 3 | 132 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ampullary cancer | Female | 1 | 41 | 0.03 | 0.03 | 0.00 | 0.08 |
| KRAS | G12R | ampullary cancer | Male | 2 | 65 | 0.03 | 0.03 | 0.01 | 0.08 |
| KRAS | G12R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | germ cell tumor | Female | 1 | 175 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | Male | 7 | 711 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | penile cancer | Male | 1 | 25 | 0.04 | 0.03 | 0.00 | 0.15 |
| KRAS | G12R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12R | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | appendiceal cancer | Male | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | colorectal cancer | Female | 66 | 3028 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12S | colorectal cancer | Male | 60 | 3696 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12S | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cancer of unknown primary | Male | 4 | 989 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Female | 30 | 5722 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Male | 22 | 4406 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | breast cancer | Female | 6 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Male | 0 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Female | 1 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | uterine cancer | Female | 6 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Female | 1 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Male | 1 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | esophagogastric cancer | Female | 1 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | Male | 3 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cervical cancer | Female | 3 | 365 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | hepatobiliary cancer | Female | 2 | 636 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Male | 1 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bladder cancer | Male | 1 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small bowel cancer | Female | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | small bowel cancer | Male | 2 | 132 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ampullary cancer | Female | 1 | 41 | 0.02 | 0.01 | 0.00 | 0.07 |
| KRAS | G12S | ampullary cancer | Male | 0 | 65 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | germ cell tumor | Male | 4 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | Male | 2 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.02 | 0.01 | 0.00 | 0.10 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | Male | 1 | 28 | 0.03 | 0.02 | 0.00 | 0.11 |
| KRAS | G12S | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12S | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | appendiceal cancer | Female | 18 | 174 | 0.11 | 0.11 | 0.07 | 0.16 |
| KRAS | G12V | appendiceal cancer | Male | 23 | 167 | 0.13 | 0.13 | 0.09 | 0.18 |
| KRAS | G12V | colorectal cancer | Female | 299 | 3028 | 0.10 | 0.10 | 0.09 | 0.11 |
| KRAS | G12V | colorectal cancer | Male | 321 | 3696 | 0.09 | 0.09 | 0.08 | 0.10 |
| KRAS | G12V | cancer of unknown primary | Female | 58 | 1000 | 0.06 | 0.06 | 0.04 | 0.07 |
| KRAS | G12V | cancer of unknown primary | Male | 49 | 989 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | non-small cell lung cancer | Female | 327 | 5722 | 0.06 | 0.06 | 0.05 | 0.06 |
| KRAS | G12V | non-small cell lung cancer | Male | 221 | 4406 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | breast cancer | Female | 30 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | soft tissue sarcoma | Female | 2 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | Male | 2 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | pancreatic cancer | Female | 257 | 1153 | 0.23 | 0.23 | 0.20 | 0.25 |
| KRAS | G12V | pancreatic cancer | Male | 326 | 1341 | 0.24 | 0.24 | 0.22 | 0.26 |
| KRAS | G12V | leukemia | Female | 9 | 637 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | leukemia | Male | 7 | 930 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Male | 2 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | uterine cancer | Female | 112 | 2254 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Female | 1 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Male | 1 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ovarian cancer | Female | 83 | 2336 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | G12V | esophagogastric cancer | Female | 4 | 504 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | Male | 11 | 1297 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | Male | 5 | 480 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | cervical cancer | Female | 11 | 365 | 0.03 | 0.03 | 0.02 | 0.05 |
| KRAS | G12V | hepatobiliary cancer | Female | 17 | 636 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | Male | 21 | 739 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | kidney cancer | Female | 1 | 420 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | Male | 3 | 1002 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | mature t and nk neoplasms | Female | 1 | 107 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | cns cancer | Female | 4 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Male | 4 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Male | 2 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | neuroendocrine tumors | Female | 2 | 166 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12V | neuroendocrine tumors | Male | 4 | 193 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12V | bladder cancer | Female | 5 | 393 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | bladder cancer | Male | 14 | 1188 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Female | 1 | 106 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | small bowel cancer | Female | 13 | 78 | 0.14 | 0.14 | 0.08 | 0.23 |
| KRAS | G12V | small bowel cancer | Male | 12 | 132 | 0.11 | 0.10 | 0.06 | 0.16 |
| KRAS | G12V | sex cord stromal tumor | Female | 2 | 97 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | G12V | sex cord stromal tumor | Male | 0 | 11 | 0.02 | 0.01 | 0.00 | 0.08 |
| KRAS | G12V | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ampullary cancer | Female | 3 | 41 | 0.10 | 0.10 | 0.03 | 0.18 |
| KRAS | G12V | ampullary cancer | Male | 9 | 65 | 0.12 | 0.12 | 0.06 | 0.21 |
| KRAS | G12V | small cell lung cancer | Female | 2 | 193 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | small cell lung cancer | Male | 1 | 205 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | germ cell tumor | Female | 2 | 175 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12V | germ cell tumor | Male | 16 | 711 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12V | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | b cell lymphoma | Male | 3 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | lung cancer | Male | 1 | 16 | 0.07 | 0.05 | 0.00 | 0.23 |
| KRAS | G12V | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | colorectal cancer | Female | 15 | 3028 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Male | 9 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cancer of unknown primary | Female | 3 | 1000 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Male | 5 | 989 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Female | 70 | 5722 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | Male | 39 | 4406 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13C | breast cancer | Female | 0 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Male | 1 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Male | 0 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Male | 1 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | Female | 5 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | anal cancer | Female | 1 | 102 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13C | anal cancer | Male | 0 | 47 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Male | 0 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | vaginal cancer | Female | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G13C | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | appendiceal cancer | Female | 6 | 174 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | appendiceal cancer | Male | 8 | 167 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | colorectal cancer | Female | 236 | 3028 | 0.08 | 0.08 | 0.07 | 0.09 |
| KRAS | G13D | colorectal cancer | Male | 265 | 3696 | 0.07 | 0.07 | 0.06 | 0.08 |
| KRAS | G13D | cancer of unknown primary | Female | 11 | 1000 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | cancer of unknown primary | Male | 15 | 989 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | non-small cell lung cancer | Female | 48 | 5722 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Male | 39 | 4406 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | breast cancer | Female | 4 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Male | 1 | 48 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G13D | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | pancreatic cancer | Female | 6 | 1153 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | Male | 8 | 1341 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | leukemia | Female | 11 | 637 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | leukemia | Male | 14 | 930 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G13D | melanoma | Female | 2 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | Male | 5 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | Male | 2 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | uterine cancer | Female | 46 | 2254 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G13D | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Female | 4 | 483 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Male | 3 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ovarian cancer | Female | 10 | 2336 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | esophagogastric cancer | Female | 8 | 504 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Male | 14 | 1297 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cervical cancer | Female | 4 | 365 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | Female | 3 | 636 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | hepatobiliary cancer | Male | 6 | 739 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | anal cancer | Female | 1 | 102 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | anal cancer | Male | 0 | 47 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | neuroendocrine tumors | Female | 2 | 166 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G13D | neuroendocrine tumors | Male | 4 | 193 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | bladder cancer | Female | 2 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | bladder cancer | Male | 2 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Female | 2 | 106 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Male | 6 | 142 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | small bowel cancer | Female | 3 | 78 | 0.05 | 0.05 | 0.02 | 0.10 |
| KRAS | G13D | small bowel cancer | Male | 10 | 132 | 0.07 | 0.07 | 0.04 | 0.11 |
| KRAS | G13D | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ampullary cancer | Female | 3 | 41 | 0.06 | 0.05 | 0.02 | 0.13 |
| KRAS | G13D | ampullary cancer | Male | 2 | 65 | 0.04 | 0.04 | 0.01 | 0.09 |
| KRAS | G13D | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | Male | 1 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | pineal tumor | Male | 1 | 12 | 0.09 | 0.07 | 0.00 | 0.30 |
| KRAS | G13D | b cell lymphoma | Female | 5 | 395 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | Male | 2 | 567 | 0.01 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Female | 1 | 3028 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Male | 1 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Male | 0 | 989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Female | 4 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Female | 0 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Male | 0 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Female | 0 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Male | 0 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G13R | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | G13R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Female | 0 | 3028 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Male | 2 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Male | 0 | 989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Female | 2 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Female | 0 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Male | 2 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Female | 0 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Male | 0 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | germ cell tumor | Male | 1 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13V | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | G13V | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | appendiceal cancer | Male | 3 | 167 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | colorectal cancer | Female | 29 | 3028 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | Q61H | colorectal cancer | Male | 35 | 3696 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Female | 8 | 1000 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Male | 7 | 989 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | non-small cell lung cancer | Female | 84 | 5722 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Male | 47 | 4406 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | breast cancer | Female | 0 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Female | 1 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | pancreatic cancer | Female | 38 | 1153 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | Q61H | pancreatic cancer | Male | 48 | 1341 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | Q61H | leukemia | Female | 2 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | Male | 2 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | uterine cancer | Female | 6 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ovarian cancer | Female | 9 | 2336 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | esophagogastric cancer | Female | 1 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | Male | 1 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | hepatobiliary cancer | Female | 7 | 636 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | Male | 7 | 739 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | kidney cancer | Female | 1 | 420 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mature t and nk neoplasms | Female | 1 | 107 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | mature t and nk neoplasms | Male | 1 | 124 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | cns cancer | Female | 1 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Male | 2 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | neuroendocrine tumors | Male | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | bladder cancer | Female | 2 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | Male | 1 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Female | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Male | 2 | 142 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | small bowel cancer | Female | 4 | 78 | 0.04 | 0.04 | 0.01 | 0.09 |
| KRAS | Q61H | small bowel cancer | Male | 2 | 132 | 0.02 | 0.02 | 0.00 | 0.05 |
| KRAS | Q61H | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | bone cancer | Female | 1 | 242 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ampullary cancer | Female | 0 | 41 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61H | ampullary cancer | Male | 2 | 65 | 0.02 | 0.02 | 0.00 | 0.07 |
| KRAS | Q61H | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61H | b cell lymphoma | Female | 4 | 395 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | b cell lymphoma | Male | 6 | 567 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | Q61H | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Female | 9 | 3028 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Male | 3 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Male | 0 | 989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Female | 1 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Male | 1 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Female | 0 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | Female | 2 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | Male | 1 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Female | 1 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Female | 1 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | anal cancer | Female | 1 | 102 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61K | anal cancer | Male | 0 | 47 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | neuroendocrine tumors | Male | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | Male | 0 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | Q61K | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | appendiceal cancer | Male | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | colorectal cancer | Female | 15 | 3028 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Male | 9 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | Female | 2 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | Male | 1 | 989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | Female | 23 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | Male | 14 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Female | 1 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | pancreatic cancer | Female | 5 | 1153 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | Male | 1 | 1341 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Male | 1 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | Female | 2 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | Female | 1 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | Male | 1 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Male | 2 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bladder cancer | Male | 0 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | penile cancer | Male | 1 | 25 | 0.04 | 0.03 | 0.00 | 0.15 |
| KRAS | Q61L | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61L | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| KRAS | Q61L | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | appendiceal cancer | Male | 1 | 167 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | colorectal cancer | Female | 8 | 3028 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | colorectal cancer | Male | 12 | 3696 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Male | 2 | 989 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Female | 5 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Female | 1 | 9284 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | pancreatic cancer | Female | 16 | 1153 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | Q61R | pancreatic cancer | Male | 22 | 1341 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | Q61R | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | Male | 1 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Female | 2 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Female | 0 | 2254 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Female | 2 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Female | 1 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thyroid cancer | Female | 9 | 537 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | Q61R | thyroid cancer | Male | 6 | 480 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | Female | 2 | 636 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hepatobiliary cancer | Male | 0 | 739 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Female | 1 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Male | 3 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Male | 1 | 1188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ampullary cancer | Female | 2 | 41 | 0.04 | 0.03 | 0.00 | 0.12 |
| KRAS | Q61R | ampullary cancer | Male | 0 | 65 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | Male | 3 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12A | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12A | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Female | 2 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bladder cancer | Male | 2 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small cell lung cancer | Female | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12C | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Female | 2 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Male | 1 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Female | 1 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Female | 3 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | Female | 3 | 1104 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | melanoma | Male | 4 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | Male | 1 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Female | 2 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | soft tissue sarcoma | Female | 1 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bladder cancer | Female | 2 | 393 | 0.01 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bladder cancer | Male | 7 | 1187 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Male | 1 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Male | 1 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Female | 1 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Female | 3 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | head and neck cancer | Female | 4 | 564 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | Male | 7 | 1179 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12S | uterine cancer | Female | 2 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-melanoma skin cancers | Female | 1 | 183 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Male | 1 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bladder cancer | Male | 3 | 1187 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | vaginal cancer | Female | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.05 |
| HRAS | G12S | thymic tumor | Female | 0 | 68 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | thymic tumor | Male | 1 | 86 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | G12S | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G12S | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Male | 1 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Female | 1 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Male | 2 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cervical cancer | Female | 1 | 365 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Male | 1 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Female | 3 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Male | 3 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Female | 1 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Male | 2 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | Male | 2 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | thymic tumor | Female | 1 | 68 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | G13D | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G13D | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | G13D | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Female | 3 | 999 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Female | 3 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Male | 1 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Female | 5 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Male | 1 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Male | 1 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | head and neck cancer | Female | 2 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | Male | 8 | 1179 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G13R | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | Female | 1 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | Male | 3 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thyroid cancer | Male | 1 | 480 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | bladder cancer | Male | 8 | 1187 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | germ cell tumor | Male | 1 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| HRAS | G13R | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | G13R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Female | 1 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Female | 4 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Female | 1 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Male | 2 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | head and neck cancer | Female | 2 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | Male | 1 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Female | 1 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | non-melanoma skin cancers | Male | 2 | 330 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bladder cancer | Female | 2 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | Male | 1 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small cell lung cancer | Female | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13V | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | G13V | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Female | 1 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61H | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Female | 1 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Male | 2 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Female | 2 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | pancreatic cancer | Female | 1 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | Female | 2 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | Male | 6 | 1742 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | head and neck cancer | Male | 5 | 1179 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | non-melanoma skin cancers | Male | 2 | 330 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Female | 1 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thyroid cancer | Female | 8 | 537 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61K | thyroid cancer | Male | 4 | 480 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61K | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Male | 1 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | prostate cancer | Male | 6 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | Male | 4 | 1187 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | Q61K | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Female | 0 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Male | 1 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61L | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | Q61L | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Female | 0 | 999 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Male | 0 | 986 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Female | 2 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Male | 1 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Female | 4 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Male | 1 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Female | 0 | 635 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Male | 0 | 925 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Female | 2 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Male | 3 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | head and neck cancer | Female | 3 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | Male | 6 | 1179 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | uterine cancer | Female | 0 | 2248 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 482 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Female | 1 | 1400 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Male | 0 | 1338 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Male | 1 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | thyroid cancer | Female | 17 | 537 | 0.03 | 0.03 | 0.02 | 0.04 |
| HRAS | Q61R | thyroid cancer | Male | 13 | 480 | 0.03 | 0.03 | 0.02 | 0.04 |
| HRAS | Q61R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Female | 0 | 1993 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | prostate cancer | Male | 6 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | neuroendocrine tumors | Male | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Female | 3 | 393 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Male | 13 | 1187 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | bone cancer | Female | 0 | 237 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Male | 0 | 318 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | thymic tumor | Female | 0 | 68 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | thymic tumor | Male | 1 | 86 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | Q61R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Male | 0 | 123 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Male | 0 | 710 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Female | 0 | 79 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Male | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | pheochromocytoma | Male | 1 | 17 | 0.07 | 0.05 | 0.00 | 0.22 |
| HRAS | Q61R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Male | 0 | 566 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| HRAS | Q61R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Male | 5 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Male | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Female | 1 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Male | 1 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | leukemia | Female | 6 | 637 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Male | 8 | 930 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | melanoma | Female | 2 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | melanoma | Male | 3 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Female | 0 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Female | 1 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Male | 3 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Male | 1 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Male | 2 | 142 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G12A | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | germ cell tumor | Male | 1 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12A | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12A | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | appendiceal cancer | Female | 1 | 174 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | colorectal cancer | Female | 7 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | Male | 9 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | Male | 1 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Female | 1 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Male | 1 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | leukemia | Female | 4 | 637 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Male | 4 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Female | 7 | 1104 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Male | 5 | 1742 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | Male | 1 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | Female | 5 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Male | 1 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | Female | 1 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | Male | 1 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Female | 1 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | Female | 1 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Male | 1 | 142 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | germ cell tumor | Female | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12C | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G12C | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | colorectal cancer | Female | 27 | 3026 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | G12D | colorectal cancer | Male | 26 | 3694 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | cancer of unknown primary | Female | 2 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | Male | 1 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Female | 5 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Male | 3 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Female | 1 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Male | 1 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Female | 1 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | leukemia | Female | 32 | 637 | 0.05 | 0.05 | 0.04 | 0.06 |
| NRAS | G12D | leukemia | Male | 39 | 930 | 0.04 | 0.04 | 0.03 | 0.06 |
| NRAS | G12D | melanoma | Female | 6 | 1104 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | Male | 11 | 1742 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | head and neck cancer | Male | 2 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | uterine cancer | Female | 8 | 2253 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | Male | 1 | 330 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Female | 8 | 483 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Male | 12 | 724 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G12D | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | ovarian cancer | Female | 2 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | hepatobiliary cancer | Female | 1 | 636 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | Male | 3 | 738 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | neuroendocrine tumors | Female | 1 | 166 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | Male | 1 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Female | 3 | 106 | 0.04 | 0.04 | 0.01 | 0.07 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Male | 7 | 142 | 0.04 | 0.04 | 0.02 | 0.08 |
| NRAS | G12D | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Male | 2 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | Female | 1 | 12 | 0.06 | 0.04 | 0.00 | 0.24 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.02 | 0.01 | 0.00 | 0.08 |
| NRAS | G12D | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | blastic plasmacytoid dendritic cell neoplasm | Male | 2 | 11 | 0.19 | 0.17 | 0.03 | 0.45 |
| NRAS | G12D | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Male | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Male | 0 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Male | 0 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Female | 0 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Male | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | Female | 1 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | Male | 2 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | Male | 2 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Female | 1 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Female | 1 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Female | 2 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Male | 3 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Male | 1 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Male | 1 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Female | 2 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Female | 1 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | leukemia | Female | 2 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | Male | 4 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | Female | 2 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | melanoma | Male | 4 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Female | 2 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Female | 2 | 483 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Male | 6 | 724 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12S | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Male | 1 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | Male | 2 | 738 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Female | 1 | 106 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Male | 3 | 142 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | G12S | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | germ cell tumor | Male | 1 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.02 | 0.01 | 0.00 | 0.10 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | Male | 1 | 28 | 0.03 | 0.02 | 0.00 | 0.11 |
| NRAS | G12S | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Female | 3 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Male | 4 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Male | 2 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Male | 3 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Female | 1 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | leukemia | Female | 5 | 637 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12V | leukemia | Male | 3 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | Male | 2 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Female | 1 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Male | 3 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Male | 1 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Male | 2 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | non-hodgkin lymphoma | Female | 0 | 12 | 0.03 | 0.02 | 0.00 | 0.15 |
| NRAS | G12V | non-hodgkin lymphoma | Male | 1 | 11 | 0.07 | 0.05 | 0.00 | 0.25 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | blastic plasmacytoid dendritic cell neoplasm | Male | 1 | 11 | 0.10 | 0.08 | 0.00 | 0.32 |
| NRAS | G12V | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Female | 2 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Male | 1 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Male | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Female | 0 | 637 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Male | 1 | 930 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Male | 4 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Female | 0 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Female | 2 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Male | 3 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Female | 6 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Male | 6 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Male | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Female | 1 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | soft tissue sarcoma | Female | 1 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Male | 2 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | leukemia | Female | 14 | 637 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | Male | 18 | 930 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | melanoma | Female | 0 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | melanoma | Male | 8 | 1742 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Female | 1 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Female | 5 | 483 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Male | 4 | 724 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13D | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Female | 1 | 504 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Male | 1 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | neuroendocrine tumors | Female | 1 | 166 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Female | 3 | 106 | 0.03 | 0.02 | 0.01 | 0.06 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Male | 3 | 142 | 0.02 | 0.02 | 0.01 | 0.05 |
| NRAS | G13D | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | Female | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G13D | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | b cell lymphoma | Male | 2 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | blastic plasmacytoid dendritic cell neoplasm | Male | 1 | 11 | 0.10 | 0.08 | 0.00 | 0.32 |
| NRAS | G13D | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | appendiceal cancer | Female | 1 | 174 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | Female | 12 | 3026 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | Male | 7 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cancer of unknown primary | Female | 2 | 1000 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Male | 3 | 988 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | non-small cell lung cancer | Female | 0 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | leukemia | Female | 1 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | Male | 6 | 930 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Female | 6 | 1104 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Male | 14 | 1742 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | Female | 2 | 564 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Female | 0 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Female | 1 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | adrenocortical carcinoma | Female | 1 | 80 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G13R | adrenocortical carcinoma | Male | 0 | 54 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thyroid cancer | Female | 1 | 537 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | Male | 1 | 480 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | hepatobiliary cancer | Female | 1 | 636 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | Male | 2 | 738 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | Male | 2 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Male | 1 | 142 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | sex cord stromal tumor | Female | 1 | 97 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G13R | sex cord stromal tumor | Male | 0 | 10 | 0.01 | 0.01 | 0.00 | 0.07 |
| NRAS | G13R | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Male | 2 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | G13R | b cell lymphoma | Female | 1 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-hodgkin lymphoma | Female | 0 | 12 | 0.03 | 0.02 | 0.00 | 0.14 |
| NRAS | G13R | non-hodgkin lymphoma | Male | 1 | 11 | 0.07 | 0.05 | 0.00 | 0.25 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.02 | 0.02 | 0.00 | 0.10 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | Male | 1 | 28 | 0.03 | 0.02 | 0.00 | 0.11 |
| NRAS | G13R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G13R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Female | 0 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Male | 0 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Male | 0 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Female | 1 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Male | 0 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Female | 0 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Male | 0 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Female | 1 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | leukemia | Female | 3 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | Male | 2 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | Female | 1 | 1104 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | Male | 3 | 1742 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Female | 0 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Female | 1 | 483 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Male | 4 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Male | 1 | 142 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13V | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Male | 0 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G13V | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Female | 6 | 3026 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Male | 11 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | Female | 1 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | Male | 2 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Female | 1 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Male | 3 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Female | 1 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Male | 2 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | leukemia | Female | 4 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | Male | 3 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | Female | 10 | 1104 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | Male | 17 | 1742 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61H | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | Male | 1 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Female | 4 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Male | 1 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Female | 0 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Male | 0 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cervical cancer | Female | 1 | 365 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | mature t and nk neoplasms | Male | 1 | 124 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cns cancer | Female | 0 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Male | 0 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Male | 2 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Female | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Male | 1 | 142 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | germ cell tumor | Female | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | germ cell tumor | Male | 2 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61H | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | b cell lymphoma | Male | 2 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | non-hodgkin lymphoma | Female | 1 | 12 | 0.06 | 0.04 | 0.00 | 0.22 |
| NRAS | Q61H | non-hodgkin lymphoma | Male | 0 | 11 | 0.04 | 0.02 | 0.00 | 0.16 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | lung cancer | Male | 1 | 16 | 0.07 | 0.05 | 0.00 | 0.23 |
| NRAS | Q61H | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.06 |
| NRAS | Q61H | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | colorectal cancer | Female | 32 | 3026 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | colorectal cancer | Male | 33 | 3694 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Female | 4 | 1000 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Male | 3 | 988 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-small cell lung cancer | Female | 6 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Male | 2 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | soft tissue sarcoma | Female | 6 | 1413 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | Male | 9 | 1360 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61K | pancreatic cancer | Female | 2 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | leukemia | Female | 5 | 637 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | Male | 9 | 930 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | melanoma | Female | 74 | 1104 | 0.07 | 0.07 | 0.06 | 0.08 |
| NRAS | Q61K | melanoma | Male | 125 | 1742 | 0.07 | 0.07 | 0.06 | 0.08 |
| NRAS | Q61K | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | head and neck cancer | Male | 3 | 1179 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Female | 6 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | ovarian cancer | Female | 5 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | Male | 2 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | thyroid cancer | Female | 16 | 537 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61K | thyroid cancer | Male | 13 | 480 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61K | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | hepatobiliary cancer | Female | 4 | 636 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | Male | 3 | 738 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | Female | 3 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | Male | 5 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bladder cancer | Male | 3 | 1187 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Female | 2 | 106 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Male | 1 | 142 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61K | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | thymic tumor | Female | 1 | 70 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | small cell lung cancer | Male | 1 | 205 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Male | 3 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61K | b cell lymphoma | Female | 2 | 395 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | Q61K | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | appendiceal cancer | Female | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | Male | 0 | 167 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | Female | 12 | 3026 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Male | 10 | 3694 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Female | 0 | 1000 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Male | 1 | 988 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Female | 18 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Male | 14 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Female | 1 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Male | 3 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Female | 0 | 1153 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Male | 0 | 1340 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | leukemia | Female | 2 | 637 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | Male | 4 | 930 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | melanoma | Female | 24 | 1104 | 0.02 | 0.02 | 0.02 | 0.03 |
| NRAS | Q61L | melanoma | Male | 64 | 1742 | 0.04 | 0.04 | 0.03 | 0.04 |
| NRAS | Q61L | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | uterine cancer | Female | 6 | 2253 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Male | 0 | 724 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Female | 1 | 2336 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Male | 1 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Female | 0 | 537 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Male | 0 | 480 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Female | 0 | 365 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Female | 0 | 636 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Male | 0 | 738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Male | 0 | 124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Female | 1 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Male | 4 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Male | 0 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Male | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Female | 0 | 393 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Male | 0 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Female | 0 | 106 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Male | 0 | 142 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | Male | 0 | 132 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | small cell lung cancer | Male | 1 | 205 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | Male | 0 | 352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Female | 1 | 175 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | germ cell tumor | Male | 0 | 711 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | Male | 0 | 74 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61L | b cell lymphoma | Female | 0 | 395 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b cell lymphoma | Male | 1 | 567 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | Q61L | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | appendiceal cancer | Female | 2 | 174 | 0.02 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | appendiceal cancer | Male | 3 | 167 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | Q61R | colorectal cancer | Female | 25 | 3026 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | Male | 21 | 3694 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Female | 3 | 1000 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Male | 5 | 988 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-small cell lung cancer | Female | 6 | 5722 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Male | 9 | 4406 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Female | 0 | 9283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Male | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Female | 2 | 1413 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Male | 4 | 1360 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | pancreatic cancer | Female | 3 | 1153 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | pancreatic cancer | Male | 4 | 1340 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | leukemia | Female | 8 | 637 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | leukemia | Male | 9 | 930 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | melanoma | Female | 82 | 1104 | 0.08 | 0.08 | 0.06 | 0.09 |
| NRAS | Q61R | melanoma | Male | 164 | 1742 | 0.09 | 0.09 | 0.08 | 0.11 |
| NRAS | Q61R | head and neck cancer | Female | 0 | 564 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | Male | 0 | 1179 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | uterine cancer | Female | 9 | 2253 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-melanoma skin cancers | Female | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | Male | 0 | 330 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Female | 0 | 483 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Male | 2 | 724 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | adrenocortical carcinoma | Female | 0 | 80 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | adrenocortical carcinoma | Male | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ovarian cancer | Female | 25 | 2336 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | esophagogastric cancer | Female | 0 | 504 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | esophagogastric cancer | Male | 3 | 1297 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thyroid cancer | Female | 48 | 537 | 0.09 | 0.09 | 0.07 | 0.11 |
| NRAS | Q61R | thyroid cancer | Male | 47 | 480 | 0.10 | 0.10 | 0.08 | 0.12 |
| NRAS | Q61R | cervical cancer | Female | 1 | 365 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | Female | 5 | 636 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | Male | 4 | 738 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | kidney cancer | Female | 0 | 420 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | Male | 0 | 1002 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mature t and nk neoplasms | Female | 0 | 107 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | mature t and nk neoplasms | Male | 1 | 124 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cns cancer | Female | 3 | 1994 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Male | 4 | 2569 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Male | 1 | 2436 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | anal cancer | Female | 0 | 102 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | anal cancer | Male | 0 | 47 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | neuroendocrine tumors | Female | 0 | 166 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | neuroendocrine tumors | Male | 1 | 193 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | bladder cancer | Female | 2 | 393 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | Male | 1 | 1187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Female | 1 | 106 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Male | 1 | 142 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | small bowel cancer | Female | 1 | 78 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | small bowel cancer | Male | 1 | 132 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | sex cord stromal tumor | Female | 0 | 97 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | sex cord stromal tumor | Male | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bone cancer | Female | 0 | 242 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Male | 0 | 328 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | vaginal cancer | Female | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | thymic tumor | Female | 0 | 70 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | Male | 0 | 86 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ampullary cancer | Female | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | ampullary cancer | Male | 0 | 65 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | small cell lung cancer | Female | 0 | 193 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | Male | 0 | 205 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mesothelioma | Female | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | mesothelioma | Male | 1 | 352 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Female | 0 | 175 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Male | 3 | 711 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | nerve sheath tumor | Female | 1 | 80 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | nerve sheath tumor | Male | 1 | 74 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | penile cancer | Male | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pheochromocytoma | Male | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | pineal tumor | Male | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | b cell lymphoma | Female | 2 | 395 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | b cell lymphoma | Male | 4 | 567 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | non-hodgkin lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | non-hodgkin lymphoma | Male | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Female | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | retinoblastoma | Female | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | retinoblastoma | Male | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | hodgkin lymphoma | Female | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | hodgkin lymphoma | Male | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | lung cancer | Male | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | blastic plasmacytoid dendritic cell neoplasm | Male | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | Q61R | peritoneal cancer | Female | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | appendiceal cancer | Primary | 1 | 151 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | colorectal cancer | Metastasis | 51 | 2354 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | Tumor Type:NA/Heme | 6 | 224 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | Primary | 88 | 4115 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12A | cancer of unknown primary | Metastasis | 13 | 1389 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | Metastasis | 70 | 3750 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12A | non-small cell lung cancer | Tumor Type:NA/Heme | 2 | 223 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12A | non-small cell lung cancer | Primary | 153 | 6059 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12A | non-small cell lung cancer | Tumor Type:Unspecified | 1 | 99 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12A | breast cancer | Metastasis | 2 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | breast cancer | Primary | 4 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | pancreatic cancer | Metastasis | 3 | 981 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | pancreatic cancer | Tumor Type:NA/Heme | 1 | 75 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | pancreatic cancer | Primary | 9 | 1429 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Tumor Type:NA/Heme | 3 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Primary | 2 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Primary | 1 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | uterine cancer | Metastasis | 6 | 586 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12A | uterine cancer | Primary | 21 | 1541 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12A | uterine cancer | Tumor Type:Unspecified | 4 | 51 | 0.04 | 0.03 | 0.01 | 0.13 |
| KRAS | G12A | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ovarian cancer | Metastasis | 3 | 1088 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | Primary | 10 | 1060 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | ovarian cancer | Tumor Type:Unspecified | 1 | 28 | 0.01 | 0.01 | 0.00 | 0.07 |
| KRAS | G12A | esophagogastric cancer | Metastasis | 1 | 462 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Tumor Type:NA/Heme | 1 | 43 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | esophagogastric cancer | Primary | 4 | 1283 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | cervical cancer | Primary | 1 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Metastasis | 3 | 438 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12A | hepatobiliary cancer | Tumor Type:NA/Heme | 1 | 34 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G12A | hepatobiliary cancer | Primary | 3 | 895 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Primary | 6 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | anal cancer | Metastasis | 1 | 59 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G12A | anal cancer | Primary | 0 | 84 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | Metastasis | 1 | 143 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | bladder cancer | Primary | 3 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Primary | 1 | 101 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | small bowel cancer | Metastasis | 3 | 78 | 0.03 | 0.02 | 0.01 | 0.07 |
| KRAS | G12A | small bowel cancer | Primary | 1 | 128 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12A | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | bone cancer | Metastasis | 1 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | bone cancer | Primary | 1 | 326 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | vaginal cancer | Metastasis | 1 | 16 | 0.05 | 0.03 | 0.00 | 0.19 |
| KRAS | G12A | vaginal cancer | Primary | 0 | 60 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | ampullary cancer | Metastasis | 0 | 23 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | ampullary cancer | Primary | 1 | 82 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12A | small cell lung cancer | Metastasis | 1 | 207 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12A | germ cell tumor | Metastasis | 2 | 274 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | Primary | 5 | 517 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12A | nerve sheath tumor | Metastasis | 1 | 16 | 0.04 | 0.02 | 0.00 | 0.18 |
| KRAS | G12A | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | G12A | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12A | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Primary | 2 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12A | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12A | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12A | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12C | appendiceal cancer | Metastasis | 6 | 174 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12C | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.03 | 0.02 | 0.00 | 0.07 |
| KRAS | G12C | appendiceal cancer | Primary | 3 | 151 | 0.02 | 0.02 | 0.01 | 0.05 |
| KRAS | G12C | colorectal cancer | Metastasis | 108 | 2354 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12C | colorectal cancer | Tumor Type:NA/Heme | 9 | 224 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12C | colorectal cancer | Primary | 95 | 4115 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G12C | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G12C | cancer of unknown primary | Metastasis | 47 | 1389 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12C | cancer of unknown primary | Tumor Type:NA/Heme | 5 | 229 | 0.03 | 0.03 | 0.01 | 0.04 |
| KRAS | G12C | cancer of unknown primary | Primary | 6 | 311 | 0.03 | 0.03 | 0.01 | 0.04 |
| KRAS | G12C | cancer of unknown primary | Tumor Type:Unspecified | 3 | 60 | 0.03 | 0.03 | 0.02 | 0.06 |
| KRAS | G12C | non-small cell lung cancer | Metastasis | 407 | 3750 | 0.11 | 0.11 | 0.10 | 0.12 |
| KRAS | G12C | non-small cell lung cancer | Tumor Type:NA/Heme | 19 | 223 | 0.10 | 0.10 | 0.07 | 0.13 |
| KRAS | G12C | non-small cell lung cancer | Primary | 779 | 6059 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12C | non-small cell lung cancer | Tumor Type:Unspecified | 8 | 99 | 0.10 | 0.10 | 0.06 | 0.14 |
| KRAS | G12C | breast cancer | Metastasis | 6 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | breast cancer | Primary | 2 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | Tumor Type:NA/Heme | 1 | 119 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | soft tissue sarcoma | Primary | 4 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | pancreatic cancer | Metastasis | 7 | 981 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | pancreatic cancer | Tumor Type:NA/Heme | 1 | 75 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | pancreatic cancer | Primary | 14 | 1429 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G12C | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Primary | 1 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | Metastasis | 1 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | head and neck cancer | Tumor Type:NA/Heme | 1 | 67 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | uterine cancer | Metastasis | 5 | 586 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | uterine cancer | Primary | 21 | 1541 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12C | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Metastasis | 5 | 1088 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Tumor Type:NA/Heme | 1 | 160 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Primary | 3 | 1060 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | ovarian cancer | Tumor Type:Unspecified | 1 | 28 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Primary | 5 | 1283 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | thyroid cancer | Metastasis | 1 | 402 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | thyroid cancer | Primary | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | cervical cancer | Metastasis | 1 | 136 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12C | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hepatobiliary cancer | Metastasis | 6 | 438 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | hepatobiliary cancer | Primary | 4 | 895 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | kidney cancer | Primary | 1 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | neuroendocrine tumors | Metastasis | 1 | 143 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | neuroendocrine tumors | Primary | 1 | 196 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | Metastasis | 4 | 390 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | bladder cancer | Primary | 4 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | small bowel cancer | Metastasis | 3 | 78 | 0.04 | 0.04 | 0.01 | 0.08 |
| KRAS | G12C | small bowel cancer | Primary | 5 | 128 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G12C | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | vaginal cancer | Metastasis | 0 | 16 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G12C | vaginal cancer | Primary | 1 | 60 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12C | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | ampullary cancer | Metastasis | 1 | 23 | 0.04 | 0.04 | 0.01 | 0.11 |
| KRAS | G12C | ampullary cancer | Primary | 3 | 82 | 0.04 | 0.04 | 0.01 | 0.08 |
| KRAS | G12C | small cell lung cancer | Metastasis | 2 | 207 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | small cell lung cancer | Primary | 1 | 183 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | germ cell tumor | Metastasis | 3 | 274 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12C | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12C | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12C | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12C | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12C | lung cancer | Primary | 1 | 17 | 0.06 | 0.05 | 0.00 | 0.21 |
| KRAS | G12C | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.06 |
| KRAS | G12D | appendiceal cancer | Metastasis | 42 | 174 | 0.25 | 0.25 | 0.19 | 0.31 |
| KRAS | G12D | appendiceal cancer | Tumor Type:NA/Heme | 1 | 10 | 0.23 | 0.25 | 0.06 | 0.36 |
| KRAS | G12D | appendiceal cancer | Primary | 48 | 151 | 0.30 | 0.29 | 0.23 | 0.37 |
| KRAS | G12D | colorectal cancer | Metastasis | 307 | 2354 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12D | colorectal cancer | Tumor Type:NA/Heme | 28 | 224 | 0.13 | 0.13 | 0.11 | 0.15 |
| KRAS | G12D | colorectal cancer | Primary | 545 | 4115 | 0.13 | 0.13 | 0.12 | 0.14 |
| KRAS | G12D | colorectal cancer | Tumor Type:Unspecified | 5 | 31 | 0.13 | 0.13 | 0.11 | 0.17 |
| KRAS | G12D | cancer of unknown primary | Metastasis | 69 | 1389 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12D | cancer of unknown primary | Tumor Type:NA/Heme | 23 | 229 | 0.09 | 0.09 | 0.05 | 0.13 |
| KRAS | G12D | cancer of unknown primary | Primary | 15 | 311 | 0.05 | 0.05 | 0.03 | 0.07 |
| KRAS | G12D | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.03 | 0.03 | 0.00 | 0.07 |
| KRAS | G12D | non-small cell lung cancer | Metastasis | 130 | 3750 | 0.04 | 0.04 | 0.03 | 0.04 |
| KRAS | G12D | non-small cell lung cancer | Tumor Type:NA/Heme | 8 | 223 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | non-small cell lung cancer | Primary | 290 | 6059 | 0.05 | 0.05 | 0.04 | 0.05 |
| KRAS | G12D | non-small cell lung cancer | Tumor Type:Unspecified | 4 | 99 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | breast cancer | Metastasis | 4 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | breast cancer | Primary | 7 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | soft tissue sarcoma | Metastasis | 4 | 939 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Primary | 7 | 1686 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | pancreatic cancer | Metastasis | 311 | 981 | 0.32 | 0.32 | 0.29 | 0.34 |
| KRAS | G12D | pancreatic cancer | Tumor Type:NA/Heme | 24 | 75 | 0.32 | 0.32 | 0.26 | 0.37 |
| KRAS | G12D | pancreatic cancer | Primary | 445 | 1429 | 0.31 | 0.31 | 0.29 | 0.33 |
| KRAS | G12D | leukemia | Metastasis | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | leukemia | Tumor Type:NA/Heme | 13 | 923 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | leukemia | Primary | 6 | 412 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12D | leukemia | Tumor Type:Unspecified | 2 | 217 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | melanoma | Metastasis | 7 | 1738 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | Primary | 7 | 898 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12D | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | head and neck cancer | Metastasis | 2 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | head and neck cancer | Primary | 2 | 938 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | uterine cancer | Metastasis | 25 | 586 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | uterine cancer | Tumor Type:NA/Heme | 6 | 76 | 0.05 | 0.05 | 0.03 | 0.09 |
| KRAS | G12D | uterine cancer | Primary | 69 | 1541 | 0.04 | 0.04 | 0.04 | 0.06 |
| KRAS | G12D | uterine cancer | Tumor Type:Unspecified | 2 | 51 | 0.05 | 0.04 | 0.03 | 0.07 |
| KRAS | G12D | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | non-melanoma skin cancers | Tumor Type:NA/Heme | 1 | 22 | 0.03 | 0.02 | 0.00 | 0.14 |
| KRAS | G12D | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 3 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ovarian cancer | Metastasis | 35 | 1088 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12D | ovarian cancer | Tumor Type:NA/Heme | 4 | 160 | 0.03 | 0.03 | 0.02 | 0.05 |
| KRAS | G12D | ovarian cancer | Primary | 42 | 1060 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | ovarian cancer | Tumor Type:Unspecified | 1 | 28 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | esophagogastric cancer | Metastasis | 9 | 462 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | esophagogastric cancer | Tumor Type:NA/Heme | 1 | 43 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12D | esophagogastric cancer | Primary | 22 | 1283 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G12D | esophagogastric cancer | Tumor Type:Unspecified | 1 | 14 | 0.02 | 0.02 | 0.01 | 0.06 |
| KRAS | G12D | thyroid cancer | Metastasis | 2 | 402 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | thyroid cancer | Primary | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | cervical cancer | Metastasis | 3 | 136 | 0.03 | 0.02 | 0.01 | 0.05 |
| KRAS | G12D | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G12D | cervical cancer | Primary | 7 | 211 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12D | hepatobiliary cancer | Metastasis | 17 | 438 | 0.04 | 0.04 | 0.03 | 0.06 |
| KRAS | G12D | hepatobiliary cancer | Tumor Type:NA/Heme | 3 | 34 | 0.05 | 0.04 | 0.03 | 0.11 |
| KRAS | G12D | hepatobiliary cancer | Primary | 35 | 895 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12D | kidney cancer | Metastasis | 4 | 445 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | kidney cancer | Primary | 1 | 944 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Metastasis | 1 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Tumor Type:NA/Heme | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Primary | 5 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | cns cancer | Tumor Type:Unspecified | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | prostate cancer | Metastasis | 1 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | Primary | 1 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | anal cancer | Metastasis | 0 | 59 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | anal cancer | Primary | 1 | 84 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12D | neuroendocrine tumors | Metastasis | 4 | 143 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12D | neuroendocrine tumors | Tumor Type:NA/Heme | 1 | 20 | 0.04 | 0.04 | 0.01 | 0.09 |
| KRAS | G12D | neuroendocrine tumors | Primary | 9 | 196 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G12D | bladder cancer | Metastasis | 8 | 390 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12D | bladder cancer | Primary | 24 | 1164 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.03 | 0.03 | 0.00 | 0.07 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 5 | 109 | 0.04 | 0.03 | 0.02 | 0.07 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Primary | 2 | 101 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12D | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 1 | 25 | 0.03 | 0.03 | 0.01 | 0.08 |
| KRAS | G12D | small bowel cancer | Metastasis | 8 | 78 | 0.12 | 0.11 | 0.06 | 0.18 |
| KRAS | G12D | small bowel cancer | Primary | 17 | 128 | 0.13 | 0.12 | 0.08 | 0.18 |
| KRAS | G12D | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | bone cancer | Primary | 2 | 326 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | vaginal cancer | Metastasis | 0 | 16 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12D | vaginal cancer | Primary | 1 | 60 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G12D | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | ampullary cancer | Metastasis | 9 | 23 | 0.32 | 0.31 | 0.19 | 0.53 |
| KRAS | G12D | ampullary cancer | Primary | 18 | 82 | 0.24 | 0.24 | 0.15 | 0.33 |
| KRAS | G12D | small cell lung cancer | Metastasis | 2 | 207 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | small cell lung cancer | Primary | 2 | 183 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | germ cell tumor | Metastasis | 2 | 274 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Primary | 7 | 517 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12D | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12D | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12D | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12D | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | Tumor Type:NA/Heme | 2 | 145 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12D | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12D | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12D | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Metastasis | 0 | 2354 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Primary | 1 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Metastasis | 2 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | Metastasis | 8 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Tumor Type:NA/Heme | 1 | 223 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | non-small cell lung cancer | Primary | 23 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | pancreatic cancer | Primary | 1 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Metastasis | 0 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Metastasis | 1 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | hepatobiliary cancer | Primary | 0 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12F | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12F | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12F | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12F | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12F | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | appendiceal cancer | Metastasis | 3 | 174 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.06 |
| KRAS | G12R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | colorectal cancer | Metastasis | 12 | 2354 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | Primary | 22 | 4115 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | Metastasis | 13 | 1389 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | Tumor Type:NA/Heme | 3 | 229 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | cancer of unknown primary | Primary | 0 | 311 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12R | cancer of unknown primary | Tumor Type:Unspecified | 1 | 60 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | non-small cell lung cancer | Metastasis | 13 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-small cell lung cancer | Tumor Type:NA/Heme | 1 | 223 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | non-small cell lung cancer | Primary | 22 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | breast cancer | Metastasis | 3 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | breast cancer | Primary | 1 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Primary | 3 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | pancreatic cancer | Metastasis | 105 | 981 | 0.11 | 0.11 | 0.09 | 0.13 |
| KRAS | G12R | pancreatic cancer | Tumor Type:NA/Heme | 11 | 75 | 0.12 | 0.11 | 0.09 | 0.17 |
| KRAS | G12R | pancreatic cancer | Primary | 160 | 1429 | 0.11 | 0.11 | 0.10 | 0.13 |
| KRAS | G12R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | leukemia | Primary | 2 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Primary | 1 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Metastasis | 1 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Primary | 1 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 1 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ovarian cancer | Metastasis | 4 | 1088 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | Tumor Type:NA/Heme | 1 | 160 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | Primary | 4 | 1060 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | ovarian cancer | Tumor Type:Unspecified | 1 | 28 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | esophagogastric cancer | Metastasis | 1 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Metastasis | 1 | 402 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cervical cancer | Metastasis | 1 | 136 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hepatobiliary cancer | Primary | 2 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Primary | 2 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | prostate cancer | Primary | 3 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | neuroendocrine tumors | Metastasis | 2 | 143 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bladder cancer | Primary | 3 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small bowel cancer | Metastasis | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | small bowel cancer | Primary | 2 | 128 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12R | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | ampullary cancer | Metastasis | 1 | 23 | 0.04 | 0.03 | 0.00 | 0.11 |
| KRAS | G12R | ampullary cancer | Primary | 2 | 82 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | G12R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | germ cell tumor | Metastasis | 3 | 274 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | Primary | 5 | 517 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | penile cancer | Metastasis | 1 | 11 | 0.06 | 0.04 | 0.00 | 0.24 |
| KRAS | G12R | penile cancer | Primary | 0 | 13 | 0.03 | 0.02 | 0.00 | 0.15 |
| KRAS | G12R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | b cell lymphoma | Tumor Type:NA/Heme | 2 | 145 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12R | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | colorectal cancer | Metastasis | 46 | 2354 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12S | colorectal cancer | Tumor Type:NA/Heme | 1 | 224 | 0.02 | 0.02 | 0.00 | 0.02 |
| KRAS | G12S | colorectal cancer | Primary | 78 | 4115 | 0.02 | 0.02 | 0.02 | 0.02 |
| KRAS | G12S | colorectal cancer | Tumor Type:Unspecified | 1 | 31 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12S | cancer of unknown primary | Metastasis | 3 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | cancer of unknown primary | Tumor Type:Unspecified | 1 | 60 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | non-small cell lung cancer | Metastasis | 21 | 3750 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Primary | 31 | 6059 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | breast cancer | Metastasis | 3 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | breast cancer | Primary | 3 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | pancreatic cancer | Primary | 0 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | leukemia | Tumor Type:NA/Heme | 1 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | uterine cancer | Metastasis | 1 | 586 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | Primary | 5 | 1541 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 2 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Metastasis | 1 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | Primary | 4 | 1283 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cervical cancer | Metastasis | 2 | 136 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12S | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | cervical cancer | Primary | 1 | 211 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | hepatobiliary cancer | Metastasis | 1 | 438 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | hepatobiliary cancer | Primary | 1 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | kidney cancer | Metastasis | 1 | 445 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | bladder cancer | Primary | 2 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small bowel cancer | Metastasis | 1 | 78 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | small bowel cancer | Primary | 2 | 128 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | ampullary cancer | Metastasis | 0 | 23 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G12S | ampullary cancer | Primary | 1 | 82 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G12S | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | germ cell tumor | Metastasis | 3 | 274 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12S | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12S | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12S | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | Primary | 2 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | b cell lymphoma | Tumor Type:Unspecified | 1 | 51 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12S | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12S | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12S | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | appendiceal cancer | Metastasis | 16 | 174 | 0.11 | 0.11 | 0.06 | 0.15 |
| KRAS | G12V | appendiceal cancer | Tumor Type:NA/Heme | 1 | 10 | 0.12 | 0.12 | 0.04 | 0.23 |
| KRAS | G12V | appendiceal cancer | Primary | 23 | 151 | 0.14 | 0.13 | 0.09 | 0.19 |
| KRAS | G12V | colorectal cancer | Metastasis | 202 | 2354 | 0.09 | 0.09 | 0.08 | 0.10 |
| KRAS | G12V | colorectal cancer | Tumor Type:NA/Heme | 26 | 224 | 0.10 | 0.10 | 0.08 | 0.13 |
| KRAS | G12V | colorectal cancer | Primary | 389 | 4115 | 0.09 | 0.09 | 0.09 | 0.10 |
| KRAS | G12V | colorectal cancer | Tumor Type:Unspecified | 3 | 31 | 0.10 | 0.09 | 0.07 | 0.13 |
| KRAS | G12V | cancer of unknown primary | Metastasis | 72 | 1389 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | cancer of unknown primary | Tumor Type:NA/Heme | 20 | 229 | 0.07 | 0.07 | 0.05 | 0.11 |
| KRAS | G12V | cancer of unknown primary | Primary | 10 | 311 | 0.04 | 0.04 | 0.02 | 0.06 |
| KRAS | G12V | cancer of unknown primary | Tumor Type:Unspecified | 5 | 60 | 0.07 | 0.06 | 0.04 | 0.12 |
| KRAS | G12V | non-small cell lung cancer | Metastasis | 166 | 3750 | 0.04 | 0.04 | 0.04 | 0.05 |
| KRAS | G12V | non-small cell lung cancer | Tumor Type:NA/Heme | 12 | 223 | 0.05 | 0.05 | 0.03 | 0.08 |
| KRAS | G12V | non-small cell lung cancer | Primary | 369 | 6059 | 0.06 | 0.06 | 0.05 | 0.07 |
| KRAS | G12V | non-small cell lung cancer | Tumor Type:Unspecified | 1 | 99 | 0.04 | 0.04 | 0.01 | 0.06 |
| KRAS | G12V | breast cancer | Metastasis | 16 | 3094 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | breast cancer | Tumor Type:NA/Heme | 3 | 105 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | breast cancer | Primary | 10 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | Metastasis | 3 | 939 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | soft tissue sarcoma | Primary | 1 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | pancreatic cancer | Metastasis | 216 | 981 | 0.22 | 0.22 | 0.20 | 0.25 |
| KRAS | G12V | pancreatic cancer | Tumor Type:NA/Heme | 16 | 75 | 0.23 | 0.23 | 0.17 | 0.28 |
| KRAS | G12V | pancreatic cancer | Primary | 350 | 1429 | 0.24 | 0.24 | 0.22 | 0.26 |
| KRAS | G12V | leukemia | Metastasis | 2 | 15 | 0.04 | 0.02 | 0.01 | 0.19 |
| KRAS | G12V | leukemia | Tumor Type:NA/Heme | 8 | 923 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | leukemia | Primary | 5 | 412 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | uterine cancer | Metastasis | 26 | 586 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | uterine cancer | Tumor Type:NA/Heme | 5 | 76 | 0.05 | 0.05 | 0.04 | 0.08 |
| KRAS | G12V | uterine cancer | Primary | 77 | 1541 | 0.05 | 0.05 | 0.04 | 0.06 |
| KRAS | G12V | uterine cancer | Tumor Type:Unspecified | 4 | 51 | 0.05 | 0.05 | 0.04 | 0.09 |
| KRAS | G12V | non-melanoma skin cancers | Metastasis | 1 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 1 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ovarian cancer | Metastasis | 33 | 1088 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | G12V | ovarian cancer | Tumor Type:NA/Heme | 3 | 160 | 0.03 | 0.03 | 0.01 | 0.05 |
| KRAS | G12V | ovarian cancer | Primary | 47 | 1060 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | G12V | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G12V | esophagogastric cancer | Metastasis | 5 | 462 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | esophagogastric cancer | Primary | 10 | 1283 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | thyroid cancer | Metastasis | 3 | 402 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | thyroid cancer | Primary | 3 | 582 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G12V | cervical cancer | Metastasis | 5 | 136 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G12V | cervical cancer | Tumor Type:NA/Heme | 1 | 12 | 0.04 | 0.03 | 0.01 | 0.14 |
| KRAS | G12V | cervical cancer | Primary | 3 | 211 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12V | hepatobiliary cancer | Metastasis | 17 | 438 | 0.03 | 0.03 | 0.02 | 0.05 |
| KRAS | G12V | hepatobiliary cancer | Tumor Type:NA/Heme | 1 | 34 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | G12V | hepatobiliary cancer | Primary | 20 | 895 | 0.02 | 0.02 | 0.02 | 0.04 |
| KRAS | G12V | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | kidney cancer | Primary | 4 | 944 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | mature t and nk neoplasms | Primary | 1 | 187 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | cns cancer | Metastasis | 2 | 409 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Primary | 6 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | prostate cancer | Primary | 2 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | neuroendocrine tumors | Metastasis | 0 | 143 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | neuroendocrine tumors | Tumor Type:NA/Heme | 2 | 20 | 0.07 | 0.05 | 0.01 | 0.23 |
| KRAS | G12V | neuroendocrine tumors | Primary | 4 | 196 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12V | bladder cancer | Metastasis | 3 | 390 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G12V | bladder cancer | Primary | 16 | 1164 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 109 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | small bowel cancer | Metastasis | 13 | 78 | 0.14 | 0.14 | 0.08 | 0.23 |
| KRAS | G12V | small bowel cancer | Primary | 12 | 128 | 0.11 | 0.11 | 0.06 | 0.16 |
| KRAS | G12V | sex cord stromal tumor | Metastasis | 1 | 49 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | sex cord stromal tumor | Primary | 1 | 54 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | G12V | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | ampullary cancer | Metastasis | 3 | 23 | 0.12 | 0.12 | 0.05 | 0.23 |
| KRAS | G12V | ampullary cancer | Primary | 9 | 82 | 0.11 | 0.11 | 0.06 | 0.18 |
| KRAS | G12V | small cell lung cancer | Metastasis | 2 | 207 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | small cell lung cancer | Primary | 1 | 183 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G12V | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | germ cell tumor | Metastasis | 5 | 274 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G12V | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G12V | germ cell tumor | Primary | 13 | 517 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G12V | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | G12V | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G12V | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G12V | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | b cell lymphoma | Primary | 4 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G12V | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G12V | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G12V | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G12V | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | colorectal cancer | Metastasis | 8 | 2354 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Tumor Type:NA/Heme | 1 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | colorectal cancer | Primary | 15 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Metastasis | 7 | 1389 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Metastasis | 42 | 3750 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Tumor Type:NA/Heme | 2 | 223 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13C | non-small cell lung cancer | Primary | 65 | 6059 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13C | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13C | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Primary | 1 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | pancreatic cancer | Primary | 0 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | Metastasis | 1 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | uterine cancer | Primary | 4 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Primary | 1 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | hepatobiliary cancer | Primary | 0 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | anal cancer | Metastasis | 0 | 59 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | anal cancer | Primary | 1 | 84 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G13C | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | vaginal cancer | Metastasis | 0 | 16 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | G13C | vaginal cancer | Primary | 1 | 60 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | G13C | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13C | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13C | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13C | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13C | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13C | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | appendiceal cancer | Metastasis | 6 | 174 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | appendiceal cancer | Tumor Type:NA/Heme | 1 | 10 | 0.05 | 0.04 | 0.02 | 0.15 |
| KRAS | G13D | appendiceal cancer | Primary | 7 | 151 | 0.04 | 0.04 | 0.02 | 0.07 |
| KRAS | G13D | colorectal cancer | Metastasis | 170 | 2354 | 0.07 | 0.07 | 0.06 | 0.08 |
| KRAS | G13D | colorectal cancer | Tumor Type:NA/Heme | 18 | 224 | 0.08 | 0.08 | 0.06 | 0.10 |
| KRAS | G13D | colorectal cancer | Primary | 311 | 4115 | 0.08 | 0.08 | 0.07 | 0.08 |
| KRAS | G13D | colorectal cancer | Tumor Type:Unspecified | 2 | 31 | 0.08 | 0.07 | 0.05 | 0.10 |
| KRAS | G13D | cancer of unknown primary | Metastasis | 18 | 1389 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | cancer of unknown primary | Primary | 6 | 311 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | cancer of unknown primary | Tumor Type:Unspecified | 2 | 60 | 0.02 | 0.02 | 0.01 | 0.06 |
| KRAS | G13D | non-small cell lung cancer | Metastasis | 39 | 3750 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Tumor Type:NA/Heme | 2 | 223 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | non-small cell lung cancer | Primary | 46 | 6059 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | G13D | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | breast cancer | Metastasis | 2 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | breast cancer | Tumor Type:NA/Heme | 1 | 105 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | breast cancer | Primary | 2 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | pancreatic cancer | Metastasis | 4 | 981 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | pancreatic cancer | Primary | 10 | 1429 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | leukemia | Metastasis | 2 | 15 | 0.03 | 0.02 | 0.01 | 0.15 |
| KRAS | G13D | leukemia | Tumor Type:NA/Heme | 14 | 923 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G13D | leukemia | Primary | 5 | 412 | 0.02 | 0.02 | 0.01 | 0.02 |
| KRAS | G13D | leukemia | Tumor Type:Unspecified | 4 | 217 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | melanoma | Metastasis | 5 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | head and neck cancer | Tumor Type:NA/Heme | 1 | 67 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | head and neck cancer | Primary | 2 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | uterine cancer | Metastasis | 9 | 586 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | G13D | uterine cancer | Tumor Type:NA/Heme | 2 | 76 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | uterine cancer | Primary | 35 | 1541 | 0.02 | 0.02 | 0.02 | 0.03 |
| KRAS | G13D | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.02 | 0.02 | 0.00 | 0.03 |
| KRAS | G13D | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Metastasis | 1 | 11 | 0.03 | 0.01 | 0.00 | 0.16 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 3 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Primary | 3 | 250 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ovarian cancer | Metastasis | 3 | 1088 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | Tumor Type:NA/Heme | 3 | 160 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | ovarian cancer | Primary | 4 | 1060 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.01 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Metastasis | 5 | 462 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Primary | 17 | 1283 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | G13D | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cervical cancer | Metastasis | 3 | 136 | 0.02 | 0.01 | 0.00 | 0.04 |
| KRAS | G13D | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | G13D | cervical cancer | Primary | 1 | 211 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | Metastasis | 3 | 438 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | hepatobiliary cancer | Primary | 6 | 895 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | G13D | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Primary | 1 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | anal cancer | Metastasis | 0 | 59 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | anal cancer | Primary | 1 | 84 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | G13D | neuroendocrine tumors | Metastasis | 1 | 143 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | G13D | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | G13D | neuroendocrine tumors | Primary | 5 | 196 | 0.02 | 0.02 | 0.01 | 0.04 |
| KRAS | G13D | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | bladder cancer | Tumor Type:NA/Heme | 1 | 25 | 0.02 | 0.01 | 0.00 | 0.10 |
| KRAS | G13D | bladder cancer | Primary | 3 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.03 | 0.03 | 0.00 | 0.07 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 4 | 109 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Primary | 4 | 101 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | G13D | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.03 | 0.03 | 0.00 | 0.06 |
| KRAS | G13D | small bowel cancer | Metastasis | 1 | 78 | 0.03 | 0.02 | 0.00 | 0.08 |
| KRAS | G13D | small bowel cancer | Primary | 12 | 128 | 0.09 | 0.08 | 0.04 | 0.14 |
| KRAS | G13D | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | ampullary cancer | Metastasis | 1 | 23 | 0.05 | 0.04 | 0.01 | 0.12 |
| KRAS | G13D | ampullary cancer | Primary | 4 | 82 | 0.05 | 0.05 | 0.02 | 0.10 |
| KRAS | G13D | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13D | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13D | pineal tumor | Primary | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| KRAS | G13D | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | b cell lymphoma | Primary | 7 | 709 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | G13D | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13D | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13D | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13D | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | G13R | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Metastasis | 1 | 2354 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Primary | 1 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Metastasis | 1 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Metastasis | 4 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Primary | 2 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | pancreatic cancer | Primary | 0 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Metastasis | 0 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | hepatobiliary cancer | Primary | 0 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Primary | 1 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Metastasis | 2 | 2354 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Primary | 0 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | cancer of unknown primary | Metastasis | 0 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Metastasis | 2 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Primary | 2 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | pancreatic cancer | Primary | 2 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Metastasis | 0 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | hepatobiliary cancer | Primary | 0 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | G13V | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | G13V | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | G13V | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | G13V | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | G13V | parathyroid cancer | Primary | 1 | 13 | 0.09 | 0.07 | 0.00 | 0.28 |
| KRAS | Q61H | appendiceal cancer | Metastasis | 3 | 174 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61H | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | colorectal cancer | Metastasis | 30 | 2354 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | colorectal cancer | Tumor Type:NA/Heme | 1 | 224 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | colorectal cancer | Primary | 32 | 4115 | 0.01 | 0.01 | 0.01 | 0.01 |
| KRAS | Q61H | colorectal cancer | Tumor Type:Unspecified | 1 | 31 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | cancer of unknown primary | Metastasis | 10 | 1389 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.01 | 0.01 | 0.00 | 0.01 |
| KRAS | Q61H | cancer of unknown primary | Primary | 4 | 311 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Metastasis | 53 | 3750 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Tumor Type:NA/Heme | 3 | 223 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Primary | 75 | 6059 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Metastasis | 1 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | pancreatic cancer | Metastasis | 27 | 981 | 0.03 | 0.03 | 0.02 | 0.04 |
| KRAS | Q61H | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.02 | 0.02 | 0.00 | 0.04 |
| KRAS | Q61H | pancreatic cancer | Primary | 58 | 1429 | 0.04 | 0.04 | 0.03 | 0.05 |
| KRAS | Q61H | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | leukemia | Tumor Type:NA/Heme | 4 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | Primary | 1 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | uterine cancer | Metastasis | 2 | 586 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | uterine cancer | Primary | 4 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ovarian cancer | Metastasis | 5 | 1088 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | Primary | 3 | 1060 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | ovarian cancer | Tumor Type:Unspecified | 1 | 28 | 0.01 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | esophagogastric cancer | Primary | 2 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | hepatobiliary cancer | Metastasis | 4 | 438 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | hepatobiliary cancer | Primary | 10 | 895 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61H | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | kidney cancer | Primary | 1 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61H | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | mature t and nk neoplasms | Primary | 2 | 187 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Primary | 3 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Primary | 1 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | neuroendocrine tumors | Primary | 1 | 196 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bladder cancer | Primary | 3 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.01 | 0.00 | 0.06 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 109 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 2 | 25 | 0.04 | 0.03 | 0.00 | 0.16 |
| KRAS | Q61H | small bowel cancer | Metastasis | 3 | 78 | 0.03 | 0.03 | 0.01 | 0.07 |
| KRAS | Q61H | small bowel cancer | Primary | 3 | 128 | 0.03 | 0.03 | 0.01 | 0.06 |
| KRAS | Q61H | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | Metastasis | 1 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | ampullary cancer | Metastasis | 0 | 23 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | Q61H | ampullary cancer | Primary | 2 | 82 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | Q61H | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61H | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61H | b cell lymphoma | Metastasis | 2 | 57 | 0.02 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61H | b cell lymphoma | Tumor Type:NA/Heme | 1 | 145 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | b cell lymphoma | Primary | 6 | 709 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61H | b cell lymphoma | Tumor Type:Unspecified | 1 | 51 | 0.01 | 0.01 | 0.00 | 0.04 |
| KRAS | Q61H | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61H | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61H | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61H | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61K | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Metastasis | 3 | 2354 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Primary | 9 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | cancer of unknown primary | Metastasis | 1 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | Metastasis | 2 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | pancreatic cancer | Primary | 1 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Metastasis | 1 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Tumor Type:NA/Heme | 1 | 160 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | thyroid cancer | Primary | 1 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | hepatobiliary cancer | Primary | 0 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Primary | 1 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | cns cancer | Tumor Type:Unspecified | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | prostate cancer | Metastasis | 1 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | anal cancer | Metastasis | 1 | 59 | 0.01 | 0.01 | 0.00 | 0.05 |
| KRAS | Q61K | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | neuroendocrine tumors | Primary | 1 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61K | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61K | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61K | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61K | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61K | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61K | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | appendiceal cancer | Metastasis | 1 | 174 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Metastasis | 9 | 2354 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | colorectal cancer | Primary | 15 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | cancer of unknown primary | Metastasis | 1 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | Tumor Type:NA/Heme | 2 | 229 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Metastasis | 13 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | Tumor Type:NA/Heme | 2 | 223 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-small cell lung cancer | Primary | 22 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | pancreatic cancer | Metastasis | 5 | 981 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | pancreatic cancer | Primary | 1 | 1429 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | Metastasis | 2 | 586 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Primary | 1 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | hepatobiliary cancer | Metastasis | 2 | 438 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | hepatobiliary cancer | Primary | 0 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Tumor Type:NA/Heme | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Primary | 1 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Metastasis | 1 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bladder cancer | Primary | 1 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | penile cancer | Metastasis | 0 | 11 | 0.03 | 0.02 | 0.00 | 0.15 |
| KRAS | Q61L | penile cancer | Primary | 1 | 13 | 0.06 | 0.04 | 0.00 | 0.21 |
| KRAS | Q61L | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61L | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61L | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61L | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61L | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61L | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| KRAS | Q61R | appendiceal cancer | Metastasis | 1 | 174 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | Metastasis | 4 | 2354 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | colorectal cancer | Primary | 16 | 4115 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | cancer of unknown primary | Metastasis | 3 | 1389 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-small cell lung cancer | Metastasis | 3 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Primary | 4 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | breast cancer | Tumor Type:NA/Heme | 1 | 105 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | breast cancer | Primary | 0 | 6125 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | pancreatic cancer | Metastasis | 22 | 981 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | Q61R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.01 | 0.01 | 0.00 | 0.03 |
| KRAS | Q61R | pancreatic cancer | Primary | 16 | 1429 | 0.01 | 0.01 | 0.01 | 0.02 |
| KRAS | Q61R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Metastasis | 0 | 586 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Metastasis | 1 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Primary | 1 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | thyroid cancer | Metastasis | 3 | 402 | 0.01 | 0.01 | 0.00 | 0.02 |
| KRAS | Q61R | thyroid cancer | Tumor Type:NA/Heme | 3 | 28 | 0.06 | 0.04 | 0.01 | 0.19 |
| KRAS | Q61R | thyroid cancer | Primary | 9 | 582 | 0.02 | 0.02 | 0.01 | 0.03 |
| KRAS | Q61R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hepatobiliary cancer | Metastasis | 1 | 438 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | hepatobiliary cancer | Primary | 1 | 895 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Metastasis | 1 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Primary | 3 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | prostate cancer | Tumor Type:Unspecified | 1 | 12 | 0.07 | 0.05 | 0.00 | 0.26 |
| KRAS | Q61R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Metastasis | 0 | 390 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | bladder cancer | Primary | 1 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | Metastasis | 0 | 49 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | ampullary cancer | Metastasis | 0 | 23 | 0.02 | 0.01 | 0.00 | 0.06 |
| KRAS | Q61R | ampullary cancer | Primary | 2 | 82 | 0.02 | 0.02 | 0.00 | 0.06 |
| KRAS | Q61R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | Tumor Type:NA/Heme | 2 | 145 | 0.01 | 0.00 | 0.00 | 0.03 |
| KRAS | Q61R | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| KRAS | Q61R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| KRAS | Q61R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| KRAS | Q61R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| KRAS | Q61R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12A | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12A | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12A | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12A | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12A | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12C | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | breast cancer | Primary | 2 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | non-melanoma skin cancers | Primary | 1 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bladder cancer | Metastasis | 1 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | bladder cancer | Tumor Type:NA/Heme | 1 | 25 | 0.02 | 0.00 | 0.00 | 0.09 |
| HRAS | G12C | bladder cancer | Primary | 1 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | small cell lung cancer | Metastasis | 1 | 207 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12C | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12C | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12C | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12C | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Primary | 3 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | breast cancer | Primary | 3 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | Metastasis | 5 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | head and neck cancer | Primary | 2 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Metastasis | 1 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Primary | 1 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | non-melanoma skin cancers | Primary | 1 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Primary | 1 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thyroid cancer | Tumor Type:NA/Heme | 1 | 28 | 0.03 | 0.02 | 0.00 | 0.12 |
| HRAS | G12D | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bladder cancer | Metastasis | 1 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bladder cancer | Tumor Type:NA/Heme | 1 | 25 | 0.01 | 0.01 | 0.00 | 0.07 |
| HRAS | G12D | bladder cancer | Primary | 7 | 1164 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12D | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12D | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12D | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12D | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12D | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | bladder cancer | Primary | 1 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12F | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12F | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12F | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12F | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12F | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Primary | 1 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | breast cancer | Primary | 2 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | head and neck cancer | Metastasis | 2 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | head and neck cancer | Primary | 9 | 938 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | G12S | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | Primary | 2 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-melanoma skin cancers | Metastasis | 1 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | non-melanoma skin cancers | Primary | 1 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Primary | 1 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bladder cancer | Metastasis | 1 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | bladder cancer | Primary | 2 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | vaginal cancer | Metastasis | 0 | 16 | 0.02 | 0.01 | 0.00 | 0.06 |
| HRAS | G12S | vaginal cancer | Primary | 1 | 60 | 0.02 | 0.01 | 0.00 | 0.06 |
| HRAS | G12S | thymic tumor | Metastasis | 0 | 60 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | thymic tumor | Primary | 1 | 83 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | G12S | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12S | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12S | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12S | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12S | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12S | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Metastasis | 2 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cervical cancer | Metastasis | 1 | 136 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G12V | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G12V | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G12V | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G12V | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G12V | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13C | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Primary | 1 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13C | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13C | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13C | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13C | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13C | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | G13D | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Metastasis | 3 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | melanoma | Primary | 3 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Primary | 1 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | prostate cancer | Primary | 2 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | bladder cancer | Primary | 2 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | thymic tumor | Metastasis | 0 | 60 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | thymic tumor | Primary | 1 | 83 | 0.01 | 0.01 | 0.00 | 0.04 |
| HRAS | G13D | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13D | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13D | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13D | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13D | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Metastasis | 2 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-small cell lung cancer | Metastasis | 2 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Primary | 2 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Metastasis | 2 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | breast cancer | Primary | 3 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | pancreatic cancer | Primary | 1 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | Metastasis | 2 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | head and neck cancer | Primary | 8 | 938 | 0.01 | 0.01 | 0.00 | 0.01 |
| HRAS | G13R | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | non-melanoma skin cancers | Primary | 1 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | Metastasis | 1 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | Tumor Type:NA/Heme | 1 | 119 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | soft tissue sarcoma | Primary | 2 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | thyroid cancer | Primary | 2 | 582 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Tumor Type:NA/Heme | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Primary | 1 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bladder cancer | Metastasis | 2 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | bladder cancer | Primary | 6 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | Tumor Type:NA/Heme | 1 | 81 | 0.01 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | non-small cell lung cancer | Metastasis | 4 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Primary | 2 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Tumor Type:NA/Heme | 1 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | Metastasis | 2 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Metastasis | 1 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | non-melanoma skin cancers | Metastasis | 1 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | non-melanoma skin cancers | Primary | 1 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bladder cancer | Primary | 3 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | small cell lung cancer | Metastasis | 1 | 207 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | G13V | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | G13V | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | G13V | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | G13V | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | G13V | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61H | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Primary | 1 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61H | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61H | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61H | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61H | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61H | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cancer of unknown primary | Primary | 2 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | breast cancer | Primary | 1 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Metastasis | 1 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | Metastasis | 5 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | Primary | 3 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Metastasis | 2 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | head and neck cancer | Primary | 3 | 938 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | non-melanoma skin cancers | Primary | 2 | 287 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Primary | 1 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thyroid cancer | Metastasis | 2 | 402 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61K | thyroid cancer | Tumor Type:NA/Heme | 1 | 28 | 0.02 | 0.01 | 0.00 | 0.07 |
| HRAS | Q61K | thyroid cancer | Primary | 9 | 582 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61K | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | hepatobiliary cancer | Primary | 1 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | prostate cancer | Metastasis | 2 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | prostate cancer | Primary | 4 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bladder cancer | Metastasis | 1 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | bladder cancer | Primary | 4 | 1164 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61K | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61K | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61K | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61K | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61K | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61K | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Metastasis | 1 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Primary | 0 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | Metastasis | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | thymic tumor | Primary | 0 | 83 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61L | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61L | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61L | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61L | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61L | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61R | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Metastasis | 2 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | breast cancer | Primary | 3 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | pancreatic cancer | Primary | 1 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Primary | 0 | 407 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | leukemia | Tumor Type:Unspecified | 0 | 215 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | melanoma | Primary | 3 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | Metastasis | 3 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | head and neck cancer | Tumor Type:NA/Heme | 1 | 67 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | head and neck cancer | Primary | 5 | 938 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | uterine cancer | Metastasis | 0 | 583 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | Primary | 0 | 1538 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | non-melanoma skin cancers | Tumor Type:NA/Heme | 1 | 22 | 0.03 | 0.02 | 0.00 | 0.14 |
| HRAS | Q61R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 914 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Metastasis | 0 | 928 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Primary | 1 | 1668 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | thyroid cancer | Metastasis | 8 | 402 | 0.03 | 0.02 | 0.01 | 0.04 |
| HRAS | Q61R | thyroid cancer | Tumor Type:NA/Heme | 1 | 28 | 0.03 | 0.03 | 0.01 | 0.07 |
| HRAS | Q61R | thyroid cancer | Primary | 21 | 582 | 0.03 | 0.03 | 0.02 | 0.05 |
| HRAS | Q61R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Primary | 0 | 3521 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | prostate cancer | Metastasis | 4 | 901 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | prostate cancer | Primary | 2 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | neuroendocrine tumors | Metastasis | 1 | 143 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | bladder cancer | Metastasis | 4 | 389 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.02 |
| HRAS | Q61R | bladder cancer | Primary | 12 | 1164 | 0.01 | 0.01 | 0.01 | 0.02 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Metastasis | 0 | 197 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Primary | 0 | 319 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | bone cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | thymic tumor | Metastasis | 1 | 60 | 0.01 | 0.01 | 0.00 | 0.05 |
| HRAS | Q61R | thymic tumor | Primary | 0 | 83 | 0.01 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Primary | 0 | 516 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | nerve sheath tumor | Primary | 0 | 115 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| HRAS | Q61R | pheochromocytoma | Primary | 1 | 18 | 0.06 | 0.05 | 0.00 | 0.20 |
| HRAS | Q61R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| HRAS | Q61R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Primary | 0 | 708 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| HRAS | Q61R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| HRAS | Q61R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| HRAS | Q61R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| HRAS | Q61R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Metastasis | 4 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Primary | 1 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | leukemia | Metastasis | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Tumor Type:NA/Heme | 9 | 923 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Primary | 3 | 412 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | leukemia | Tumor Type:Unspecified | 2 | 217 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12A | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | melanoma | Primary | 3 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 4 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 2 | 109 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12A | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12A | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12A | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12A | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12A | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12C | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | appendiceal cancer | Primary | 1 | 151 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | colorectal cancer | Metastasis | 4 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | Primary | 12 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Tumor Type:NA/Heme | 1 | 223 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Metastasis | 1 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | leukemia | Metastasis | 0 | 15 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Tumor Type:NA/Heme | 5 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Primary | 2 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Metastasis | 5 | 1738 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Primary | 7 | 898 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | head and neck cancer | Metastasis | 1 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | Metastasis | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | uterine cancer | Primary | 4 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | hepatobiliary cancer | Primary | 2 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Primary | 2 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | bladder cancer | Primary | 1 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 109 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | germ cell tumor | Metastasis | 1 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12C | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12C | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12C | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12C | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12C | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | colorectal cancer | Metastasis | 20 | 2352 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | G12D | colorectal cancer | Tumor Type:NA/Heme | 2 | 224 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12D | colorectal cancer | Primary | 31 | 4113 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | G12D | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12D | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Tumor Type:NA/Heme | 2 | 223 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | non-small cell lung cancer | Primary | 5 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Primary | 2 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | pancreatic cancer | Metastasis | 1 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | leukemia | Metastasis | 0 | 15 | 0.04 | 0.04 | 0.02 | 0.07 |
| NRAS | G12D | leukemia | Tumor Type:NA/Heme | 43 | 923 | 0.05 | 0.04 | 0.04 | 0.06 |
| NRAS | G12D | leukemia | Primary | 17 | 412 | 0.04 | 0.04 | 0.03 | 0.06 |
| NRAS | G12D | leukemia | Tumor Type:Unspecified | 11 | 217 | 0.05 | 0.05 | 0.03 | 0.07 |
| NRAS | G12D | melanoma | Metastasis | 8 | 1738 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | melanoma | Primary | 9 | 898 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12D | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | head and neck cancer | Metastasis | 3 | 731 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | uterine cancer | Metastasis | 2 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | Primary | 6 | 1541 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | Metastasis | 1 | 203 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.02 | 0.02 | 0.00 | 0.06 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 12 | 915 | 0.02 | 0.02 | 0.01 | 0.02 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Primary | 8 | 250 | 0.02 | 0.02 | 0.01 | 0.05 |
| NRAS | G12D | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.02 | 0.02 | 0.00 | 0.04 |
| NRAS | G12D | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Metastasis | 1 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Primary | 1 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | hepatobiliary cancer | Metastasis | 1 | 438 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hepatobiliary cancer | Primary | 3 | 894 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Tumor Type:NA/Heme | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Primary | 1 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | neuroendocrine tumors | Metastasis | 1 | 143 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bladder cancer | Primary | 1 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.03 | 0.03 | 0.00 | 0.10 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 8 | 109 | 0.06 | 0.06 | 0.02 | 0.11 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Primary | 1 | 101 | 0.02 | 0.02 | 0.00 | 0.06 |
| NRAS | G12D | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 1 | 25 | 0.04 | 0.04 | 0.00 | 0.11 |
| NRAS | G12D | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Primary | 2 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12D | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12D | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 25 | 0.04 | 0.03 | 0.00 | 0.12 |
| NRAS | G12D | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.03 | 0.01 | 0.00 | 0.12 |
| NRAS | G12D | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12D | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12D | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12D | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Metastasis | 0 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12F | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12F | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12F | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12F | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12F | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | leukemia | Tumor Type:NA/Heme | 2 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | Tumor Type:NA/Heme | 1 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | melanoma | Primary | 0 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Metastasis | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 4 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Metastasis | 1 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Primary | 2 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | breast cancer | Primary | 1 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | leukemia | Tumor Type:NA/Heme | 5 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | Metastasis | 3 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | melanoma | Primary | 3 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Primary | 2 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 6 | 915 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Primary | 2 | 250 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12S | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G12S | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | hepatobiliary cancer | Primary | 2 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Primary | 1 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.02 | 0.01 | 0.00 | 0.05 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 3 | 109 | 0.02 | 0.02 | 0.00 | 0.05 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Primary | 1 | 101 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | G12S | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | G12S | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12S | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G12S | b cell lymphoma | Metastasis | 1 | 57 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 25 | 0.04 | 0.03 | 0.00 | 0.12 |
| NRAS | G12S | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.02 | 0.01 | 0.00 | 0.11 |
| NRAS | G12S | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12S | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12S | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12S | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Metastasis | 2 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Primary | 5 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cancer of unknown primary | Tumor Type:Unspecified | 1 | 60 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Primary | 2 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Primary | 1 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | leukemia | Metastasis | 0 | 15 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | leukemia | Tumor Type:NA/Heme | 5 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | leukemia | Tumor Type:Unspecified | 2 | 217 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Primary | 1 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 2 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | hepatobiliary cancer | Metastasis | 1 | 438 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Primary | 2 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G12V | b cell lymphoma | Metastasis | 1 | 57 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | G12V | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G12V | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | non-hodgkin lymphoma | Primary | 1 | 14 | 0.08 | 0.06 | 0.00 | 0.26 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G12V | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G12V | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G12V | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13C | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Metastasis | 1 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Primary | 2 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | leukemia | Tumor Type:NA/Heme | 0 | 923 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | leukemia | Tumor Type:Unspecified | 0 | 217 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Metastasis | 2 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 3 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Primary | 2 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13C | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13C | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13C | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13C | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13C | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | G13D | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Metastasis | 8 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Primary | 4 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Primary | 0 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Metastasis | 1 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Metastasis | 1 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Primary | 2 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | leukemia | Metastasis | 1 | 15 | 0.02 | 0.02 | 0.01 | 0.05 |
| NRAS | G13D | leukemia | Tumor Type:NA/Heme | 19 | 923 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | Primary | 7 | 412 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | G13D | leukemia | Tumor Type:Unspecified | 5 | 217 | 0.02 | 0.02 | 0.01 | 0.04 |
| NRAS | G13D | melanoma | Metastasis | 5 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | melanoma | Tumor Type:NA/Heme | 1 | 188 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | melanoma | Primary | 2 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Primary | 1 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 6 | 915 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Primary | 3 | 250 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13D | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Tumor Type:NA/Heme | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | neuroendocrine tumors | Primary | 1 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.02 | 0.02 | 0.00 | 0.07 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 3 | 109 | 0.03 | 0.02 | 0.01 | 0.05 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Primary | 1 | 101 | 0.02 | 0.02 | 0.00 | 0.05 |
| NRAS | G13D | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 2 | 25 | 0.04 | 0.03 | 0.01 | 0.12 |
| NRAS | G13D | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | Tumor Type:NA/Heme | 1 | 81 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13D | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | b cell lymphoma | Tumor Type:NA/Heme | 1 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13D | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13D | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13D | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | appendiceal cancer | Metastasis | 1 | 174 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | Metastasis | 7 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | Tumor Type:NA/Heme | 1 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | colorectal cancer | Primary | 11 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Metastasis | 4 | 1388 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | non-small cell lung cancer | Metastasis | 1 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | leukemia | Metastasis | 1 | 15 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | G13R | leukemia | Tumor Type:NA/Heme | 4 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Metastasis | 14 | 1738 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Tumor Type:NA/Heme | 1 | 188 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Primary | 5 | 898 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | G13R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | G13R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | head and neck cancer | Primary | 2 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Primary | 1 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | adrenocortical carcinoma | Metastasis | 1 | 55 | 0.01 | 0.01 | 0.00 | 0.05 |
| NRAS | G13R | adrenocortical carcinoma | Primary | 0 | 72 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thyroid cancer | Metastasis | 2 | 402 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | hepatobiliary cancer | Metastasis | 2 | 438 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hepatobiliary cancer | Primary | 1 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | bladder cancer | Primary | 2 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 109 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | sex cord stromal tumor | Metastasis | 0 | 48 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | sex cord stromal tumor | Primary | 1 | 54 | 0.02 | 0.01 | 0.00 | 0.05 |
| NRAS | G13R | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Primary | 2 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 25 | 0.04 | 0.03 | 0.00 | 0.12 |
| NRAS | G13R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.03 | 0.02 | 0.00 | 0.11 |
| NRAS | G13R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13R | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Metastasis | 0 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Primary | 0 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Metastasis | 0 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Primary | 1 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Metastasis | 0 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Primary | 0 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | pancreatic cancer | Primary | 1 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | leukemia | Tumor Type:NA/Heme | 2 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | leukemia | Tumor Type:Unspecified | 2 | 217 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | melanoma | Metastasis | 1 | 1738 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | Tumor Type:NA/Heme | 0 | 188 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | melanoma | Primary | 3 | 898 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Metastasis | 0 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Primary | 0 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 3 | 915 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Primary | 2 | 250 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Primary | 1 | 101 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Metastasis | 0 | 274 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | G13V | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Primary | 0 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | G13V | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | G13V | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | G13V | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | G13V | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61H | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Metastasis | 4 | 2352 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Tumor Type:NA/Heme | 0 | 224 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Primary | 13 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cancer of unknown primary | Tumor Type:NA/Heme | 1 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | non-small cell lung cancer | Metastasis | 0 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Primary | 4 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Metastasis | 1 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Primary | 2 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | leukemia | Metastasis | 0 | 15 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | leukemia | Tumor Type:NA/Heme | 3 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | Primary | 1 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | leukemia | Tumor Type:Unspecified | 3 | 217 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | melanoma | Metastasis | 14 | 1738 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61H | melanoma | Tumor Type:NA/Heme | 2 | 188 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | melanoma | Primary | 11 | 898 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61H | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61H | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | head and neck cancer | Primary | 1 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Metastasis | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | uterine cancer | Primary | 3 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 1 | 31 | 0.02 | 0.01 | 0.00 | 0.10 |
| NRAS | Q61H | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Primary | 0 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cervical cancer | Primary | 1 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | mature t and nk neoplasms | Primary | 1 | 187 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | cns cancer | Metastasis | 0 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Primary | 0 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | prostate cancer | Primary | 2 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 1 | 109 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Primary | 1 | 101 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61H | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | germ cell tumor | Metastasis | 2 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61H | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61H | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | b cell lymphoma | Tumor Type:NA/Heme | 1 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61H | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61H | lung cancer | Primary | 1 | 17 | 0.07 | 0.05 | 0.00 | 0.22 |
| NRAS | Q61H | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | colorectal cancer | Metastasis | 28 | 2352 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61K | colorectal cancer | Tumor Type:NA/Heme | 3 | 224 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61K | colorectal cancer | Primary | 34 | 4113 | 0.01 | 0.01 | 0.01 | 0.01 |
| NRAS | Q61K | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | cancer of unknown primary | Metastasis | 4 | 1388 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Primary | 2 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cancer of unknown primary | Tumor Type:Unspecified | 1 | 60 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | non-small cell lung cancer | Metastasis | 2 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Primary | 5 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-small cell lung cancer | Tumor Type:Unspecified | 1 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | soft tissue sarcoma | Metastasis | 2 | 939 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | Tumor Type:NA/Heme | 1 | 119 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | soft tissue sarcoma | Primary | 12 | 1686 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61K | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | pancreatic cancer | Metastasis | 1 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | pancreatic cancer | Primary | 1 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | leukemia | Metastasis | 1 | 15 | 0.01 | 0.01 | 0.00 | 0.05 |
| NRAS | Q61K | leukemia | Tumor Type:NA/Heme | 8 | 923 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | Primary | 3 | 412 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | leukemia | Tumor Type:Unspecified | 2 | 217 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61K | melanoma | Metastasis | 128 | 1738 | 0.07 | 0.07 | 0.06 | 0.08 |
| NRAS | Q61K | melanoma | Tumor Type:NA/Heme | 16 | 188 | 0.07 | 0.07 | 0.05 | 0.10 |
| NRAS | Q61K | melanoma | Primary | 55 | 898 | 0.07 | 0.07 | 0.05 | 0.08 |
| NRAS | Q61K | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.07 | 0.07 | 0.02 | 0.10 |
| NRAS | Q61K | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | head and neck cancer | Primary | 3 | 938 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Metastasis | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | uterine cancer | Primary | 4 | 1541 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | uterine cancer | Tumor Type:Unspecified | 1 | 51 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | ovarian cancer | Metastasis | 0 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | Primary | 5 | 1060 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | esophagogastric cancer | Metastasis | 1 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | thyroid cancer | Metastasis | 5 | 402 | 0.02 | 0.02 | 0.00 | 0.03 |
| NRAS | Q61K | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.02 | 0.02 | 0.00 | 0.06 |
| NRAS | Q61K | thyroid cancer | Primary | 24 | 582 | 0.04 | 0.04 | 0.02 | 0.06 |
| NRAS | Q61K | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | hepatobiliary cancer | Metastasis | 3 | 438 | 0.01 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | hepatobiliary cancer | Primary | 4 | 894 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | Metastasis | 2 | 409 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | Primary | 6 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Primary | 1 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bladder cancer | Metastasis | 1 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bladder cancer | Primary | 2 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.01 | 0.00 | 0.05 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 2 | 109 | 0.02 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61K | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 1 | 25 | 0.02 | 0.01 | 0.00 | 0.08 |
| NRAS | Q61K | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | thymic tumor | Metastasis | 0 | 61 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | thymic tumor | Primary | 1 | 84 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61K | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | small cell lung cancer | Primary | 1 | 183 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | germ cell tumor | Metastasis | 2 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Primary | 1 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61K | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61K | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | Primary | 3 | 709 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61K | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61K | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61K | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61L | appendiceal cancer | Metastasis | 0 | 174 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | appendiceal cancer | Primary | 0 | 151 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | Metastasis | 8 | 2352 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Tumor Type:NA/Heme | 2 | 224 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | colorectal cancer | Primary | 12 | 4113 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | colorectal cancer | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | cancer of unknown primary | Metastasis | 1 | 1388 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Primary | 0 | 311 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cancer of unknown primary | Tumor Type:Unspecified | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Metastasis | 14 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Tumor Type:NA/Heme | 1 | 223 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-small cell lung cancer | Primary | 17 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Metastasis | 1 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Primary | 3 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Metastasis | 0 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | pancreatic cancer | Primary | 0 | 1428 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | leukemia | Metastasis | 0 | 15 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | leukemia | Tumor Type:NA/Heme | 5 | 923 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | Primary | 0 | 412 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | leukemia | Tumor Type:Unspecified | 1 | 217 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | melanoma | Metastasis | 56 | 1738 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61L | melanoma | Tumor Type:NA/Heme | 4 | 188 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61L | melanoma | Primary | 28 | 898 | 0.03 | 0.03 | 0.02 | 0.04 |
| NRAS | Q61L | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.03 | 0.03 | 0.01 | 0.05 |
| NRAS | Q61L | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | uterine cancer | Metastasis | 1 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | Primary | 5 | 1541 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 0 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 0 | 31 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Metastasis | 1 | 1088 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Tumor Type:NA/Heme | 0 | 160 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Primary | 0 | 1060 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Metastasis | 0 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Primary | 1 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | thyroid cancer | Metastasis | 0 | 402 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Tumor Type:NA/Heme | 0 | 28 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thyroid cancer | Primary | 0 | 582 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Metastasis | 0 | 136 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Metastasis | 0 | 438 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | hepatobiliary cancer | Primary | 0 | 894 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mature t and nk neoplasms | Primary | 0 | 187 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Metastasis | 1 | 409 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | cns cancer | Tumor Type:NA/Heme | 0 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Primary | 3 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | cns cancer | Tumor Type:Unspecified | 1 | 108 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | prostate cancer | Metastasis | 0 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | neuroendocrine tumors | Primary | 0 | 196 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Metastasis | 0 | 389 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bladder cancer | Primary | 0 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | Metastasis | 0 | 78 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | small cell lung cancer | Metastasis | 1 | 207 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | mesothelioma | Primary | 0 | 408 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Metastasis | 1 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | germ cell tumor | Primary | 0 | 517 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | nerve sheath tumor | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | Tumor Type:NA/Heme | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | nerve sheath tumor | Primary | 0 | 117 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61L | b cell lymphoma | Metastasis | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | b cell lymphoma | Tumor Type:NA/Heme | 0 | 145 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b cell lymphoma | Primary | 1 | 709 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61L | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61L | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61L | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61L | parathyroid cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | appendiceal cancer | Metastasis | 3 | 174 | 0.02 | 0.02 | 0.00 | 0.03 |
| NRAS | Q61R | appendiceal cancer | Tumor Type:NA/Heme | 0 | 10 | 0.02 | 0.01 | 0.00 | 0.05 |
| NRAS | Q61R | appendiceal cancer | Primary | 2 | 151 | 0.02 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | colorectal cancer | Metastasis | 13 | 2352 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | Tumor Type:NA/Heme | 1 | 224 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | Primary | 30 | 4113 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | colorectal cancer | Tumor Type:Unspecified | 2 | 31 | 0.02 | 0.01 | 0.00 | 0.08 |
| NRAS | Q61R | cancer of unknown primary | Metastasis | 6 | 1388 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Tumor Type:NA/Heme | 0 | 229 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Primary | 1 | 311 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | cancer of unknown primary | Tumor Type:Unspecified | 1 | 60 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | non-small cell lung cancer | Metastasis | 5 | 3750 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Tumor Type:NA/Heme | 0 | 223 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Primary | 10 | 6059 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-small cell lung cancer | Tumor Type:Unspecified | 0 | 99 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Metastasis | 0 | 3094 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Tumor Type:NA/Heme | 0 | 105 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | breast cancer | Primary | 0 | 6124 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Metastasis | 3 | 939 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Tumor Type:NA/Heme | 0 | 119 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | soft tissue sarcoma | Primary | 3 | 1686 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | soft tissue sarcoma | Tumor Type:Unspecified | 0 | 29 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | pancreatic cancer | Metastasis | 2 | 981 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | pancreatic cancer | Tumor Type:NA/Heme | 0 | 75 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | pancreatic cancer | Primary | 5 | 1428 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | leukemia | Metastasis | 0 | 15 | 0.01 | 0.01 | 0.00 | 0.05 |
| NRAS | Q61R | leukemia | Tumor Type:NA/Heme | 5 | 923 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | leukemia | Primary | 9 | 412 | 0.02 | 0.02 | 0.01 | 0.03 |
| NRAS | Q61R | leukemia | Tumor Type:Unspecified | 3 | 217 | 0.01 | 0.01 | 0.00 | 0.03 |
| NRAS | Q61R | melanoma | Metastasis | 174 | 1738 | 0.10 | 0.10 | 0.08 | 0.11 |
| NRAS | Q61R | melanoma | Tumor Type:NA/Heme | 13 | 188 | 0.07 | 0.07 | 0.04 | 0.10 |
| NRAS | Q61R | melanoma | Primary | 59 | 898 | 0.07 | 0.07 | 0.05 | 0.09 |
| NRAS | Q61R | melanoma | Tumor Type:Unspecified | 0 | 22 | 0.06 | 0.07 | 0.01 | 0.11 |
| NRAS | Q61R | head and neck cancer | Metastasis | 0 | 731 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | Tumor Type:NA/Heme | 0 | 67 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | head and neck cancer | Primary | 0 | 938 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | uterine cancer | Metastasis | 3 | 585 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | Tumor Type:NA/Heme | 0 | 76 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | Primary | 6 | 1541 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | uterine cancer | Tumor Type:Unspecified | 0 | 51 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | non-melanoma skin cancers | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | Tumor Type:NA/Heme | 0 | 22 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | non-melanoma skin cancers | Primary | 0 | 287 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Tumor Type:NA/Heme | 1 | 915 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Primary | 0 | 250 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | myelodysplastic/myeloproliferative syndromes | Tumor Type:Unspecified | 1 | 31 | 0.01 | 0.00 | 0.00 | 0.07 |
| NRAS | Q61R | adrenocortical carcinoma | Metastasis | 0 | 55 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | adrenocortical carcinoma | Primary | 0 | 72 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ovarian cancer | Metastasis | 13 | 1088 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | ovarian cancer | Tumor Type:NA/Heme | 3 | 160 | 0.01 | 0.01 | 0.01 | 0.03 |
| NRAS | Q61R | ovarian cancer | Primary | 9 | 1060 | 0.01 | 0.01 | 0.01 | 0.02 |
| NRAS | Q61R | ovarian cancer | Tumor Type:Unspecified | 0 | 28 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | esophagogastric cancer | Metastasis | 1 | 462 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | esophagogastric cancer | Tumor Type:NA/Heme | 0 | 43 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | esophagogastric cancer | Primary | 2 | 1283 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | esophagogastric cancer | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | thyroid cancer | Metastasis | 36 | 402 | 0.09 | 0.09 | 0.07 | 0.11 |
| NRAS | Q61R | thyroid cancer | Tumor Type:NA/Heme | 1 | 28 | 0.08 | 0.09 | 0.03 | 0.12 |
| NRAS | Q61R | thyroid cancer | Primary | 56 | 582 | 0.09 | 0.09 | 0.07 | 0.12 |
| NRAS | Q61R | cervical cancer | Metastasis | 1 | 136 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cervical cancer | Tumor Type:NA/Heme | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | cervical cancer | Primary | 0 | 211 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | Metastasis | 2 | 438 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | hepatobiliary cancer | Tumor Type:NA/Heme | 0 | 34 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | hepatobiliary cancer | Primary | 7 | 894 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | kidney cancer | Metastasis | 0 | 445 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | Tumor Type:NA/Heme | 0 | 24 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | kidney cancer | Primary | 0 | 944 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mature t and nk neoplasms | Metastasis | 0 | 10 | 0.01 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | mature t and nk neoplasms | Tumor Type:NA/Heme | 0 | 29 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | mature t and nk neoplasms | Primary | 1 | 187 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | cns cancer | Metastasis | 1 | 409 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Tumor Type:NA/Heme | 1 | 526 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Primary | 5 | 3522 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | cns cancer | Tumor Type:Unspecified | 0 | 108 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Metastasis | 1 | 901 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Tumor Type:NA/Heme | 0 | 57 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Primary | 0 | 1468 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | prostate cancer | Tumor Type:Unspecified | 0 | 12 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | anal cancer | Metastasis | 0 | 59 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | anal cancer | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | neuroendocrine tumors | Metastasis | 0 | 143 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | neuroendocrine tumors | Tumor Type:NA/Heme | 0 | 20 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | neuroendocrine tumors | Primary | 1 | 196 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | Metastasis | 1 | 389 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | bladder cancer | Primary | 2 | 1164 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Metastasis | 0 | 13 | 0.01 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 109 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Primary | 0 | 101 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | b-lymphoblastic leukemia/lymphoma | Tumor Type:Unspecified | 2 | 25 | 0.06 | 0.05 | 0.00 | 0.19 |
| NRAS | Q61R | small bowel cancer | Metastasis | 1 | 78 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | small bowel cancer | Primary | 0 | 128 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | sex cord stromal tumor | Metastasis | 0 | 48 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | sex cord stromal tumor | Primary | 0 | 54 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Metastasis | 0 | 203 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Primary | 0 | 326 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | bone cancer | Tumor Type:Unspecified | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | vaginal cancer | Metastasis | 0 | 16 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | vaginal cancer | Primary | 0 | 60 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | Metastasis | 0 | 61 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | thymic tumor | Primary | 0 | 84 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | ampullary cancer | Metastasis | 0 | 23 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | ampullary cancer | Primary | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | Metastasis | 0 | 207 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | small cell lung cancer | Primary | 0 | 183 | 0.00 | 0.00 | 0.00 | 0.00 |
| NRAS | Q61R | mesothelioma | Metastasis | 0 | 82 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | mesothelioma | Primary | 1 | 408 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Metastasis | 1 | 274 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Tumor Type:NA/Heme | 0 | 81 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Primary | 2 | 517 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | germ cell tumor | Tumor Type:Unspecified | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | nerve sheath tumor | Metastasis | 0 | 16 | 0.02 | 0.01 | 0.00 | 0.06 |
| NRAS | Q61R | nerve sheath tumor | Tumor Type:NA/Heme | 1 | 17 | 0.03 | 0.02 | 0.00 | 0.12 |
| NRAS | Q61R | nerve sheath tumor | Primary | 1 | 117 | 0.01 | 0.01 | 0.00 | 0.04 |
| NRAS | Q61R | penile cancer | Metastasis | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | penile cancer | Primary | 0 | 13 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | pheochromocytoma | Primary | 0 | 18 | 0.00 | 0.00 | 0.00 | 0.03 |
| NRAS | Q61R | pineal tumor | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.05 |
| NRAS | Q61R | b cell lymphoma | Metastasis | 0 | 57 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | b cell lymphoma | Tumor Type:NA/Heme | 1 | 145 | 0.01 | 0.01 | 0.00 | 0.02 |
| NRAS | Q61R | b cell lymphoma | Primary | 5 | 709 | 0.01 | 0.01 | 0.00 | 0.01 |
| NRAS | Q61R | b cell lymphoma | Tumor Type:Unspecified | 0 | 51 | 0.01 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | non-hodgkin lymphoma | Primary | 0 | 14 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Tumor Type:NA/Heme | 0 | 25 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | t-lymphoblastic leukemia/lymphoma | Primary | 0 | 11 | 0.00 | 0.00 | 0.00 | 0.02 |
| NRAS | Q61R | retinoblastoma | Tumor Type:NA/Heme | 0 | 10 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | retinoblastoma | Primary | 0 | 41 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | hodgkin lymphoma | Primary | 0 | 35 | 0.00 | 0.00 | 0.00 | 0.01 |
| NRAS | Q61R | lung cancer | Primary | 0 | 17 | 0.00 | 0.00 | 0.00 | 0.04 |
| NRAS | Q61R | parathyroid cancer | Primary | 1 | 13 | 0.08 | 0.06 | 0.00 | 0.28 |
R version 3.6.1 (2019-07-05)
Platform: x86_64-apple-darwin15.6.0 (64-bit)
Running under: macOS High Sierra 10.13.4
Matrix products: default
BLAS: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRblas.0.dylib
LAPACK: /Library/Frameworks/R.framework/Versions/3.6/Resources/lib/libRlapack.dylib
locale:
[1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8
attached base packages:
[1] stats graphics grDevices utils datasets methods base
other attached packages:
[1] here_1.0.1 gt_0.6.0 forcats_0.5.1 stringr_1.4.0
[5] dplyr_1.0.9 purrr_0.3.4 readr_2.1.2 tidyr_1.2.0
[9] tibble_3.1.7 ggplot2_3.3.6 tidyverse_1.3.1 magrittr_2.0.3
[13] workflowr_1.7.0
loaded via a namespace (and not attached):
[1] Rcpp_1.0.8.3 lubridate_1.8.0 getPass_0.2-2 ps_1.7.0
[5] assertthat_0.2.1 rprojroot_2.0.3 digest_0.6.29 utf8_1.2.2
[9] R6_2.5.1 cellranger_1.1.0 backports_1.4.1 reprex_2.0.1
[13] evaluate_0.15 httr_1.4.3 pillar_1.7.0 rlang_1.0.2
[17] readxl_1.4.0 rstudioapi_0.13 whisker_0.4 callr_3.7.0
[21] jquerylib_0.1.4 checkmate_2.1.0 rmarkdown_2.14 bit_4.0.4
[25] munsell_0.5.0 broom_0.8.0 compiler_3.6.1 httpuv_1.6.5
[29] modelr_0.1.8 xfun_0.31 pkgconfig_2.0.3 htmltools_0.5.2
[33] tidyselect_1.1.2 fansi_1.0.3 withr_2.5.0 crayon_1.5.1
[37] tzdb_0.3.0 dbplyr_2.2.0 later_1.3.0 rappdirs_0.3.3
[41] grid_3.6.1 jsonlite_1.8.0 gtable_0.3.0 lifecycle_1.0.1
[45] DBI_1.1.2 git2r_0.30.1 scales_1.2.0 vroom_1.5.7
[49] cli_3.3.0 stringi_1.7.6 fs_1.5.2 promises_1.2.0.1
[53] xml2_1.3.3 bslib_0.3.1 ellipsis_0.3.2 generics_0.1.2
[57] vctrs_0.4.1 tools_3.6.1 bit64_4.0.5 glue_1.6.2
[61] hms_1.1.1 parallel_3.6.1 processx_3.5.3 fastmap_1.1.0
[65] yaml_2.3.5 colorspace_2.0-3 rvest_1.0.2 knitr_1.39
[69] haven_2.5.0 sass_0.4.1